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ABSTRACT 
THE DESIGN AND SYNTHESIS OF ALLOSTERIC EFFECTORS OF CARBON 
MONOXIDE BINDING TO HEMOGLOBIN 
Sara R. Goldstein 
Jeffrey D. Winkler 
 
The development of small molecule allosteric inhibitors of carbon monoxide (CO) binding 
to hemoglobin (Hb) is important for the treatment of CO poisoning. We have found that 
the synthetic peptide IRL 2500 leads to inhibition of CO binding, but with concomitant 
hemolytic activity. We describe herein the design, synthesis and biological evaluation of 
analogs of IRL 2500 that inhibit CO binding without hemolysis. The most potent 
compounds that we have prepared to date contain heteroaromatic biaryls in place of the 
biphenyl moiety of IRL 2500. These compounds show improved solubility and reduced 
hemolytic activity. We also describe the synthesis of conformationally constrained analogs 
of IRL 2500 based on a piperazine-derived scaffold.   
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CHAPTER 1 INTRODUCTION  
SECTION 1.1 INTRODUCTION TO HEMOGLOBIN 
Hemoglobin (Hb), an α2β2 tetrameric globular protein found in red blood cells (RBCs),1,2 is 
arguably the most well studied and understood allosteric protein.3 In fact, Hb followed 
shortly after myoglobin (Mb) as the first protein x-ray crystal structures to be elucidated in 
1958 and 1960, respectively.1,4 Although Hb does not catalyze a reaction, it has been 
labeled an honorary enzyme due to its unique ability to bind oxygen and other small 
gaseous molecules.1 Hb’s primary function is to transport oxygen from the lungs to the 
outlying muscles and tissue, and then to carry carbon dioxide from these tissues to the 
lungs for export.5 
 
SECTION 1.2 STRUCTURAL FEATURES OF HEMOGLOBIN 
Hb contains four hemes, pentacoordinate iron (II) chelated porphyrins, which bind 
reversibly to oxygen thereby carrying it throughout the bloodstream.1,2 Hb has two main 
conformational states. The relaxed (R) state occurs when Hb is ligated at the heme and 
the tense (T) state occurs when Hb is unligated at the heme.1,3 The T and R state 
conformations both contain a 2-fold axis of symmetry around a central water cavity (see 
Figure 1.1, below). This central water cavity is particularly large in the T state with a 
distance of about 20 Å across along the entire 50 Å length of the protein. The a subunits 
and b subunits meet their respective counterparts across this distance and are known as 
the a and b clefts, respectively. Upon conformational change from the T state to the R 
state, there is about a 15° rotation and 1 Å translation of the α1β1 interface with respect to 
α2β2.1 
  
2 
 
Figure 1.1 Comparison of oxy (R state) and deoxyhemoglobin (T state) crystal 
structures. 
 
Conformational change from the T to R state 
induces the cleavage of several T state 
hydrogen-bond and salt bridge interactions. 
These changes particularly occur between the 
αC and βFG regions, known as the switch, 
while the joint, containing the symmetrical βC 
and αFG regions undergoes only a small 
conformational change and reorganization 
(see Figure 1.2).1,3 Additionally the C-terminal 
Arg141α breaks two salt bridges in the transition (not shown), which have been shown to 
be crucial to binding cooperativity.1,3 
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Figure 1.2 Representation of switch and 
joint regions of Hb.1 
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SECTION 1.3 SMALL MOLECULE INTERACTIONS WITH HEMOGLOBIN 
Small molecules are known to bind to Hb in various ways. In addition to the binding of 
small gaseous ligands at the heme, there are a number of compounds that bind to Hb and 
allosterically affect function. These ligands can have large effects on the stability of 
different conformational states.  
 
Section 1.3.1 Binding of Ligands to Heme 
The heme consists of four pyrrole rings linked by methylenes, forming the porphyrin unit, 
which in the case of Hb is protoporphyrin IX, due to the specific substituents attached to 
the pyrrole rings (see Figure 1.3A, below). The centrally bound iron, in the ferrous (II) 
state, is responsible for the distinct color of Hb and RBCs.1 In the deoxy (or unligated) 
state, the iron is five-coordinate and has square pyramidal geometry among the four 
nitrogens of the porphyrin and a nitrogen of the proximal histidine (His). Upon the binding 
of a ligand, specifically oxygen, the iron becomes octahedrally coordinated.1 This binding 
event changes the electronics of the iron, accounting for the dark blue color of venous 
blood, while arterial blood is red (see Figure 1.3B).1 This color change can be quantified 
in the visible light spectrum, where the absorption of Hb shifts from a λmax of 559 nm in the 
deoxy state, to a λmax of 575 nm in the oxy state (see Figure 1.3C). Additionally, there is 
a strong diagnostic signal in the near-UV known as the Soret band (λmax of 400-436 nm), 
which indicates the presence of a porphyrin.6 The Soret band shifts when a ligand binds 
to the heme and also with a change in pH or oxidation state of the iron. 
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Figure 1.3 A. Heme bound to oxygen. B. λmax of oxy and dHb. C. Visible light spectra of 
oxy and dHb.1 
 
It is hypothesized that the T to R conformational change is a result of the changing 
stereoelectronic demands of the iron. Closer 
investigation of the pocket surrounding the 
heme explains the sterics of gaseous ligand 
binding during the T to R transition. The most 
widely recognized steric effects are the 
proximal push and proximal pull (see Figure 
1.4, right).7 Proximal push is a process 
involving heme deformation when the iron is 
forced towards the gaseous ligand, resulting 
in a 0.6 Å shift in the proximal histidine’s 
position. This is thought to catalyze the 
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restructuring of the Hb from T to R.1 
Proximal pull is the deformation when the 
iron is forced away from the ligand. When 
there is no ligand bound to the heme, the 
iron-porphyrin bonds (Fe – Nporphyrin) are 
unable to adopt a planar binding mode 
with the iron center. However, when a 
ligand binds to the heme, the electronics 
surrounding the iron change, promoting a 
0.1 Å shortening of the Fe – Nporphyrin 
bonds, thereby bringing the iron in plane with the porphyrin (see Figure 1.5, left). In 
addition, there are some distal steric effects that limit the ligand’s access to the heme and 
may also play a role in binding cooperativity.7 It is important to note that these effects differ 
widely by gaseous ligand. Specifically, while the proximal pull only increases the rate of 
oxygen dissociation from the heme, it both the decreases the rate of association and 
increases the rate of dissociation of carbon monoxide. This information could prove useful 
in differentiating the binding of carbon monoxide and oxygen. 
  
As previously discussed, the transition between the T and R states of Hb has large 
implications on the ability of oxygen and other ligands to bind to Hb. Although there are 
four hemes in Hb, the binding of oxygen at a single heme leads to the T to R 
conformational change and, due to decreased steric bulk and proximal push, oxygen 
subsequently binds to the other three hemes of the R state of Hb. This increase in oxygen 
affinity upon conformational change to the R state leads to the Hb’s unique ability to have 
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Figure 1.5 Shift in proximal his and helix F 
upon oxygen binding to Hb.1 
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a very high saturation (YO2) for oxygen at high partial pressures (pO2) of oxygen and a low 
saturation at low partial pressures of oxygen (see Figure 1.6, below).1 This property is 
defined as binding cooperativity, and leads to the canonical sigmoidal oxygen binding 
curve of Hb (see Figure 1.6, represented by purple line). If instead, Hb were only able to 
access the T state, oxygen would have a very low affinity for Hb and its binding curve 
would have a shallow, linear slope (see blue line below). In contrast, if Hb were only able 
to access the R state, Hb’s affinity for oxygen would always be high and would exhibit a 
logarithmic binding curve (see red line below). As it is, Hb is able to access both 
conformations, therefore having a binding curve (purple line) that at lower partial pressures 
of oxygen more closely resembles the binding curve of the T state (blue line) and at higher 
partial pressures of oxygen more closely resembles the R state (red line). 
 
Figure 1.6 The oxygen dissociation curve of Hb. YO2 refers to the saturation of oxygen 
on the heme. pO2 is the partial pressure of oxygen.1 
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Cooperativity explains Hb’s unique ability to transport oxygen in the bloodstream. In the 
lungs, where the partial pressure of oxygen is high, Hb becomes saturated with oxygen. 
When Hb reaches the capillaries, where the partial pressure of oxygen is low, Hb releases 
the stored oxygen, allowing it to diffuse into tissue.1,5 
 
Section 1.3.2 Allosteric Effectors of Binding 
In addition to binding cooperativity, 
some molecules bind allosterically to 
Hb and induce a shift in the oxygen 
dissociation curve (ODC). In 1967, 
Benesch and Benesch reported the 
discovery of the first allosteric effector 
of human Hb.8 It had previously been 
shown, as early as 1909, that the 
concentration of certain salts can 
affect the ODC.9,10 However, Benesch 
and Benesch noticed that the ODC was strongly affected by the concentration of inorganic 
phosphate and hypothesized that 2,3-diphosphoglycerate (DPG, see Figure 1.7, above), 
which has multiple phosphates and was known to be present in RBCs at a concentration 
of about 3.6-5 mM,5,8 might induce a similar shift. Not only did DPG affect the ODC, but it 
greatly increased (right shifted) the oxygen dissociation relative even to inorganic 
phosphate (see Figure 1.8, below). They further found that the use of a nonspecific source 
of anionic charge (potassium ferricyanide) did not affect the ODC, which led to the 
proposal that DPG was acting allosterically to regulate the ODC.8 In 1972, five years after 
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the Benesch hypothesis, a crystal structure of DPG bound to Hb was first published by 
Arnone and coworkers and the mechanism of action was resolved.11 Arnone showed that 
DPG binds to the β cleft, making interactions with six histidines, two lysines and the two 
N-terminal valines (see Figure 1.7, above). Additionally, he demonstrated that DPG had 
a stabilizing effect on deoxyhemoglobin (dHb)/T state Hb, slightly deforming the structure 
of dHb and shortening the distance between Val β1006 and Val β2006 by about 2Å, which 
he postulated would affect Hb solubility.  
  
 
Figure 1.8 The effect of DPG on the ODC.8 
 
One might further extrapolate that molecules containing a greater number of phosphates 
than DPG would induce an even greater effect on the ODC. Benesch and coworkers used 
three inositol esters, inositol hexaphosphate (IHP) and inositol pentaphosphate (IPP) as 
well as DPG to establish a positive correlation between the number of polyanions and the 
Hb
 O
xy
ge
n 
Sa
tu
ra
tio
n 
(Y
o 2
)
Partial Pressure of Oxygen (pO2)
1.0
Hb Right Shift
without DPG with DPG
  
9 
ODC.12 Unfortunately, measuring these effects in vivo is challenging due to the polyanions’ 
inability to cross the phospholipid bilayer.13 However, Teisseire et al. were able to 
demonstrate that piglets treated with erythrocytes preloaded with IHP had a lower cardiac 
output and increased oxygen release capacity for the lifespan of the erythrocytes. This 
indicates that treatment with a natural or synthetic ODC right-shifter (referring to the ability 
for the compound to shift the ODC towards the right, stabilizing the T state) might be a 
useful tool for tissue reoxygenation in the case of interrupted or poor blood flow.13 
  
In addition to organophosphates, there has been an ongoing search for organic 
compounds that can bind allosterically to affect an ODC shift. In the search for these 
compounds, Perutz and coworkers discovered clofibrate (1, see Figure 1.9, below), an 
aromatic propionate that shifted the ODC to the right, stabilizing the T state.3 These and 
other propionates were crystallized with Hb to determine their mechanism of action. It was 
found that clofibrate and bezafibrate (2) bind to Hb in a 2:1 ratio at a site within the water 
cavity about 20 Å away from the binding site of DPG.3,14 L35, an analog of benzafibrate 
(3), was then synthesized and greatly increased the effect on the ODC relative to its 
progenitor. They were proposed as radiation enhancing compounds for the treatment of 
hypoxic tumors, as the compounds could help to reoxygenate the tumor mass during 
radiation therapy. The efficacy of these initial compounds was thwarted by their strong 
binding affinity to serum albumin,3 but Efaproxiral (4), a compound introduced by Allos 
Therapeutics, was able to resolve this issue by eliminating the urea linkage present in L35. 
Although Efaproxiral advanced to phase III clinical trials as a radiation enhancing 
compound, it was found through meta-analysis that it was likely not efficacious.3 
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Figure 1.9 Organic right-shifters. 
 
In addition to organic right-shifters, several organic left-shifters have also been discovered. 
These compounds all contain an electrophilic warhead, normally in the form of an aromatic 
aldehyde, that acts as a Schiff base, attaching to the α-N-terminal valines.3,15 Vanillin (5, 
see Figure 1.10, below) was the first aldehyde discovered with this ability, followed by 
Tucaresol (6). Tucaresol was the first left-shifter to be crystallized with Hb, confirming the 
mechanism of action to be Schiff base formation.3,16 The acidic moiety of Tucaresol was 
shown to disrupt the αArg141 salt bridges that are crucial for T state stability. Due to their 
left-shifting ability, these compounds showed promise for the treatment of sickle cell 
disease. Unfortunately, large doses of these compounds were needed clinically to 
overcome poor their bioavailability and they were abandoned as potential therapeutics. 
More recently, 5HMF (7) was discovered as an even more potent left-shifter with improved 
bioavailability. 5HMF is currently undergoing pre-clinical and phase I clinical antisickling 
studies.3 
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Figure 1.10 Organic left-shifters. 
  
Section 1.3.3 CO2Hb and the Bohr Effect 
As indicated previously, the 
environment in which Hb exists can 
dramatically affect its function. 
Specifically, concentration, ionic 
strength, pH and allosteric effectors 
all play a great role in the 
conformational state of Hb and thus 
its ability to bind ligands. The binding 
of carbon dioxide to Hb differs greatly from its mechanism of binding oxygen. In fact, 
carbon dioxide does not bind to the heme at all, but rather to the α-N-terminal amino 
groups (10) in a process known as carbamoylation.1,5 In tissue, carbon dioxide (CO2) is 
rapidly converted to carbonic acid (9) by carbonic anhydrase (see Scheme 1.1). This 
causes the pH of carbon dioxide rich tissue to drop. Hb can be protonated by carbonic 
acid, which allows it to transport carbon dioxide as bicarbonate ion pairs with Hb.1,5 In 
addition, carbon dioxide (8) can also undergo nucleophilic attack by N-terminal Val (10), 
leading to the formation of carbaminohemoglobin (CO2Hb, 11). These processes are 
driven significantly by the pH of the system.  
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To further complicate this issue, pH also has a great effect on the oxygen affinity of Hb, a 
property first discovered by Christian Bohr, which is named the Bohr effect.5,17 The oxygen 
affinity begins to increase at a pH greater than 6 and plateaus at 7.4. This effect is mainly 
attributed to three residues, in the absence of DPG: Val α001, Lys β082 and His β146, 
which liberate their protons at high pH.18 It is hypothesized that the T state has a higher 
affinity for protons than the R state.17 Therefore, at physiological pH, protohemoglobin 
(HHb) is normally in equilibrium with oxyHb. This allows HHb to liberate its proton in the 
presence of high concentrations of oxygen also liberating carbon dioxide which is trapped 
as a bicarbonate ion pair. Conversely, in tissues with high concentrations of carbon dioxide 
and low concentrations of oxygen, the reverse reaction occurs, liberating oxygen from Hb 
and trapping carbon dioxide as a bicarbonate ion pair. Bicarbonate ion pairs account for 
60-70% of all carbon dioxide transport. 
 
SECTION 1.4 CARBON MONOXIDE POISONING 
Another molecule known to cause a left shift in the ODC is carbon monoxide, a toxic gas 
which has a 240 times greater affinity for Hb than oxygen. Carbon monoxide is an 
odorless, tasteless and colorless gas responsible for 40,000 emergency room visits and 
5000 to 6000 deaths per year in the United States.19–21 While nonsmokers have up to 3 
percent carboxyhemoglobin (COHb), smokers may have up to 10 to 15 percent 
concentration in their blood.19 Upon binding to the heme, CO induces a conformation 
similar to the R state, which increases the oxygen affinity of the three remaining heme 
sites, but will not allow oxygen to be released in low partial pressures.22 This effect causes 
a leftward shift in the ODC, making oxygen less available to the tissues (see Figure 1.11).  
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Figure 1.11 A. Carbon monoxide depresses the ODC by reducing the total amount of 
Hb able to be saturated. B. CO also causes a left-shift of ODC by inducing the R 
state.22 
 
Treatment of carbon monoxide poisoning generally involves the use of either a high-flow 
oxygen mask or a hyperbaric oxygen chamber.19 Normally, the half-life (T1/2) of COHb in 
the human body is 300 minutes, but with the use of a high-flow oxygen mask, this can be 
lowered to 90 minutes, and in a pressurized hyperbaric oxygen chamber, the T1/2 is further 
lowered to 30 minutes. Generally, hyperbaric oxygen is only used when the concentration 
of COHb in the blood is greater than 25 percent. Only about 1500 patients are treated with 
hyperbaric oxygen in the US yearly, mainly due to the low availability of these chambers 
of which there are only about 250 in the United States.  
 
Section 1.4.1 Carbon monoxide as a neurotransmitter 
Carbon monoxide is already present in very small concentrations in the body, and plays 
an important role in cellular function.23–25 Carbon monoxide is endogenously produced by 
two means: the recycling of heme by heme oxygenase and the peroxidation of liposomal 
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lipids. Heme oxygenase produces most of the endogenous carbon monoxide when it 
reacts with heme (13) to release iron, biliverdin (14), and a molecule of carbon monoxide 
(see Scheme 1.2). Biliverdin is thought to then block further heme oxygenase activity 
through feedback inhibition. Secondarily, a lesser source of carbon monoxide has been 
observed in the brain, kidney, lung, spleen and blood during lipid peroxidation. 
 
Scheme 1.2 Degradation of heme by heme oxygenase. 
 
Some amount of the endogenous carbon monoxide is exhaled and the rest is stored as 
carboxyhemoglobin (COHb).25 This carbon monoxide is thought to inhibit enzymes with 
Fe-S centers and also upregulate the production of cyclic GMP, through activation of 
guanylyl cyclase. Endogenous carbon monoxide is also thought to act as a 
neurotransmitter in conjunction with nitrous oxide.23,26 While heme oxygenase in 
peripheral tissue is present in its inducible isoform (HO1), heme oxygenase (HO2) in nerve 
tissue is constitutively expressed, and it is believed that endogenous CO is necessary for 
nerve function.26 Furthermore, mice with a genomic deletion of either HO2, NO2 (the 
nitrous oxide equivalents to HO2) or both HO2 and NO2, all show decreased function in 
gastrointestinal neurotransmission. Additionally, loss of function in mouse smooth muscle 
tissue due to HO2 inhibition can be rescued with exogenous CO.  
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SECTION 1.5 LEAD COMPOUNDS AND BACKGROUND 
Although CO plays an important role in intercellular 
function, exposure to large volumes of CO can be deadly, 
and there are very few current treatment methods 
available for CO exposure. To address this need, we, in 
collaboration with Professor Warren Zapol at 
Massachusetts General Hospital, have designed several 
small molecules that allosterically inhibit the binding of 
CO to Hb. Our lead compound, IRL 2500 (Figure 1.12, 15a) lowers the half-life of CO 
bound Hb (COHb) in vitro.27 
 
Section 1.5.1 IRL 2500 
X-ray crystallographic 
analysis shows that IRL 
2500 and DPG both bind to 
the β cleft of Hb in a similar 
position (Figure 1.13).28 
Since DPG and IRL 2500 
both bind to the β cleft and 
DPG is known to stabilize 
deoxy-Hb (dHb),28,29 we 
propose that IRL 2500 is 
Figure 1.13 IRL 2500 (orange) and DPG (tan) bound in the 
b cleft. 
Figure 1.12 IRL 2500. 
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able to similarly enforce the dHb conformation (T state) and block CO and other ligands 
from binding to the heme. Unfortunately, IRL 2500 induces hemolysis, making it 
incompatible with in vivo studies.27 
 
IRL 2500 (15a) was first reported by Fruh et al. in 1996 as a selective ETB endothelin 
antagonist.30 Endothelins are a family of vasoactive peptides that play a role in a number 
of diseases including renal failure, vasospasm, hypertension and asthma. These peptides 
act on two receptors, ETA and ETB and various endothelins show selectivity for one over 
the other. IRL 2500 was discovered through an SAR screen of the C-terminal 
dodecapeptide of ET-1 and has a 1 nM affinity for ETB and a 440 nM affinity for ETA. 
 
The first synthesis of IRL 2500 was reported in a 1995 patent by Fruh, et al. shortly before 
the publication of their subsequent paper (see Scheme 1.3, below).31 IRL 2500 was 
constructed in six steps from (D)-3-(biphenyl-4-yl)-alanine (16). Following esterification of 
acid 16, ester 17 is treated with formaldehyde and freshly distilled cyclopentadiene leading 
to hetero Diels Alder adduct 18 as masking group for the imine. Following isolation, the 
bicyclic intermediate is treated with trifluoroacetic acid in triethylsilane to induce the retro 
Diels-Alder and subsequent reduction of the imine to N-methyl ester 19. Reaction with 
benzoyl chloride 20 followed by saponification gives acid 21 which is then coupled to L-
tryptophan methyl ester 22, followed by a final saponification to give IRL 2500. No yields 
for the initial synthesis were reported.  
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Scheme 1.3 First reported synthesis of IRL 2500. 
 
Unfortunately, their initial route did not allow them to 
readily access a variety of analogs, particularly derivatives 
of the biphenyl moiety. Therefore, each analog was 
synthesized individually. This proved a hindrance for the 
synthesis of analogs for which precursors corresponding 
to 16 were commercially unavailable. For example, in the 
synthesis of IRL 3461 (23, Figure 1.14), the isoxazole 
amino ester 27 had to be synthesized prior to the commencing the synthesis of the 
analog.32 This required beginning with ketone 24, which was converted to isoxazole 25 in 
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two steps (see Scheme 1.4, below). Subsequent bromination of the benzylic methyl group 
allowed for installation of the amino ester moiety in two steps. First, bromo isoxazole 26 
was reacted with N-(diphenylmethylene)glycine ethyl ester. Subsequently, hydrolysis 
yielded amino ester 27. Prior to completion of the ten-step synthesis, the diastereomers 
of isoxazole 23 had to be separated, leading to the effective loss of half of the final 
compound.  
 
Scheme 1.4 Synthesis of biaryl amino ester towards the synthesis of IRL 3461. 
 
In July of 2015, Zapol and coworkers reported an improved approach to the synthesis of 
IRL 2500 that allowed for diversification at various stages of the route and used either 
racemic or enantiopure D-tyrosine amino acid starting material (28, see Scheme 1.5).33 
By converting the phenol of tyrosine to a triflate (30), Zapol and coworkers were able to 
install the biphenyl moiety through a Suzuki-Miyaura cross-coupling. It is important to note, 
however, that they chose to install the biphenyl early in the synthesis, which makes 
diversification step-intensive. Furthermore, if tyrosine were to be used as the functional 
handle for installation of the biphenyl later in the synthetic route, it would be necessary to 
protect the free phenol, as phenols are often incompatible with coupling conditions. 
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Scheme 1.5 Updated synthesis of IRL 2500. 
 
Section 1.5.2 High-throughput Screening 
Due to IRL 2500’s propensity to cause hemolysis, our collaborators at Massachusetts 
General Hospital undertook a screen of structurally similar analogs to find a compound 
with similar potency but with no hemolytic activity.27 Shown on the next page are the 
results of the screen (Table 1.1). 
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Table 1.1 Original HTS of IRL analogs. 
 
entry Compound (2-10x tetramer) R R’ 
T1/2 of COHb 
(min) Hemolysis 
1 DMSO - - 19 No 
2 IRL 2500 (15a) Ph Me 17 Yes (major) 
3 IRL 1 (15b) H Me 17 No 
4 15c H H Not tested No 
5 32a H H 16 Yes 
6 32b H Me 17 Yes 
7 32c Me H 16 Yes 
8 33a Me Me 20 No 
9 33b Me 3,5-DiMe-C6H4 19 No 
10 33c Me 4-Ph-Ph 18 No 
 
Through the screen, they discovered IRL 1 (15b, Table 1.1), which proved effective in 
lowering the half-life of CO without inducing hemolysis. We decided to proceed with a 
more robust SAR screen using 15b as the framework upon which to design derivatives. 
 
SECTION 1.6 GOALS OF PROJECT 
We chose 15b as the lead compound for our SAR studies because it did not cause 
hemolysis. We also wished to design an analog that would reduce the COHb half-life at 
least as much as the original lead compound IRL 2500 (15a). Finally, we set out to design 
a compound that would be significantly more soluble than 15b in aqueous media. It is 
important to note that we anticipated problems with the solubility of 15b analogs, but we 
believed we could overcome these issues by introduction of solubilizing groups.  
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SECTION 1.7 CORRELATION BETWEEN HEMOLYSIS AND CLOGP 
In order to appropriately design our analogs, we wanted to develop a simple metric for 
evaluating solubility. For this, we decided to examine cLogP, the calculated logarithmic 
value of the partitioning coefficient between octanol and water. cLogP has been 
popularized for evaluating drug candidates for solubility and cell permeability. Most 
notably, cLogP, or Log P (in its experimentally determined form), is included as one of 
Lipinski’s “rule of five”, where no drug candidate should have a Log P greater than 5. This 
means that the given compound has no more than 100,000 times greater solubility in 
octanol than water.34 Currently, we calculate a Log P (cLogP) using BioByte in 
Chemdraw®, which gives us a metric for the relative aqueous solubilities of our analogs. 
If we compare, for instance, IRL 2500 and IRL 1, there is a notable difference between 
their respective cLogPs of 6.6 and 4.7. This difference tells us that IRL 1 should have 
significantly greater aqueous solubility (almost 100x) than IRL 2500. We, in fact, observe 
this experimentally, where IRL 1 can be dissolved at 400 µM in DPBS with 5 volume 
percent DMSO, whereas IRL 2500 can only be evaluated at 200 µM in DPBS with 5 
volume percent DMSO. 
 
While evaluating the cLogPs of the previously screened compounds, we observed a trend 
in which the compounds with lower cLogP are less likely to cause hemolysis. To quantify 
this relationship, we did a retrospective study of the previously screened analogs to 
determine whether cLogP could be used as a predictor of hemolytic activity. We observed 
a direct correlation between the cLogP the IRL analogs and their hemolytic activity. 
Summarized in Table 1.2, we established a correlation between hemolytic activity and the 
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cLogP of the ligands, where compounds with a cLogP lower than 4.8 did not cause 
hemolysis while those higher than 5 caused hemolysis. This metric allows for rational 
design of candidates going forward that are less likely to affect hemolysis. 
Table 1.2 Comparison of cLogP and hemolytic activity. 
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SECTION 1.8 PROPOSED STUDIES 
Starting with IRL 1 (15b) as our lead compound, we decided to investigate the SAR of 
three distinct regions of IRL (see Figure 1.15, below): the region derived from L-
tryptophan (described in Chapter 2), the region derived from D-phenylalanine (described 
in Chapter 3) and the region derived from 3,5-dimethylbenzoic acid (described in Chapter 
2). To improve the expediency of synthesis, we imagined that the analogs of each of these 
regions would come from a common intermediate, which will be described in detail in the 
following chapters. 
 
Figure 1.15 Deconstruction of IRL 1 for SAR. 
 
Given our goal of designing a compound with greater CO half-life lowering activity than 
IRL 1 and with greater aqueous solubility and a lower cLogP than IRL 2500, we decided 
to prepare compounds that had a greater number of solubilizing functional groups. 
Additionally, we wished to expand the scope of SAR that had been previously explored. 
We expected to use the crystal structure for the rational design of analogs that would be 
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able to pick up on further interactions in the b cleft. Particularly, given the rich cation 
density in the cleft, and the history of polyanionic allosteric effectors that bind to the cleft, 
we believed that the design of polyanionic molecules would lead to improved activity and 
solubility. With these ideas in mind, we set about the synthesis of our first generation of 
IRL derivatives. 
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CHAPTER 2 FIRST GENERATION DERIVATIVES 
SECTION 2.1  TRYPTOPHAN DERIVATIVES 
As described in Chapter 1, Chapter 2 will be divided into two parts to establish the 
structure activity relationships (SAR) for IRL 1: the L-tryptophan (L-Trp) derived region 
and the 3,5-dimethylbenzoic acid-derived region. Retrosynthetically, one could imagine all 
analogs of L-Trp 37 (where R=CO2H, R”= 3-CH2-1H-indole) arising from an intermediate, 
acid 39, which can be synthesized by coupling 3,5-dimethylbenzoic acid (35) and D-Phe 
ester 40, derived from amino acid 36 (see Scheme 2.1). The analogs would be accessed 
by coupling this intermediate with various amines (38), to generate L-Trp analogs (37). 
 
Scheme 2.1 Retrosynthesis of L-Trp derivatives. 
 
Section 2.1.1 Phosphorylated analogs 
Close investigation of the crystal structure indicates that IRL 2500 is bound in the β cleft 
in a similar manner to DPG. We therefore hypothesized that a hybridized IRL/DPG, where 
the charge-bearing region of IRL 1 is replaced with a phosphate, might improve the 
potency and aqueous solubility. The proposed IRL 1/DPG hybrid is shown below (41, see 
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Figure 2.1, below). We hypothesized that this substitution would provide multiple 
improvements to IRL 1. Specifically, the polyanionic character of the phosphate would 
form a stronger interaction with the highly cationic β cleft (where IRL 1 is only able to make 
a salt bridge with one Lys β082). Additionally, because of its lower pKa,1 we expected the 
phosphate to be charged at physiological pH, which would greatly improve solubility. 
Finally, the phosphate was estimated to have a cLogP of 3.9, which is significantly lower 
than the IRL 1 value of 4.7. We hypothesized that this decrease in cLogP would improve 
the aqueous solubility and decrease the likelihood that the analog would cause hemolysis. 
Additionally, we proposed the synthesis of alcohol 42 as a negative control to confirm the 
necessity for an anionic charge source in the IRL series. Alcohol 42 is also the precursor 
to phosphate 41, giving us access to both analogs in one route. 
 
Figure 2.1 IRL/DPG hybrid structure and control. 
 
This alcohol would be derived from the coupling of intermediate 39 with L-tryptophanol 43 
(see Scheme 2.2, below). 
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Scheme 2.2 Retrosynthesis of phosphate analogs. 
 
In the forward sense, alcohol 42, the penultimate compound in the synthesis of phosphate 
47 was produced in relatively short order (see Scheme 2.3, below). Ester 40, synthesized 
in one step from D-Phe, was coupled with 3,5-dimethylbenzoic acid (35). The resulting 
ester (44) was saponified and coupled with tryptophanol 43, which was synthesized 
quantitatively in one step from L-Trp using known conditions.2 The synthetic peptide 42, 
the first of the analogs to be screened, was poised for phosphorylation.  
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Scheme 2.3 Synthesis of alcohol 42, precursor to phosphate 41. 
 
Phosphorylation of alcohol 42 proved difficult. Initial attempts were undertaken with 
several chlorophosphates, summarized in Table 2.1 below, with very little success. 
Screening of different bases and solvents did not improve reaction yields. The most 
successful phosphorylation conditions involved the use of sodium hydride to deprotonate 
alcohol 42 followed by treatment with diethylchlorophosphate. However, deprotection of 
the resulting ethyl phosphate esters proved problematic, and this route was ultimately 
abandoned. 
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Table 2.1 Initial phosphorylation conditions. 
 
entry reagent base solvent temp yield 
1 diethylchlorophosphate NaH THF 0 oC - rt 43% 
2 diethylchlorophosphate Pyridine Neat 0 oC - rt N.R. 
3 dibenzylchlorophosphate NaH THF 0 oC - rt >20% 
4 dibenzylchlorophosphate Pyridine Neat 0 oC - rt N.R. 
5 dibenzylchlorophosphite, N-chlorosuccinimide NaH THF 0 
oC - rt N.R.  
6 dibenzylchlorophosphate KHMDS THF 0 oC - rt N.R. 
 
Further investigation with a model system showed that the tryptophanol alcohol was 
incredibly resistant to phosphorylation, particularly with chlorophosphates. In an attempt 
to improve the reactivity of the electrophile with alcohol 42, we decided to employ 
phosphoramidite chemistry, which was originally developed for use in oligonucleotide 
synthesis in solid phase.3,4 We had initially avoided the use of phosphoramidites due to 
the need to oxidize the intermediate phosphite because we believed the oxidation might 
prove problematic in the presence of the unprotected indole. Fortuitously, after screening 
conditions, di-tert-butyl-N,N-diisopropylphosphoramidite proved to be an effective 
phosphorylating reagent with oxidation proceeding uneventfully and selectively at the 
phosphine (Scheme 2.4). Deprotection of the resultant tert-butylphosphate (46) occurred 
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readily and in good yield, generating the final phosphate (41), which was submitted for 
biological testing. 
 
Scheme 2.4 Phosphoramidite phosphorylation. 
 
The results of the biological screen of the COHb half-life of our two initial analogs, 
phosphate 41 and alcohol 42 are listed below in Table 2.2. Unfortunately, the insolubility 
of alcohol 42 precluded testing. However, we were encouraged to find that compound 41 
showed identical activity to IRL 1 in the screen. Both compounds were subjected to a 
screen for hemolysis and neither of the compounds exhibited hemolytic activity. From 
these data, we concluded that there was no significant perturbation in activity by 
converting the carboxylic acid to the phosphate. 
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Table 2.2 Phosphorylated analog COHb half-life evaluation. 
 
 
Section 2.1.2 Tetrazole analog 
Given our interest in developing analogs with lower cLogPs, 
we synthesized the IRL 1 analog containing an isosteric 
tetrazole (see Figure 2.2) in place of the carboxylate. 
Tetrazoles are the among the most commonly used 
isosteres for carboxylic acid.5 They are favored among 
isosteres because they are highly planar, similar to the 
planar carboxylic acid, and they have a similar pKa to the 
carboxylic acid (~4.5–4.9). However, one drawback is that they are somewhat larger than 
the carboxylic acid and tend to have lower membrane permeability.1 As alluded to above, 
the tetrazole analog (47) has a significantly depressed cLogP of 3.9 relative to IRL 1, which 
has a cLogP of 4.7. We chose to use 39 to synthesize tetrazole 47, which could be 
generated through coupling reaction of 39 with tetrazole 48 derived from L-Trp (see 
Scheme 2.5).  
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Scheme 2.5 Retrosynthetic analysis of tetrazole 47. 
 
In the forward sense, beginning with N-Cbz L-tryptophan (49, see Scheme 2.6, below), 
we converted the carboxylic acid of 49 to the corresponding primary amide (not shown). 
This amide intermediate was subsequently dehydrated to generate nitrile 50. The nitrile 
was then subjected to cycloaddition conditions with sodium azide to provide the Cbz-
protected tetrazole, which upon hydrogenation liberated amino tetrazole 48. The resulting 
amino tetrazole was then coupled to 39 using EDC to generate IRL tetrazole 47.  
 
Scheme 2.6 Synthesis of tetrazole 47. 
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Biological results for COHb half-life lowering activity indicated that the presence of the 
tetrazole led to significantly reduced activity relative to IRL 1 (see Table 2.3, below). This 
suggests that in the case of the IRL analogs, the tetrazole is not a good isostere for the 
carboxylate. The difference in activity might be due to the increased size of the tetrazole 
making it more difficult to bind to the β cleft, or the increased hydrophilicity of the tetrazole 
may make it less able to bind to the hydrophobic β cleft.  
Table 2.3 COHb half-life lowering activity for tetrazole 53. 
 
 
Section 2.1.3 A/B ring analogs 
To further explore the SAR of IRL 1, we wished to determine 
whether the indole (A/B ring) was necessary for potency 
(Figure 2.3). Changing the A/B ring system would allow us 
to understand the role of the indole in binding, as a function 
of aromaticity and hydrogen bond (H-bond) donation. Thus, 
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we chose to explore three analogs: a des-indole analog (51a, see Figure 2.4), a des-
pyrrole analog (51b) and an imidazole analog (51c).  
 
Figure 2.4 Proposed A/B ring analogs. 
To synthesize the proposed analogs, we planned to couple various amino esters 52 with 
the same intermediate 39 that was used in the synthesis of phosphate 41 and tetrazole 
47 (see Scheme 2.7).  
 
Scheme 2.7 Retrosynthesis of A/B ring analogs using intermediate 39. 
 
In the forward sense, the synthesis of 51a, b and c was achieved, readily generating two 
analogs for testing. First, various amino esters 52 were coupled with intermediate 39 (see 
Table 2.4, below). 
HN O
NH
O
51a
O
OH
HN O
NH
O
51b
O
OH
HN O
NH
O
51c
O
OH
H
N
N
R
HN O
NH
O
51
HO
O H
N
O
39
O
OH
R
NH3
O
OMe
52
+
Cl
  
38 
Table 2.4 Synthesis of A/B ring esters. 
 
entry R solvent 52 53 yield (%) 
1 H CH3CN 52a 53a 61 
2 Bn DMF 52b 53b 69 
3 
 
DMF 52c 53c 71 
 
The resulting analogs 53a, b and c were then saponified to their corresponding acids 51a, 
b and c (Table 2.5). Unfortunately, while the coupling of acid 39 to L-His methyl ester 52c 
proved fruitful, attempts at saponification were unsuccessful, possibly due to the formation 
of a zwitterion resulting from deprotection of the acid. We plan further exploration of this 
analog in the future. 
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Table 2.5 Hydrolysis of A/B ring esters. 
 
entry R 53 51 yield (%) 
1 H 53a 51a 100 
2 Bn 53b 51b 100 
3 
 
53c 51c 0 
  
This second series of analogs was evaluated for activity in the COHb half-life assay as 
well as in a hemolysis screen (see Table 2.6, below). We found that both analogs had 
longer COHb half-lives relative to IRL 1 but that neither caused hemolysis. Eliminating the 
indole ring completely (51a) significantly increased the half-life, indicating the importance 
of a substituent in that position. Furthermore, simple replacement of the indole ring with a 
phenyl ring (51b) did slightly decrease the activity. This allows us to conclude that not only 
is it necessary to have an aromatic substituent in this position, but it is also important to 
have the pyrrole ring of the indole. It is possible that the indole is making some H-bond 
interactions or helping to improve aqueous solubility. To further investigate this, we would 
like to continue to pursue the synthesis of imidazole 51c, while also exploring the 
replacement of the L-Trp moiety with other amino acids, such as L-tyrosine, L-lysine and 
L-alanine. 
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Table 2.6 Evaluation of COHb half-life of A/B ring analogs 
 
 
SECTION 2.2 BENZOYL ANALOGS  
The most readily modified region of IRL 1 is arguably the D 
ring (see Figure 2.5), where one could imagine readily 
substituting other benzoyl groups for the 3,5-dimethyl 
benzoyl moiety. We chose to explore different analogs of 
the D ring, beginning with the introduction of H-bond donors 
and acceptors, to tease out any further SAR that could be 
exploited for the improvement of our analogs. 
Retrosynthetically, we planned to introduce variations to the D ring using Boc-protected 
amino ester 55 as an intermediate (see Scheme 2.8, below), which would  be derived 
from L-Trp (34) and D-Phe (36).  
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Scheme 2.8 Retrosynthetic analysis of D ring analogs. 
 
Section 2.2.1 Hydrogen bond donors and acceptors 
There are several potential H-bonding partners surrounding the binding site of IRL 1/2500 
that we hoped to recognize with suitably substituted benzoyl analogs 54. Specifically, 
there are several histidines (His β143 and His β002) in proximity of the D ring with which 
suitably substituted analogs could interact (see Figure 2.6, below). 
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Figure 2.6 IRL 2500 in β cleft surrounded by labeled cationic residues. 
 
Additionally, increasing the number of heteroatoms in IRL would likely increase the 
aqueous solubility and decrease the cLogP. Further, we wished to explore the removal of 
the methyl substituents on the D ring, which we expected would improve solubility and 
lead to decreased cLogP values. Finally, we wanted to explore the functional group 
tolerance of the IRL D ring. Due to the ready availability of substituted benzoic acid 
precursors, we chose to look at a series of pyridyl D rings, including picolinyl peptide 54c, 
nicotinyl peptide 54d and isonicotinyl peptide 54e, for our H-bond acceptors (see Figure 
2.7, below). For H-bond donors/acceptors, we chose to look at a series of phenolic D rings, 
specifically salicyl peptide 54f and 3 and 4-hydroxy benzoyl peptides (54g and 54h, 
respectively). In addition to these derivatives’ ability to make H-bonds, they allow us to 
  
43 
explore the effect of both electron donating and electron withdrawing groups on this ring. 
Additionally, we decided to look at the 3,5-dimethylbenzoyl derivative (54b) lacking IRL 
1’s N-methyl group to determine whether this perturbation would affect activity. We also 
decided to explore the bare benzoyl ring (54a). 
 
Figure 2.7 Initially proposed D ring analogs. 
 
Synthesis of dipeptide 55 proceeded quantitatively in three steps from the starting amino 
acids (see Table 2.7, below). The Boc-group of intermediate 55 was then deprotected and 
the resulting amine was coupled with the corresponding benzoic acids. While the benzoyl 
and picolinoyl analogs (56a-e) were obtained in good yield, the phenolic acids were less 
efficient partners in the coupling reaction, specifically for the 2- and 4-hydroxybenzoyl 
analogs. 
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Table 2.7 Coupling of dipeptide 61 with benzoic acids. 
 
entry R’ 56 yield (%) 
1 Ph 56a 82 
2 3,5-di-Me-C6H3 56b 82 
3 2-pyridyl 56c 100 
4 3-pyridyl 56d 100 
5 4-pyridyl 56e 100 
6 2-HO-C6H4 56f 0 
7 3-HO-C6H4 56g 86 
8 4-HO-C6H4 56h 30 
 
We hypothesize that this is due to the lower electrophilicity of the phenol due to its ability 
to donate electron density into the ring (see Scheme 2.9, below). We also believe that the 
coupling of salicylic acid may have also been problematic because of the phenol’s ability 
to coordinate with the HATU intermediates and hinder reactivity (see 57). To resolve this, 
we decided to protect the salicyl phenol (58) as an acetate group prior to coupling (59), 
which allowed us to generate acetate 56r in modest yield. 
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Scheme 2.9 Synthesis of modified salicylic acid 56r. 
 
Saponification of the methyl esters proceeded smoothly for all analogs (see Table 2.8, 
below). 
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Table 2.8 Saponification of D ring derivatives. 
 
entry R’ R 56 54 yield (%) 
1 Ph Ph 56a 54a 90 
2 3,5-di-Me-C6H3 3,5-di-Me-C6H3 56b 54b 81 
3 2-pyridyl 2-pyridyl 56c 54c 92 
4 3-pyridyl 3-pyridyl 56d 54d 100 
5 4-pyridyl 4-pyridyl 56e 54e 68 
6 2-AcO-C6H4 2-HO-C6H4 56r 54f 80 
7 3-HO-C6H4 3-HO-C6H4 56g 54g 100 
8 4-HO-C6H4 4-HO-C6H4 56h 54h 96 
 
The COHb half-life activity proved very 
interesting for this series. Specifically, 54b 
was equipotent with IRL 1, which 
established that the N-methyl group is 
unnecessary for activity (see Table 2.9, 
below). As a result, the analogs were all 
prepared as the secondary amides. The next 
most potent analog was 54f. We noticed an interesting trend among the H-bond donors 
and acceptors where the most potent of both the pyridyl (54c-54e) and phenolic series 
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Figure 2.8 Close up of D ring contacts 
with Lys β082. 
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(54f-54h) had substitution in the 2-position (54c and 54f, respectively). The next most 
potent in this series is the analog with substitution in the 3-position (54d and 54g, 
respectively) and the least potent analog has substitution at the 4-position (54e and 54h, 
respectively). We hypothesized that this might be occurring due to a H-bond between the 
substituents at the 2- and 3-position and Lys β082, which have distances of 4 (shown in 
Figure 2.9) and 4.5 Å, respectively. The difference between the activity of the analogs 
with substitution at the 2-position and the 3-position, respectively, might be due to the 
increasing distance from the Lys as the substituent moves from the 2- to the 3- to the 4-
position (see Figure 2.8, above). Finally, it is interesting to note that the bare benzoyl 
analog 54a showed significantly decreased activity relative to IRL 1, likely due to the 
reduced hydrophobicity of this analog. 
Table 2.9 Results of biological screen of initial D ring analogs 
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Section 2.2.2 Polyacid analogs 
Based on the results of our previous 
biological study, indicating possible H-
bonding with a Lys residue in the β cleft, we 
designed derivatives of IRL 1 that would allow 
us to further exploit these proposed 
interactions. As discussed in Section 2.2.1, 
there are several cationic residues in the β 
cleft surrounding the binding site of DPG and 
IRL 2500 (see Figure 2.10) and some are in 
close proximity to IRL 2500 (see Figure 2.9, 
above). Using the crystal structure, we designed several carboxylic acid containing 
analogs that would allow us to pick up interactions with these residues. Specifically, His 
β002 and His β143 in reasonable proximity to (7.4-7.8 Å) the D ring. 
 
Figure 2.10 Pictorial representation of IRL in binding site. 
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To target these residues, we chose to synthesize carboxylic acids with varying distances 
from the D ring (see Figure 2.11, below). However, based on length and position, we 
expected that the derivatives 54i and 54k to be most successful. This is because the 2-
position of the D ring appeared most poised to reach the His β002, with a 7.4 Å distance 
from the methyl group of IRL 2500 (see Figure 2.9, previous page and Figure 2.10, 
above). Examining analogs with carboxylic acids either directly attached to the D ring or 
alkylated to a phenol also allowed us to further explore the effect of electron donating and 
withdrawing substituents on the ring. We also decided to explore an analog of the IRL C 
ring (60), which also is closely positioned to two His residues, as illustrated in Figure 2.9 
and 2.10. 
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Figure 2.11 Initially proposed polyacid derivatives. 
 
To synthesize 54i and 54k, we began with their parent D ring hydroxybenzoic acids (61, 
see Table 2.10, below). Following deprotonation with excess sodium hydride, the acids 
were treated with ethyl bromoacetate to alkylate the resultant phenoxides. 
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Table 2.10 Synthesis of m-carboxymethyl esters. 
 
entry R R’ R" 61 62 56 yield (%) over 3 steps 
1 H H 
3-(EtOOCCH
2
O)-
C
6
H
4
 61i 62i 56i 20 
2 OH OCH2OOEt 
3,5-di(EtOOCCH
2
O)-
C
6
H
4
 61k 62k 56k 28 
 
The resulting alkylated acids (62) were then subjected to standard coupling conditions to 
generate the alkylated esters 56. Saponification under our standard conditions produced 
polyacids 54i and 54k (see Table 2.11, below). Similar conditions were initially attempted 
in the synthesis of 54j but were unsuccessful. 
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Table 2.11 Synthesis of m-carboxymethyl acids. 
 
entry R’ R 56 54 yield (%) 
1 3-(EtOOCCH2O)-C6H4 
3-(HOOCCH2O)-
C6H4 56i 54i 83 
2 3,5-di(EtOOCCH2O)-C6H4 
3,5-di(HOOCCH2O)-
C6H4 56k 54k 49 
 
The synthesis of 54j was undertaken beginning from 54h, synthesized in our previous 
screen (see Table 2.7, above).  Alkylation with ethyl bromoacetate, followed by 
saponification, yielded compound 54j in good yield (Scheme 2.10). 
 
Scheme 2.10 Synthesis of 54j. 
 
The C ring derivative 60 was synthesized similarly to the D ring analogs (see Scheme 
2.11, below). Initially, to build the dipeptide scaffold we coupled L-Trp methyl ester 22 and 
Boc protected D-Tyr (63). The resulting phenol (64) was then alkylated with ethyl 
bromoacetate. Amino ester 65 was then deprotected and coupled to 3,5-dimethybenzoic 
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acid (35) to generate the full-length scaffold 66, which was saponified to generate the final 
compound (60).  
 
Scheme 2.11 Synthesis of 60. 
 
Next, we synthesized the two phthalic acid analogs (54m and 54l). Using intermediate 55 
from previous syntheses, we first coupled the mono methyl ester phthalic acids to the IRL 
scaffold (see Table 2.12, below). 
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Table 2.12 Coupling of diesters 56m and l. 
 
entry R’ 56 yield (%) 
1 m-MeOOC-C6H4 56m 49 
2 p-MeOOC-C6H4 56l 34 
 
We then saponified the resulting esters (56m and 56l) to generate the final two 
dicarboxylic acid analogs (Table 2.13). 
Table 2.13 Saponification of diacids 54m and l. 
 
entry R’ R 56 54 yield (%) 
1 m-MeOOC-C6H4 m-HOOC-C6H4 56m 54m 49 
2 p-MeOOC-C6H4 p-HOOC-C6H 56l 54l 34 
 
This series was analyzed for its ability to reduce COHb half-life. Interestingly, none of the 
analogs were more potent than IRL 1 (see Table 2.14, below). In fact, none of the 
screened analogs had potency even approaching IRL 1. This led us to conclude that not 
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only were these analogs unable to pick up interactions within the β cleft of Hb, but these 
analogs might not even be effectively binding to Hb at all. We hypothesized that this 
decrease in activity might be due to increased negative charge, which could make it more 
difficult for our analogs to leave the aqueous environment and bind in the hydrophobic 
pocket.  
Table 2.14 Biological activity of polyacid analogs. 
 
 
Section 2.2.3 Hydrophobic IRL analogs 
Based on this and previous results, we hypothesized that our binding affinity might be 
affected significantly by hydrophobicity. Due to the reduced activity of the polyacid 
analogs, we decided to explore the effect of adding more hydrophobic groups to the D ring 
(see Figure 2.12, below). To that end, we synthesized an IRL 1 D ring sulfonamide 
isostere (67), a bis-trifluoromethyl isostere (54n), two naphthyl derivatives (54o and 54p) 
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and finally an ortho aniline (54q), which we wished to explore based on the relative 
success of the ortho phenol analogs (54f). 
 
Figure 2.12 Hydrophobic analogs. 
 
The synthesis of analogs 54n-q, was similar to the previous D ring analogs. Intermediate 
55 was first deprotected and then coupled to the benzoyl derivatives (see Table 2.15, 
below). 
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Table 2.15 Coupling of hydrophobic analogs. 
 
entry R 56 yield (%) 
1 3,5-di-CF3-C6H3 56n 70 
2 α-naphthyl 56o 100 
3 β-naphthyl 56p 85 
4 o-BocNH-C6H4 56q 88 
 
These analogs were then saponified to yield the products (see Table 2.16). 
Table 2.16 Saponification of hydrophobic analogs. 
 
entry R 56 54 yield (%) 
1 3,5-di-CF3-C6H3 56n 54n 92 
2 α-naphthyl 56o 54o 76 
3 β-naphthyl 56p 54p 86 
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In the case of 54q, where the resulting carbamate acid was then Boc deprotected to yield 
the ammonium salt (54q) (Scheme 2.12). 
 
Scheme 2.12 Deprotection of amine 54q. 
 
Sulfonamide 67 was synthesized from the same intermediate 55, but the coupling reaction 
was performed with sulfonyl chloride 69 to generate ester 70 which was ultimately 
saponified (see Scheme 2.13). 
 
Scheme 2.13 Synthesis of sulfonamide isostere. 
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This final series of D ring analogs was analyzed for COHb half-life lowering activity. 
Interestingly, each of these analogs, except for 54q, had activity that was extremely close 
to that of IRL 1 (see Table 2.17). In fact, one of the naphthyl analogs (54o) had significantly 
improved activity relative to IRL 1. Additionally, two of the analogs, bis-trifluoromethyl 
benzamide acid 54n and naphthyl acid 54p, caused hemolysis when screened. This was 
not unexpected given their cLogPs of 5.9 and 4.8, respectively, but it does highlight a 
significant conundrum. Based on these data, the pocket containing the D ring appears to 
best accommodate highly hydrophobic moieties, which lead to undesired hemolytic 
activity. 
Table 2.17 COHb Half-life for hydrophobic D ring analogs. 
Significance relative to IRL 1 * where P ≤ 0.05, ** where P ≤ 0.01, *** where P ≤ 0.001 
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SECTION 2.3 N-SUBSTITUTED ANALOG 
Given the poor success introducing solubilizing groups to 
the D ring, we decided to explore the introduction of 
solubilizing groups in place of the N-methyl group in IRL 1 
(Figure 2.13). Because the N-methyl group is not 
necessary for activity (see Figure 2.7, 54b), we expected 
that the addition of further functionality to this position 
would not have a deleterious effect on activity. To explore 
this, we decided to introduce a carboxy methyl group in this position to further improve 
solubility. We imagined that we could access this analog through reductive amination on 
the N-Boc deprotected intermediate 55 (see Scheme 2.14, below). 
 
Scheme 2.14 Retrosynthetic analysis of N-substituted analog. 
 
In the forward sense, from dipeptide 55 (see Scheme 2.15), we first deprotected the Boc 
group, then performed a reductive amination with ethyl glyoxylate to generate the 
disubstituted amine, which was benzoylated with 3,5-dimethylbenzoyl chloride to generate 
ester 73. This ester was then saponified to generate the target diacid 71. 
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Figure 2.13 N-substituted 
IRL analog. 
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Scheme 2.15 Synthesis of N-carboxymethylated analog. 
 
We submitted this analog for biological testing and hemolytic assay (see Table 2.18). 
Although the N-carboxymethylated compound did not cause hemolysis, it showed almost 
no activity against COHb and it was concluded that further alterations at this nitrogen 
would likely not retain or improve activity. 
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Table 2.18 COHb half-life lowering activity of N-carboxymethylated IRL analog. 
 
 
SECTION 2.4 CONCLUSIONS 
To summarize, our first generation of IRL 1 derivatives 
include substitution in both the L-Trp (A/B) and the 
dimethyl benzoyl regions (D). For the L-Trp derivatives, 
we explored the substitution of the carboxylic acid with 
either a phosphate or tetrazole. We also probed the 
functional group tolerance of the L-Trp sidechain (see 
Figure 2.15, below). We found that substitution of the 
phosphate for a carboxyl had no effect on activity, while the tetrazole significantly 
decreased activity, suggesting that introduction of a phosphate to further IRL derivatives 
might improve the solubility and cLogP without adversely affecting activity. Assay of the 
A/B ring analogs indicates that the indole is important for COHb half-life lowering activity, 
but there is still the potential for further exploration in this region. 
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Figure 2.15 Summary of L-Trp analogs. 
 
The dimethyl benzoyl region (or D ring) shows very poor functional group tolerance, 
particularly for the introduction of heteroatoms and other hydrophilic groups (see Figure 
2.16, below). The most well tolerated analogs appear to be those that introduce a greater 
degree of hydrophobicity into the ring system. One of our most hydrophobic analogs, 
naphthyl 54o, is significantly more potent than IRL 1. This leads us to conclude that greater 
activity can be obtained by increasing the hydrophobic surface area of the D ring. 
Unfortunately, it also presents a conundrum given that both aqueous solubility and 
hemolytic activity are negatively affected by increasing hydrophobicity. To overcome this 
in our second generation derivatives, we decided to explore analogs that introduce a 
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greater number of aromatic substituents, while also introducing more heteroatoms to 
mitigate the adverse effect on cLogP, which we will discuss in Chapter 3. 
 
Figure 2.16 Summary of D ring analogs. 
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CHAPTER 3 SECOND GENERATION DERIVATIVES  
SECTION 3.1 BIARYL DERIVATIVES 
Following the SAR survey of the L-Trp derived region and 
the benzoyl moiety of IRL 1, we concluded that the most 
effective analogs also had the greatest hydrophobic surface 
area. This conclusion led to a conundrum. Based on the 
analysis that we had performed, we determined that 
analogs with greater hydrophilicity would be less likely to 
cause hemolysis and would also have better solubility for in 
vivo studies. This directly contradicts the COHb half-life data, which indicated that the 
more hydrophobic compounds had better activity. For this reason, we decided to explore 
alterations to the biphenyl ring (see Figure 3.1). Specifically, we wanted to introduce 
different heterocycles at the 4-position of the D-Phe derived ring (C ring) to try to improve 
the solubility and cLogP, while maintaining a large hydrophobic surface area. 
 
Section 3.1.1 Synthesis of biaryl precursor 
We envisioned accessing the biaryl analogs through Suzuki cross-coupling on a full length 
IRL scaffold (see Scheme 3.1, 75, where X = Hal or OTf). We planned to derive this 
intermediate from amino acid 76 (where X = Hal or OTf) and coupling partners 22 and 35. 
Figure 3.1 IRL C ring 
analogs. 
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Scheme 3.1 Retrosynthetic analysis of biaryl analogs. 
 
In the forward sense, D-Phe was subjected to oxidative iodination conditions to install 
iodine in the para position, generating para-iodo-D-Phe in good yield (see Scheme 3.2, 
below). This reaction occurs through a well-precedented acid-catalyzed oxidative 
iodination, whereby periodate, in the presence of strong acid, forms a reactive 
protoperiodate (HIO4), which subsequently generates the iodosulfate ion pair (IOSO3H).1 
In such strongly ionizing conditions, the iodosulfate functions as a source I+, which is able 
to promote electrophilic aromatic substitution (SEAr) on the arene substrate, generating 
the final iodinated product 77. 
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3 I2 + I(VII) → 7 I+	 preliminary stoichiometry 	
NaIO4 + H2SO4 → NaHSO4 + HIO4 true oxidant in the system  
7 ArH + 7 IOSO3H → 7 ArI + 7 H2SO4 arenium ion mechanism, SE2  
7 ArH + 3I2 + NaIO4 + H2SO4 → 7 ArI + NaHSO4 + 4 H2O 
Scheme 3.2 Oxidative iodination.1 
 
Iodide 77 was then Boc protected and the resulting carbamate was coupled to amino ester 
22. The resulting amino ester was Boc deprotected to generate dipeptide 79 (see Scheme 
3.3, below). Amine 79 was then coupled to benzoic acid 35 to generate the penultimate 
full-length scaffold 80. The resulting indole 80 was Boc protected to prepare intermediate 
81 to be used in Suzuki cross-coupling reactions. Overall, the synthesis of iodo coupling 
partner 81 was completed in six steps with a 61% overall yield.  
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Scheme 3.3 Synthesis of iodide Suzuki precursor. 
 
Section 3.1.2 Optimization of Suzuki cross-coupling 
Initially, we screened coupling conditions using the simplest aryl boronic acid: phenyl 
boronic acid (82) to allow correlation with IRL 2500. After screening two palladium sources 
and several different bases and solvents, summarized in Table 3.1 below, we determined 
the optimal conditions to be PdCl2(PPh3)2 and potassium acetate in dioxane (entry 4). 
With our most successful conditions in hand, we then began to screen other boronic acids 
using these coupling conditions. 
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Table 3.1 Initial Suzuki cross-coupling optimization on phenyl boronic acid. 
 
entry palladium source base solvent time temp (°C) yield 
1 Pd(PPh3)4 Cs2CO3 dioxane 24h 80 24% 
2 Pd(PPh3)4 Cs2CO3 toluene 24h 80 
59% 
(inseparable 
mixture) 
3 Pd(PPh3)4 Na2CO3 tol/MeOH 24h 80 36% 
4 PdCl2(PPh3)2 KOAc dioxane 24h 80 58% 
 
We next tested these conditions on a heteroaromatic system, 4-pyridylboronic acid (84, 
see Table 3.2). Unfortunately, the conditions identified in our previous screen yielded no 
desired product. After screening further, we found that PdCl2(dppf)·CH2Cl2 and sodium 
carbonate in a mixture of DMF and water at 80 °C gave us a moderate yield of pyridine 
83b (entry 6). 
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Table 3.2 Optimization of Suzuki cross-coupling on heteroaryl boronic acid. 
 
entry palladium source base solvent time temp (°C) yield 
1 PdCl2(PPh3)2 KOAc dioxane 48h 80-110 No rxn 
2 PdCl2(PPh3)2 KOAc toluene 48h 110 No rxn 
3 PdCl2(PPh3)2 KOAc tol/MeOH 48h 110 10% 
4 Pd(PPh3)4 Na2CO3 dioxane 48h 110 No rxn 
5 Pd(PPh3)4 Cs2CO3 dioxane 48h 80 No rxn 
6 PdCl2(dppf)·CH2Cl2 Na2CO3 DMF/H2O 24h 80 34% 
 
We applied our optimized coupling conditions from the synthesis of 83b to the coupling of 
the iodo-scaffold (81) with 2-furyl boronic acid (85, see Scheme 3.4, below). 
Unfortunately, these conditions were only modestly successful and gave a low yield of 
product with concomitant Boc deprotection. 
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Scheme 3.4 Further optimization of Suzuki cross-coupling. 
 
We hypothesized that the low yield might be due to hydrolysis of the ester. For this reason, 
we decided to switch to a weaker base (potassium acetate) in dry N,N-dimethylformamide, 
which should be less likely to cause hydrolysis. These conditions proved very successful, 
yielding furan 83c in a 96% yield, without loss of the Boc group (see Scheme 3.5). 
 
 
Scheme 3.5 Final conditions for Suzuki cross-coupling. 
 
Section 3.1.3 Application of Suzuki cross-coupling to SAR 
For SAR purposes, we wanted to explore heterocycles containing both nitrogen and 
oxygen and a combination of each. Beginning from inexpensive, commercially available 
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heterocyclic boronic esters and acids, we applied the optimized conditions from Scheme 
3.5 to the coupling reaction and they proved very robust (see Table 3.3).  
Table 3.3 Scope of Suzuki cross-coupling. 
 
entry R R’ 83 yield (%) 
1 Ph (OH)2 83a 76 
2 5-pyrimidyl (OH)2 83d 78 
3 
 
pin 83e 75 
4 
 
pin 83f 80 
 
These Boc esters were then deprotected and saponified to yield the final biaryl analogs 
74a-f (Table 3.4, below). 
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Table 3.4 Deprotection of biaryl analogs. 
 
entry R 83 74 yield (%) 
1 Ph 83a 74a 45 
2 2-furyl 83c 74c 43 
3 5-pyrimidyl 83d 74d 56 
4 
 
83e 74e 70 
5 
 
83f 74f 70 
 
Section 3.1.4 Biological results of initial biaryl derivatives 
With these analogs in hand, we tested the COHb half-life. After initially screening the biaryl 
analogs at 20 times the concentration of Hb (20x), we found that both furan 74c and 
isoxazole 74e, as well as biphenyl 74a had significantly improved activity compared to IRL 
1 (see Table 3.5). Due to their increased activity, we decided to also screen the 
compounds at five times the concentration (5x) of Hb, the highest concentration at which 
IRL 2500 can be screened. At 5x, biphenyl 74a, isoxazole 74e and furan 74c, were all 
significantly more potent than IRL 1. The furan 74c was found to have slight hemolytic 
activity (1-2% of total Hb at 5x Hb), which tracks with its cLogP of 5.9. It is important to 
note that although biphenyl 74a did not cause hemolysis, it was screened for hemolysis 
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at a much lower concentration (2x Hb) because of its poor solubility in the assay. IRL 2500 
caused significant hemolytic activity (>10% of total Hb at 4x Hb). Pyrazole 74f, pyrimidine 
74d and furan 74c are the only three compounds screened that had aqueous solubility at 
a concentration that would allow for in vivo experiments (2.5 mM in 1% DMSO). Based on 
these data, the two most promising analogs are isoxazole 74e and furan 74c. However, 
each showed problems, 74e with solubility and 74c with hemolytic activity. 
Table 3.5 Biological results for initial biaryl analogs. 
Significance relative to IRL 1 * where P ≤ 0.05, ** where P ≤ 0.01, *** where P ≤ 0.001 
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Section 3.1.5 Further biaryl design optimization 
Although the aforementioned analogs significantly 
improved potency relative to our lead compound, 
IRL 1, we believed there was still room for further 
improvement. Specifically, we wanted to develop an 
analog that retained the COHb half-life of the other 
analogs, but had improved solubility and no 
hemolytic activity. We proposed the synthesis of a 
second series of biaryl analogs derived from the 
best hits of the previous series. These analogs 
contain added solubilizing groups that we believed 
would reduce hemolytic activity while increasing solubility (furan 74g, isoxazole 74h, and 
alcohol 74i, see Figure 3.2, above). The isoxazole boronic ester precursors were not 
commercially available and therefore needed to be synthesized. The synthesis of the 
isoxazole boronic esters was undertaken starting from acid 87, which was first esterified 
to produce ester 88a using known conditions2,3 (see Scheme 3.8). 
 
Scheme 3.6 Synthesis of isoxazole precursors to iodination. 
 
This ester was either reduced to the alcohol 88b then iodinated or directly iodinated to 
produce iodo compounds 89a and 89b (Table 3.6, below). 
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Table 3.6 Iodination of isoxazoles. 
 
entry R 88 89 yield (%) 
1 CO2Me 88a 89a 100 
2 CH2OH 88b 89b 73 
 
Iodide 91b was then silyl protected to produce iodo precursor 89c (Scheme 3.7). 
 
Scheme 3.7 Silyl protection of isoxazole 89b. 
 
These iodides were then subjected to Miyaura borylation conditions to generate the 
corresponding boronic esters 90a and c (Table 3.7). 
Table 3.7 Miyaura borylation of isoxazoles. 
 
entry R 89 90 yield (%) 
1 CO2Me 89a 90a 100 
2 CH2OH 89c 90c 100a 
aproduct carried forward to the next reaction without further purification. 
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The boronic esters 90a and c, and 2-furyl-5-formyl boronic acid, which is commercially 
available, were then coupled to the iodo-IRL scaffold 81 (see Table 3.8). In the case of 
silyl alcohol 93c, coupling occurred with concomitant silyl ether deprotection to generate 
ester 83i.  
Table 3.8 Coupling of biaryl analogs 83h, i and k. 
 
entry R R’ R” 83 yield (%) 
1 
  
pin 83h 32 
2 
  
pin 83i 30 
3 5-furfural 5-furfural (OH)2 83k 59 
 
Aldehyde 83k was further subjected to reductive amination conditions to generate 
dimethyl amine 83j (Scheme 3.8, below).  
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Scheme 3.8 Reductive amination of biaryl furfural. 
 
All three analogs were then Boc deprotected and saponification to yield the second 
generation hetero-biaryl analogs (74h, i and j, see Table 3.9). 
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Table 3.9 Biaryl analog deprotection. 
 
entry R R’ 83 74 yield (%) 
1 
  
83h 74h 88 
2 
  
83i 74i 35 
3 
  
83j 74j 76 
 
Section 3.1.6 Biological activity of next generation of biaryl analogs 
These optimized biaryl analogs were then screened for COHb half-life lowering activity, 
solubility and hemolytic activity (see Table 3.10). Both alcohol 74i and furan 74j were 
significantly more potent than IRL 1. Of particular interest, alcohol 74i had activity on the 
order of the other most potent compounds, including IRL 2500, and did not cause 
hemolysis at high concentrations relative to Hb (5x). Additionally, 74i is one of the most 
soluble compounds we have prepared, with solubility well within the threshold for in vivo 
experiments (2.5 mM in 1% DMSO), making it an excellent candidate to advance for 
testing in mouse models. 
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Table 3.10 Biological results for optimized biaryls. 
Significance relative to IRL 1 * where P ≤ 0.05, ** where P ≤ 0.01, *** where P ≤ 0.001 
 
 
SECTION 3.2 NOVEL STRUCTURALLY CONSTRAINED DERIVATIVES 
Upon examination of the crystal structure of IRL 2500 in the β cleft, we observed that IRL 
2500 is bound in a relatively high energy conformation (see Figure 3.3, below). The 
constrained nature of this conformation is highlighted by the fact that the two opposite 
ends of the molecule, the D ring and the A/B rings, are proximally positioned, while the C 
ring is arrayed in the opposite direction in the cleft. This led us to hypothesize that if we 
were to tether IRL in such an orientation, we might be able to pre-organize the molecule 
in its optimal binding mode, thus improving its activity. 
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Figure 3.3 Space filling model of IRL 2500 in cleft with green arrow to indicate tether 
point. 
 
Section 3.2.1 Diketopiperazine derivatives 
  We decided that piperazine scaffold 91 would provide 
the best overlap with IRL 2500 in the crystal structure 
(see Figure 3.4). As initially designed the piperazine 
would contain either one or two acid moieties (91, R” and 
R”’) positioned to interact with the Lys β082 on either side 
of the cleft mimicking the acid in IRL 2500 (see Figure 
3.5, below). Also, it is important to note that all the rings 
align in the appropriate manner, with the A/B and D rings 
oriented to the left side of the central piperazine and the C ring positioned to the right. To 
position the D ring in the appropriate position, it is necessary to differentiate the two sides 
Figure 3.4 Piperazine 
analogs derived from 
diketopiperazines. 
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of the diketopiperazine ring by either N-methylating the R’ group of 91 or protecting it 
during the synthesis. Furthermore, the C ring of 91 would either contain an aryl ring in the 
para-position at the R, or a hydrogen, mimicking either IRL 1 or IRL 2500. 
 
Figure 3.5 Overlay of piperazine 91 (orange, where R=Ph, R’=H and R”=R”’=CO2H) on 
IRL 2500 (purple). 
 
We envisioned the synthesis of piperazine 91 occurring via nucleophilic addition of a 
carboxylate surrogate onto the imine 92, which would be generated in situ through partial 
reduction of diketopiperazine 93 (see Scheme 3.9, below). Diketopiperazine 93, in turn, 
would be derived from cyclization of the linear precursor 94. 
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Scheme 3.9 Retrosynthetic analysis of piperazine analog derived from 
diketopiperazine. 
 
These types of in situ nucleophilic additions have been performed on similar systems. We 
decided to use cyanide as our nucleophile, given its broad use and ability to be hydrolyzed 
to the acid. Recently, in the synthesis of (−)-renieramycin T, Yokoya, et. al. employed 
reductive cyanation to stereoselectively install the amino nitrile 96 of (−)-renieramycin, 
which is present in many 1,2,3,4-tetrahydroisoquinoline marine natural products (see 
Scheme 3.10, below).4 Additionally, reductive cyanations have been used in the total 
synthesis of aspeverin,5 (−)-lemonomycin,6 (−)-jorumycin,7 and others. As far as we are 
aware, reductive cyanation has never been attempted on a diketopiperazine. 
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Scheme 3.10 Reductive cyanation to generate advanced intermediate 96 in the 
synthesis of (−)-Renieramycin.4 
 
We first decided to access a diketopiperazine with a 
protecting group (PG) on the amide nitrogen that could 
be unmasked to the free amide/amine at the end of the 
synthesis (see Figure 3.6, 97). This would allow us to 
differentially benzoylate the advanced diketopiperazine. 
Initially, we chose to use an N-benzyl protecting group (97, where PG = -CH2Ph), which 
we planned to hydrogenate at the end of the synthesis. However, attempts to couple 
benzyl protected secondary amine 99 to N-Boc tryptophan proved very low yielding under 
a variety of coupling conditions (Scheme 3.11). 
 
Scheme 3.11 Attempted coupling of N-benzyl secondary amine. 
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We then decided we might have better success coupling a primary amine and protecting 
it after amide formation. Thus, N-phthaloyl tryptophan 101 and para-iodophenylalanine 
methyl ester 102 were coupled to generate dipeptide 103 (see Scheme 3.12, below). After 
initially attempting the ethyl carbamate protection of the amide and the indole in one step, 
we screened conditions to first protect the indole generating monocarbamate 104 and then 
to protect the amide generating the desired dicarbamate 105. Following protection, we 
attempted phthalamide deprotection and diketopiperazine formation, but were unable to 
achieve this transformation, in either a single or stepwise manner.  
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Scheme 3.12 Progress towards synthesis of bis carbamoyl diketopiperazine. 
 
We next pursued the N-methylated amino analog, 
which would simplify the protection scheme and 
allow for a more easily removed protecting group on 
the terminal nitrogen prior to diketopiperazine 
formation (see Figure 3.7). Beginning from the Boc 
protected para-iodophenylalanine (78), which can be accessed in two steps from D-Phe, 
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we N-methylated, then esterified and deprotected the resulting Boc-protected amino acid 
to yield N-methyl amino ester 109 (see Scheme 3.13, below). This ester was then coupled 
to N-Boc L-Trp, to yield the linear precursor 110, which was subsequently cyclized to the 
diketopiperazine 111. The diketopiperazine was then protected as the di-Boc to yield the 
precursor to Suzuki cross-coupling 112. Suzuki cross-coupling proved successful and the 
resulting isoxazole 113 was deprotected to yield the precursor to reductive cyanation 108. 
Unfortunately, we screened variety of cyanation conditions, but were never able to access 
bis-nitrile 114. 
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Scheme 3.13 Synthesis of isoxazole diketopiperazine 108. 
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nucleophilic displacement with cyanide followed by reduction, we could access nitrile 114 
(see Scheme 3.14). 
 
Scheme 3.14 Retrosynthesis of piperazine 114 through S-methyl 116. 
 
The electrophilicity of thioimidates has been used previously, particularly with Grignard 
reagents, such as in the synthesis of histrionicotoxin by Evans and coworkers.8 However, 
displacement of the thioimidate with cyanide is unprecedented. We decided to test this 
reaction with a model system. Beginning with δ-valerolactam 117, the thiolactam model 
system was made with Lawesson’s reagent yielding thiolactam 118. This thioamide was 
then quantitatively converted to thioimidate 119, which was ready for displacement 
screening (Scheme 3.15). 
 
Scheme 3.15 Synthesis of reductive cyanation model system. 
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Unfortunately, although several cyanation conditions were attempted (summarized in 
Table 3.11, below), we never observed the formation of the desired nitrile addition product. 
For this reason, we decided to forgo attempts to try this reaction with our advanced 
precursor 116. 
Table 3.11 Reductive cyantion conditions. 
 
entry reagents solvent temperature result 
1 KCN, 18-crown-6 DMF 100 °C recovered S.M. 
2 KCN, 18-crown-6 MeOH 60 °C MeOH addition product 
3 TMSCN, neat; NaBH3CN THF r.t. decomposition 
4 TMSCN, TiCl4, Et2O, CH2Cl2; NaBH4 THF r.t. 
ring opened 
products 
5 t -BuNC CH2Cl2 r.t. to reflux recovered S.M. 
6 4N HCl/dioxane, t-BuNC THF r.t. decomposition 
 
We next attempted to generate the carboxymethyl piperazine analog (121, see Scheme 
3.16) through S-alkylation with bromoacetate (122) followed by rearrangement and sulfur 
extrusion to give the unsaturated β-aminoester (not shown).9,10 As far as we are aware, 
this rearrangement has never been attempted on a bis-thiolactam.  
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Scheme 3.16 Retrosynthesis of carboxymethylpiperazine 121 through S-alkylated 122. 
 
To do this, we needed the bis-thioamide of diketopiperazine 108. Unfortunately, 
thioamidation proved to be more problematic than originally anticipated. Treatment of 108 
with Lawesson’s reagent at room temperature in either tetrahydrofuran or 
dichloromethane only ever led to partial conversion to the mono-thiolactam (see Scheme 
3.17, 123), which NMR analysis suggested was regioisomer 123. 
 
Scheme 3.17 Partial thiolactam formation. 
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With more forcing conditions, we achieved conversion to the bis-thiolactam 116, but with 
concomitant epimerization (see Scheme 3.18). This result led us to conclude that access 
to the second lactam of diketopiperazine 108 is likely very hindered. 
 
Scheme 3.18 Conversion to the bis-thiolactam with concomitant epimerization. 
 
We proceeded to take one epimer of thiolactam 116 and subject it to the bromoacetate 
alkylation conditions, however, we only observed decomposition of the starting material 
(see Scheme 3.19, below). 
 
Scheme 3.19 Attempted thiolactam alkylation with ethyl bromoacetate. 
 
Section 3.2.2 Piperazine derivatives 
At this point, we decided to explore other compounds that might similarly overlay with IRL 
2500 in the cleft. The most logical analogs we could imagine were mono-acid piperazines 
124, which could be generated from hydrolysis of the nitrile 125, which could result from 
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cyclization of nitrile 126 (see Scheme 3.20). Nitrile 126 could be derived from a Strecker 
reaction between L-Trp aldehyde 128 and a D-Phe amino ester derivative 127. 
 
Scheme 3.20 Retrosynthetic analysis of mono acid 124 derived from a Strecker 
reaction. 
 
Starting from acid 129, we generated Weinreb amide 130 which was subsequently 
reduced to aldehyde 131 using known conditions (see Scheme 3.21).11 Aldehyde 131 was 
taken directly to the Strecker reaction with D-Phe methyl ester to generate linear nitrile 
132 as a single diastereomer. This pseudo-peptide was then cyclized with morpholine in 
tetrahydrofuran, to generate ketopiperazine 133. 
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Scheme 3.21 Synthesis of cyclized cyano-piperazinone 133. 
 
We next decided to screen conditions for the hydrolysis of nitrile 133 to either an ester or 
acid (134, see Scheme 3.22). The most well-precedented approach to hydrolyzing nitriles 
uses strongly acidic conditions.12,13  
 
Scheme 3.22 Retrosynthesis of carboxylic acid/ester 134 from nitrile 133. 
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Because of this, we expected that the Boc group would also be deprotected in the same 
step. For ease of purification, we decided to synthesize the ester instead of the acid. 
Normally nitrile hydrolysis to the ester is more mild than hydrolysis to the acid. These 
conditions typically call for a source of hydrochloric acid (HCl) (either thionyl chloride, 
acetyl chloride or aqueous HCl) and use ethanol or methanol as the solvent.14 
 
We employed these conditions with our substrate, but found them to be unsuccessful in 
hydrolyzing nitrile 133 (see Scheme 3.23, below). We instead only observed an 
inseparable mixture of de-Boc starting material and a side product, which we believed to 
be the result of indole cyclization and aromatization based on the absence of aliphatic 
peaks observed in the proton NMR (see proposed side product 136, Scheme 3.23). The 
proto-nitrile intermediate 135 that is formed during hydrolysis is poised to undergo 
cyclization which could further undergo aromatization to a b-carboline, leading to several 
possible undesired side products. Unfortunately, the side product that was observed was 
not stable to isolation. We therefore decided that acid hydrolysis might prove challenging 
and that we would pursue alternate methods of hydrolysis. 
 
Scheme 3.23 Attempted acid hydrolysis of nitrile 132 yielded undesired side product 
tentatively assigned as 135, via intermediate 134. 
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Base hydrolysis of nitriles to acids is not nearly as well precedented, with relatively few 
examples in the chemical literature,15–17 and our attempts at hydrolysis under basic 
conditions only led to decomposition. Given that direct hydrolysis to the acid or ester was 
problematic, we hypothesized that hydrolysis to the amide, followed by further hydrolysis 
to the acid in two discreet steps might be less likely to generate the reactive intermediate 
135 observed in Scheme 3.23. To that end, we first hydrolyzed nitrile 133 to the amide 
137, which proceeded smoothly (see Scheme 3.24, below). Using forcing acid hydrolysis 
conditions in a sealed vessel, we hydrolyzed the primary amide to the ester, but with 
concomitant hydrolysis of the secondary amide to generate linear diester 138. While we 
were unable to affect selective hydrolysis, re-cyclization of diester 138 led to formation of 
hydrolysis product 139 of the original nitrile 133.  
 
Scheme 3.24 Hydrolysis of nitrile 132 to ester 138. 
 
As stated previously, the Strecker reaction leads to the formation of only one of two 
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Scheme 3.24) were not well resolved, we observed excellent resolution between the three 
methines of amide 137 (see Figure 3.8A). Based on the observed splitting of methine 4 
(J = 4.1 Hz) we deduced that the two adjacent protons 3 and 4 were likely on the same 
face of the ring. Using NOESY, we observed a non-sequential correlation between 
methine 4 and one of the protons of methylene 7, further validating this observation. We 
have used these data to assign the relative stereochemistry of compound 137, and by 
reference 132, 133, 138 and 139, as indicated in Figure 3.8B, below. 
 
 
Figure 3.8 A. 1HNMR indicating methine protons. B. NOE observed between methine 4 
and methylene 7. 
 
We are currently screening conditions for the reduction of lactam 139 to secondary amine 
140, in order to advance ester 140 to the benzoylated analog 141 (Scheme 3.25).  
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Scheme 3.25 Advancement to tethered analog 141. 
 
However, we also saponified the diaryl ester 139 to acid 142, to generate another analog, 
which was sent for biological evaluation (see Scheme 3.26, below). 
 
Scheme 3.26 Completion of acid 141 for biological evaluation. 
 
We have modeled acid 142 in the Hb binding site, overlaid on IRL 2500 and it shows good 
overlap with the indole and biphenyl substituents (see Figure 3.9). However, it lacks the 
dimethylbenzoyl functionality of IRL 1 and 2500. 
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Figure 3.9 Overlay of acid 142 (purple) with IRL 2500 (tan) in b cleft. 
 
Section 3.2.3 Biological results for de novo analogs 
We have submitted two piperazine analogs, diketopiperazine 108 and ketopiperazine 142, 
for biological evaluation, while working to complete the synthesis of our triaryl acid 141. 
 
Figure 3.10 Novel analogs screened for biological activity. 
 
Biological assay of these analogs indicate that the cyclic analogs have almost no half-life 
lowering activity (see Table 3.12, below). Given that acid 142 contains the same 
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carboxylic acid present in IRL 1, but does not show any half-life lowering activity, it is likely 
that it is unable to interact with the Lys β082 in the cleft. However, the addition of the 
dimethylbenzoyl ring in the proposed triaryl analog (141) may overcome the shortcomings 
of acid 142. Diketopiperazine 108 did not cause hemolysis but was not aqueous soluble 
at the concentration necessary for in vivo work. The hemolysis and solubility screening of 
ketopiperazine 142 is still underway as of this writing. 
Table 3.12 COHb half-life results for current de novo analogs. 
Significance relative to IRL 1 * where P ≤ 0.05, ** where P ≤ 0.01, *** where P ≤ 0.001 
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SECTION 3.3 CARBON MONOXIDE ON AND OFF RATES 
Although we know that the IRL compounds promote the conversion of COHb to oxyHb, 
we did not know how these compounds affected the kinetics of CO binding to Hb (see 
Scheme 3.26).18 
 
Scheme 3.27 Reversible binding of CO to Hb.18 
 
To determine this, the on and off rates of CO binding to Hb using stop flow spectrometry 
were measured in the Zapol Laboratory. The CO on rate (kon) and CO off rate (koff) were 
measured with most potent analogs (54p, 74a, 74c, 74e, 74i and 74j) and the least potent 
analogs (54i and 54j) from our COHb half-life assay. The results of this assay indicate that 
both kon and koff are affected by treatment with the IRL analogs (see Table 3.13). 
Table 3.13 Summary of CO on and off rates. 
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Furthermore, we correlated kon and koff with the COHb half-life data and found that in both 
cases the R-squared coefficient is above 0.9, indicating a good linear correlation between 
these two measures of efficacy (see Table 3.14A and B). 
Table 3.14 A. Correlation between COHb half-life and Kon. B. Correlation between 
COHb half-life and Koff. 
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These new data further validate our initial COHb half-life results using a different measure 
of CO binding Hb. In addition, these data indicate that the IRL analogs can both decrease 
the rate that CO binds to Hb, and also to increase the rate that CO dissociates from Hb. 
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SECTION 3.4 CONCLUSIONS 
We have prepared 35 analogs, exploring modifications to 
the carboxylic acid, the A/B rings, the C ring, the D ring and 
the N-methyl amide (see Figure 3.11). We chose to explore 
the functional group tolerance across the entire scaffold, 
with a focus on decreasing the cLogP to improve aqueous 
solubility and prevent hemolysis. Our results indicate a 
delicate balance between adequate hydrophilicity to 
improve aqueous solubility and prevent hemolysis, and sufficient hydrophobicity to afford 
potency. For this reason, in our second generation, we have pursued compounds in which 
the 4-position of the C ring is modified by adding heteroaromatic rings that aid in solubility 
while retaining the hydrophobic surface area necessary for potency. 
  
With the introduction of the second generation, we demonstrated that we can reduce the 
COHb half-life significantly relative to IRL 1, without causing hemolysis. Five of the biaryl 
analogs we assayed, biphenyl 74a, furan 74c, isoxazole 74e, alcohol 74i and 
dimethylamine 74j, are significantly more potent than IRL 1 (see Figure 3.12). 
Additionally, three analogs, biphenyl 74a, furan 74c and alcohol 74i are within the potency 
range desired to forward them to in vivo studies. Of these analogs, furan 74c and alcohol 
74i also exhibit the solubility necessary for further studies, and alcohol 74i does not cause 
hemolysis at high concentrations relative to Hb (5x). For this reason, we are planning to 
forward alcohol 74i to a mouse model of carbon monoxide poisoning. 
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Figure 3.12 Second generation analogs with greater potency than IRL 1. 
 
In addition to these modified IRL analogs, we explored the synthesis of a several novel 
piperazine-derived analogs that demonstrated good modeled structural overlap with IRL 
2500 in the crystal structure. The intermediates in our proposed reaction sequence do not 
achieve potency comparable to that seen with IRL 1. We hypothesize that introduction of 
a third ring, mimicking the D ring of IRL 2500, will lead to increased potency. Synthesis of 
this series is ongoing. 
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APPENDIX A. GENERAL METHODS AND 
EXPERIMENTAL PROCEDURES 
SECTION	A.1 GENERAL METHODS 
Section A.1.1 Measurement of COHb half-life 
Carboxyhemoglobin (COHb) was prepared by mixing oxyhemoglobin with CO saturated 
Dulbecco’s phosphate buffered saline (DPBS) buffer. CO buffer was prepared by bubbling 
DPBS with 1% CO gas (balanced with nitrogen) for 30 minutes. COHb and compounds 
(dissolved in dimethyl sulfoxide) were mixed in Falcon tubes and then dispensed to a 384-
well plate. The final concentration of hemoglobin was 10 μM and dimethyl sulfoxide 
(DMSO) was 5 vol % in DPBS. The final concentration of tested compound was 200 μM 
(20 fold excess) or 50 μM (5 fold excess).   
 
The prepared 384 well plate was placed in an inflatable polyethylene chamber (AtmosBag, 
Sigma) and the chamber was inflated with 1% CO (balanced with nitrogen). The plate was 
shaken at 2000/minute for 1 hour to equilibrate CO gas with the COHb solution. The plate 
was then sealed with a plastic seal (Cag. 60941-120, VWR) and centrifuged at 2000g for 
10 second. The plastic seal was removed before the plate was transported to the plate 
reader. Absorption spectrum of solution in each well was measured at from 500nm to 
700nm every 15 minutes for 90 minutes using a plate reader (Multiskan Go, Thermo 
Scientific). COHb percentage of each solution at each time point was calculated by 
deconvoluting the spectrum. The COHb half-life for each solution was calculated by fitting 
the COHb percentages at all time points with a single exponential decay equation. Method 
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provided and used with permission by Liu, C.; Nakagawa, A.; Zapol, W. M.; 2016. 
Massachusetts General Hospital. 
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Section A.1.2 Hemolysis assay 
Human whole blood was collected under the approval by the IRB of Partners Human 
Research Committee. After obtaining informed consent from volunteers, blood was drawn 
from the volunteers into tubes coated with EDTA. The concentration of hemoglobin 
tetramer of the blood was determined using a blood gas analyzer (ABL 800 FLEX, 
Radiometer Medical). The blood was diluted using TES buffer and mixed with DMSO 
and/or compound. The final concentration of hemoglobin tetramer and compound was 50 
µM and 1 mM in 0.1 vol % DMSO respectively. The mixture was incubated at 37 °C for 60 
minand then the mixture was centrifuged at 2,800g for 20 min. After the centrifugation, the 
absorption of the supernatant was measured at wavelength of 415 nm and compared to 
the absorption of 0.5 µM hemoglobin (A415ctrl , 0.5 µM of hemoglobin tetramer corresponds 
to 1% hemolysis of RBCs). If A415sample was smaller than A415ctrl, we concluded that 
hemolysis caused by the tested compound was below 1%. Method provided and used 
with permission by Liu, C.; Nakagawa, A.; Zapol, W. M.; 2016. Massachusetts General 
Hospital. 
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Section A.1.3 Determination of kon(CO) and koff(CO)   
The association and dissociation rate constants of carbon monoxide for hemoglobin 
kon(CO) and koff(CO) were measured using a stopped flow apparatus (SX20 stopped flow 
spectrometer, Applied Photophysics, Surrey, UK) at 22oC.   
 
In the association rate constant measurement, the stopped flow instrument was loaded 
with deoxygenated hemoglobin solution (deoxyHb, 2.5µM in hemoglobin tetramer) and 
carbon monoxide solution (CO concentration was about 200 µM). A stock solution of 
deoxyHb (400µM in hemoglobin tetramer) was prepared by purging nitrogen gas to 
oxyhemoglobin solution for at least 2 hours. Carbon monoxide solution was prepared by 
bubbling PBS solution using 20% carbon monoxide gas balanced with nitrogen for at least 
1 hour. The stopped flow instrument was deoxygenated by flushing the system using 
deoxygenated PBS for at least three times before using. Before mixing, CO concentration 
in the CO solution was determined by mixing CO solution with the deoxyHb stock and 
collecting the spectrum of the mixture from 500nm to 700nm. The CO concentration in the 
CO solution was calculated using the COHb concentration in the mixture that was 
determined from deconvolution of the spectrum. Before mixing, PBS was added to one of 
the syringes and deoxygenated for at least 30 minutes. The deoxyHb stock and 
compound/DMSO were added to the deoxygenated PBS in this syringe to get 2.5µM 
deoxyHb, 50µM compound (25µM for IRL2500) with 2vol% DMSO. CO solution was 
loaded to the other syringe. The loaded deoxyHb solution and CO solution were mixed 
and the absorbance of the measurement at 436 nm (A436) was recorded for 0.3 seconds. 
Three mixings were recorded for each repeat and four repeats were measured for each 
compound or control. The value of apparent rate was determined by fitting the time course 
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of A436 with a single exponential equation using Pro-Data Viewer (version 4.2.16, Applied 
Photophysics, Surrey, UK). The kon(CO) was obtained by dividing the apparent rate by 
the CO concentration after mixing (half of the CO concentration in the CO saturated 
solution).  
 
In the dissociation rate constant measurement, the stopped flow instrument was loaded 
with carboxyhemoglobin solution (COHb, 20µM in hemoglobin tetramer) and nitric oxide 
(NO) solution. Compound or DMSO was added to PBS solution and bubbled using 10% 
CO gas (balanced with nitrogen) for 30 minutes at room temperature. Oxyhemoglobin was 
added to the CO saturated PBS solution to obtain COHb. The final DMSO percentage was 
2 vol% and concentrations of hemoglobin and compound before mixing were 20µM and 
400µM (200µM for IRL 2500), respectively. The absorption spectrum of the sample was 
measured from 500 to 700nm and the formation of COHb was confirmed by deconvoluting 
the measured spectrum. Aqueous solution of NO was obtained by adding 
MAHMANONOate (50µL, 20mg/mL in 0.01M NaOH) to 3 mL deoxygenated DPBS 
solution right before the mixing. The loaded COHb solution and NO solution were mixed 
and the absorbance of the measurement at 584 nm (A584) was recorded for 600 seconds. 
Three mixings were recorded for each repeat and four repeats were measured for each 
compound or control. The value of koff(CO) was determined by fitting the time course of 
A584 using single exponential equation using Pro-Data Viewer (version 4.2.16, Applied 
Photophysics, Surrey, UK). Method provided and used with permission by Liu, C.; 
Nakagawa, A.; Zapol, W. M.; 2016. Massachusetts General Hospital. 
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SECTION	A.2 EXPERIMENTAL PROCEDURES  
General. Solvents used for extraction and purification were HPLC grade from Fisher. 
Unless otherwise indicated, all reactions were run under an inert atmosphere of argon. 
Room temperature is considered 20 °C, unless otherwise noted. Merck pre-coated silica 
gel plates (250 mm, 60 F254) were used for analytical TLC. Spots were visualized using 
254 nm ultraviolet light. Chromatographic purifications were performed on Sorbent 
Technologies silica gel (particle size 32-63 microns). 1H and 13C NMR spectra were 
recorded at 500 MHz and 125 MHz, in d6-DMSO, CDCl3 and MeOD on a Bruker AM-500 
or a DRX-500 spectrometer. Chemical shifts are reported relative to internal d6-DMSO (δ 
2.54 for 1H), CDCl3 (δ 7.26 for 1H), MeOD (δ 3.34 for 1H).  Infrared spectra were recorded 
as a solid using a Perkin-Elmer 1600 series Fourier transform spectrometer.  UV/VIS 
spectra were obtained using a Varian-530.  High resolution mass spectra were obtained 
by Dr. Rakesh Kohli and Dr. Charles Ross at the University of Pennsylvania Mass 
Spectrometry Service Center on an Autospec high resolution double-focusing 
electrospray ionization/chemical ionization spectrometer with either DEC 11/73 or OPUS 
software data system. Melting points were obtained on a Thomas Hoover capillary melting 
point apparatus and are uncorrected. 
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Methyl (3,5-dimethylbenzoyl)-D-phenylalaninate (44). To D-phenylalanine methyl ester1 
(1.0 g, 5 mmol, 1 eq) was added 3,5-dimethylbenzoic acid (0.75 g, 5 mmol, 1 eq), 
anhydrous N,N-diisopropylethylamine (4.4 mL, 25 mmol, 5 eq) and anhydrous acetonitrile 
(16.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and HATU (2.9 g, 7.5 mmol, 
1.5 eq) was added. The reaction mixture was allowed to warm to room temperature (20 
°C) for 18 h. The reaction mixture was quenched with saturated ammonium chloride (10 
mL) and extracted with ethyl acetate (10 mL). The organic layer was washed twice with 
deionized water (10 mL), followed by brine (10 mL). The organic was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as an orange foam. This residue was purified by flash chromatography (20% 
EtOAc/Hexanes) to afford the product as an off-white foam (1.53 g, 98%). IR (solid) 1737, 
1643, 1604, 1534, 1495 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 1.5 Hz, 
2H), 7.31 – 7.26 (m, 2H), 7.13 (dt, J = 5.5, 1.6 Hz, 3H), 6.53 (d, J = 7.6 Hz, 1H), 5.09 (dt, 
J = 7.6, 5.6 Hz, 1H), 3.77 (s, 3H), 3.29 (dd, J = 13.8, 5.8 Hz, 1H), 3.22 (dd, J = 13.8, 5.3 
Hz, 1H), 2.34 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 172.28, 167.28, 138.46, 136.04, 
134.02, 133.53, 129.53, 128.72, 127.31, 124.91, 53.62, 52.55, 38.11, 21.38. HRMS (ESI) 
m/z calc’d for C20H22N2O4 [M+Na]+ 377.1461, found 377.1467. 
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(3,5-Dimethylbenzoyl)-D-phenylalanine (39). To a stirring solution of 44 (311 mg, 1 mmol, 
1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 15 mL, 0.067 M), lithium 
hydroxide monohydrate (419 mg, 10 mmol, 10 eq) was added portionwise. The reaction 
mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture was then 
concentrated to remove the organic solvents. 1N hydrochloric acid was added until a pH 
of 4 was reached. The aqueous was two times extracted with ethyl acetate (30 mL). The 
organic layer was washed twice with brine (30 mL). The organic was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the product as 
a white foam (300 mg, quant). IR (solid) 1709, 1643, 1601, 1532, 1496 cm-1. 1H NMR (500 
MHz, Chloroform-d) δ 9.42 (s, 1H), 7.34 – 7.23 (m, 5H), 7.20 (d, J = 7.2 Hz, 2H), 7.13 (s, 
1H), 6.65 – 6.55 (m, 1H), 5.08 (q, J = 7.4, 5.8 Hz, 1H), 3.37 (dd, J = 14.0, 5.6 Hz, 1H), 
3.26 (dd, J = 14.0, 5.7 Hz, 1H), 2.32 (d, J = 2.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
175.13, 168.30, 138.55, 135.85, 133.83, 133.53, 129.61, 128.80, 127.40, 124.99, 53.81, 
37.46, 21.34. HRMS (ESI) m/z calc’d for C18H19NO3 [M+H]+ 298.1443, found 298.1440. 
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N-((R)-1-(((S)-1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-
yl)-3,5-dimethylbenzamide (42). To L-tryptophanol4,5 (95 mg, 0.5 mmol, 1 eq) was added 
44 (148 mg, 0.5 mmol, 1 eq), anhydrous N,N-diisopropylethylamine (440 µL, 2.5 mmol, 5 
eq) and anhydrous N,N-dimethylformamide (1.7 mL, 0.3 M). The reaction mixture was 
then cooled to 0 °C and HATU (285 mg, 0.75 mmol, 1.5 eq) was added. The reaction 
mixture was allowed to warm to room temperature (20 °C) for 18 h. The reaction mixture 
was poured over cold water (100 mL) and filtered. The solid was then dissolved in 
dichloromethane. Organic was then concentrated to dryness in vacuo to afford the product 
an off-white foam (240 mg, quant). IR (thin film) 3390, 2922, 1627, 1598, 1453 cm-1. 1H 
NMR (500 MHz, Methanol-d4) δ 7.61 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.29 (s, 
2H), 7.15 (dd, J = 5.5, 1.7 Hz, 4H), 7.10 – 7.04 (m, 3H), 7.03 (s, 1H), 7.00 (t, J = 7.3 Hz, 
1H), 4.75 (dd, J = 8.3, 6.0 Hz, 1H), 4.22 (p, J = 6.0 Hz, 1H), 3.61 – 3.53 (m, 2H), 2.99 (td, 
J = 15.2, 14.5, 6.3 Hz, 2H), 2.84 (ddd, J = 17.0, 14.1, 8.0 Hz, 2H), 2.31 (s, 6H). 13C NMR 
(126 MHz, MeOD) δ 172.08, 169.00, 138.10, 137.08, 136.87, 133.90, 132.97, 129.13, 
128.06, 127.71, 126.42, 124.79, 122.95, 121.05, 118.42, 118.21, 114.65, 110.97, 63.01, 
55.30, 52.27, 37.76, 26.27, 19.96. HRMS (ESI) m/z calc’d for C29H31N3O3 [M+H]+ 
470.2444, found 470.2430. 
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Di-tert-butyl ((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-phenylpropanamido)-3-(1H-indol-3-
yl)propyl) phosphate (46) To a stirring solution of alcohol 42 (235 mg, 0.5 mmol, 1 eq) in 
anhydrous tetrahydrofuran (3 mL, 0.18 M), 1H-tetrazole (3 wt%, 3 mL, 1 mmol, 2 eq) was 
added followed by di-tert-butyl N,N-diisopropylphosphoramidite (240 µL, 0.75 mmol, 1.5 
eq). After stirring for 18 hours at room temperature (20 °C), reaction was cooled to 0 °C 
and hydrogen peroxide (30 % wt/vol in water, 250 µL, 2.2 mmol, 4.4 eq) was added. 
Reaction was warmed to room temperature for one hour, then quenched with 10% sodium 
sulfite solution (6 mL). Partitioned between ethyl acetate (10 mL) and water (10 mL), the 
organic layer was then washed with brine, dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the product as a crude off-white foam. This 
residue was purified by flash chromatography (1-3% MeOH/CH2Cl2) followed by a prep 
plates (2-4% MeOH/CH2Cl2) to afford the product as an off-white foam (146 mg, 44%). IR 
(thin film) 3280, 3060, 2980, 1652, 1602 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.22 
(s, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.40 – 7.32 (m, 3H), 7.23 – 7.15 (m, 6H), 7.15 – 7.08 (m, 
2H), 7.03 (s, 1H), 6.97 (d, J = 7.9 Hz, 1H), 6.89 (s, 1H), 4.90 (q, J = 7.7, 6.7 Hz, 1H), 4.37 
(ddt, J = 12.2, 8.0, 4.3 Hz, 1H), 3.97 – 3.83 (m, 2H), 3.18 (d, J = 6.6 Hz, 2H), 3.01 (dd, J 
= 14.4, 5.3 Hz, 1H), 2.85 (dd, J = 14.4, 9.0 Hz, 1H), 2.33 (s, 6H), 1.44 (d, J = 6.4 Hz, 18H). 
13C NMR (126 MHz, CDCl3) δ 170.63, 167.23, 138.26, 136.77, 136.41, 134.12, 133.33, 
129.66, 128.67, 127.63, 127.07, 125.05, 123.20, 122.29, 119.78, 119.06, 111.38, 111.30, 
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83.01 (dd, J = 7.4, 3.4 Hz), 66.69, 54.92, 50.25 (d, J = 5.6 Hz), 39.14, 29.98 (d, J = 4.0 
Hz), 26.50, 21.33. 31P NMR (203 MHz, CDCl3) δ -8.66. HRMS (ESI) m/z calc’d for 
C37H48N3O6P [M+H]+ 662.3359, found 662.3392. 
 
 
(S)-2-((R)-2-(3,5-dimethylbenzamido)-3-phenylpropanamido)-3-(1H-indol-3-yl)propyl 
dihydrogen phosphate (41). To a flask containing phosphate ester 46 (73 mg, 0.1 mmol, 
1 eq) in 1,4-dioxane (200 µL, 0.55 M), HCl in dioxane (4 M, 67 µL, 0.24 mmol, 2.4 eq) was 
added. After four hours stirring at room temperature (20 °C), a precipitate had formed. The 
suspension was concentrated in vacuo, resuspended in dichloromethane and 
concentrated in vacuo a second time to yield the product as an off-white film (56 mg, 92%) 
without further purification. IR (solid) 3279, 2923, 1636, 1602, 1515 cm-1. 1H NMR (500 
MHz, Methanol-d4) δ 7.60 (d, J = 7.9 Hz, 1H), 7.37 – 7.23 (m, 3H), 7.20 – 6.93 (m, 9H), 
4.78 (s, 1H), 4.38 (s, 1H), 4.00 (d, J = 5.3 Hz, 2H), 2.96 (dd, J = 67.1, 10.8 Hz, 4H), 2.29 
(s, 6H). 13C NMR (126 MHz, MeOD) δ 173.39, 170.31, 139.35, 138.26, 138.12, 135.07, 
134.24, 130.38, 129.34, 128.82, 127.69, 126.06, 124.47, 122.39, 119.81, 119.38, 112.29, 
111.49, 68.11, 56.55, 51.66, 39.02, 27.36, 21.23. 31P NMR (203 MHz, CDCl3) δ 0.66. 
HRMS (ESI) m/z calc’d for C29H32N3O6P [M-H]- 548.1950, found 548.1969. 
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Methyl (3,5-dimethylbenzoyl)-D-phenylalanylglycinate (53a) To 39 (297 mg, 1 mmol, 1 eq) 
was added glycine methyl ester hydrochloride (125 mg, 1 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (870 µL, 5 mmol, 5 eq) and anhydrous acetonitrile (3 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (570 mg, 1.5 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (10-50% 
EtOAc/Hexanes) to afford the product as an off-white foam (114 mg, 31%). IR (solid) 1746, 
1658, 1633, 1600, 1570 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.29 (q, J = 7.1 Hz, 
6H), 7.24 (d, J = 7.6 Hz, 1H), 7.12 (s, 1H), 6.73 (s, 1H), 6.45 (s, 1H), 4.90 (q, J = 7.2 Hz, 
1H), 4.07 – 3.89 (m, 2H), 3.72 (d, J = 1.6 Hz, 3H), 3.31 – 3.12 (m, 2H), 2.33 (s, 6H). 13C 
NMR (126 MHz, CDCl3) δ 171.27, 169.79, 167.81, 138.47, 136.65, 133.75, 133.60, 
129.49, 128.88, 127.26, 124.93, 54.78, 52.49, 41.37, 38.37, 21.32. HRMS (ESI) m/z calc’d 
for C21H24N2O4 [M+H]+ 369.1814, found 369.1818. 
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SRG-III-091: (3,5-dimethylbenzoyl)-D-phenylalanylglycine (51a). To a stirring solution of 
53a (60 mg, 0.16 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
2.5 mL, 0.067 M), lithium hydroxide monohydrate (30 mg, 0.7 mmol, 4 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 1N hydrochloric 
acid was added until a pH of 4 was reached. The aqueous was then extracted two times 
with ethyl acetate (10 mL). The organic layer was washed twice with brine (10 mL). The 
organic was then dried over anhydrous sodium sulfate and concentrated to dryness in 
vacuo to afford the product as a white foam (57.7 mg, quant). IR (thin film) 3292, 2922, 
1726, 1633, 1600 cm-1. 1H NMR (500 MHz, MeOD) δ 7.32 – 7.28 (m, 4H), 7.25 (t, J = 7.6 
Hz, 2H), 7.20 – 7.15 (m, 1H), 7.12 (s, 1H), 4.90 (dd, J = 9.7, 5.1 Hz, 1H), 3.93 (s, 2H), 
3.35 – 3.31 (m, 1H), 3.05 (dd, J = 13.9, 9.7 Hz, 1H), 2.29 (s, 6H). 13C NMR (126 MHz, 
MeOD) δ 174.19, 172.88, 170.45, 139.27, 138.74, 135.10, 134.19, 130.35, 129.39, 
127.69, 126.14, 56.34, 41.97, 38.73, 21.25. HRMS (ESI) m/z calc’d for C20H22N2O4 
[M+Na]+ 377.1461, found 377.1467. 
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Methyl (tert-butoxycarbonyl)-D-phenylalanyl-L-tryptophanate (55). To (tert-
butoxycarbonyl)-D-phenylalanine3 (2.65 g, 10 mmol, 1 eq) was added tryptophan methyl 
ester hydrochloride2 (2.54 g, 10 mmol, 1 eq), anhydrous N,N-diisopropylethylamine (9 mL, 
50 mmol, 5 eq) and anhydrous acetonitrile (33 mL, 0.3M). The reaction mixture was then 
cooled to 0 °C and HATU (5.7 g, 15 mmol, 1.5 eq) was added. The reaction mixture was 
quenched with saturated ammonium chloride (50 mL) and extracted with ethyl acetate (50 
mL).  The organic layer was washed twice with deionized water (50 mL), followed by brine 
(50 mL). The organic was then dried over anhydrous sodium sulfate and concentrated to 
dryness in vacuo to afford the crude product as an orange foam. This residue was purified 
through a plug of silica (20% EtOAc/Hexanes) to afford the product as a white foam (4.65 
g, quant). IR (solid) 3342, 1733, 1684, 1658, 1544 cm-1. 1H NMR (500 MHz, Chloroform-
d) δ 8.11 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.22 (dd, J = 12.6, 6.9 
Hz, 3H), 7.17 (t, J = 7.7 Hz, 1H), 7.15 – 7.04 (m, 3H), 6.76 (s, 1H), 6.45 (s, 1H), 4.97 (s, 
1H), 4.85 (q, J = 6.3 Hz, 1H), 4.35 (s, 1H), 3.61 (s, 3H), 3.25 (dd, J = 15.1, 5.6 Hz, 1H), 
3.13 (dd, J = 14.8, 5.6 Hz, 1H), 3.05 (dd, J = 13.8, 7.0 Hz, 1H), 2.98 (s, 1H), 1.36 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 172.12, 171.03, 155.47, 136.80, 136.25, 129.48, 128.75, 
127.49, 127.03, 122.99, 122.39, 119.84, 118.58, 111.37, 109.81, 80.28, 55.96, 52.80, 
52.46, 38.57, 28.36, 27.75. HRMS (ESI) m/z calc’d for C26H31N3O5 [M+H]+ 466.2342, found 
466.2361. 
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Methyl benzoyl-D-phenylalanyl-L-tryptophanate (56a). To a stirring solution of 55 (100 mg, 
0.2 mmol, 1 eq) in anhydrous dichloromethane (5 mL, 0.04 M), trifluoroacetic acid (160 
µL, 2 mmol, 10 eq) was added dropwise at room temperature (20 °C). The reaction mixture 
was allowed to stir for 18 h. The reaction was then concentrated to dryness in vacuo. To 
the crude amine salt was added benzoic acid (26 mg, 0.2 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (220 µL, 1.3 mmol, 6 eq) and anhydrous acetonitrile (0.7 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (120 mg, 0.3 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (1% MeOH/CH2Cl2) to 
afford the product as an off-white foam (83 mg, 82%). IR (thin film) 3515, 3445, 1735, 
1632, 1530 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.15 (s, 1H), 7.64 (d, J = 6.7 Hz, 
2H), 7.46 (dd, J = 13.6, 7.8 Hz, 2H), 7.37 (q, J = 6.9 Hz, 2H), 7.30 (d, J = 8.5 Hz, 1H), 7.20 
(s, 3H), 7.16 (t, J = 7.6 Hz, 1H), 7.13 – 7.04 (m, 3H), 6.76 (d, J = 2.4 Hz, 2H), 6.59 (s, 1H), 
4.90 – 4.80 (m, 2H), 3.60 (s, 3H), 3.25 (dd, J = 14.8, 5.4 Hz, 1H), 3.19 – 3.08 (m, 3H). 13C 
NMR (126 MHz, CDCl3) δ 171.87, 170.46, 167.10, 136.33, 136.03, 133.62, 131.69, 
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129.29, 128.56, 128.48, 127.16, 126.94, 126.89, 122.89, 122.19, 119.60, 118.30, 111.20, 
109.50, 54.70, 52.63, 52.28, 38.24, 27.39. HRMS (ESI) m/z calc’d for C28H27N3O4 [M+H]+ 
470.2080, found 470.2085. 
 
 
Methyl (3,5-dimethylbenzoyl)-D-phenylalanyl-L-tryptophanate (56b). To a stirring solution 
of 55 (100 mg, 0.2 mmol, 1 eq) in anhydrous dichloromethane (5 mL, 0.04 M), 
trifluoroacetic acid (160 µL, 2 mmol, 10 eq) was added dropwise at room temperature (20 
°C). The reaction mixture was allowed to stir for 18 h. The reaction was then concentrated 
to dryness in vacuo. To the crude amine salt was added 3,5-dimethylbenzoic acid (33 mg, 
0.2 mmol, 1 eq), anhydrous N,N-diisopropylethylamine (220 µL, 1.3 mmol, 6 eq) and 
anhydrous acetonitrile (0.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and 
HATU (120 mg, 0.3 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm 
to room temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL). The organic layer 
was washed twice with deionized water (10 mL), followed by brine (10 mL). The organic 
layer was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo 
to afford the crude product as an orange foam. This residue was purified by flash 
chromatography (1% MeOH/CH2Cl2) to afford the product as an off-white foam (88 mg, 
82%). IR (thin film) 3290, 1734, 1654, 1636, 1602 cm-1. 1H NMR (500 MHz, CDCl3) δ 8.38 
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(s, 1H), 7.49 – 7.40 (m, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.25 (s, 2H), 7.21 – 7.12 (m, 4H), 
7.12 – 7.02 (m, 4H), 6.84 (t, J = 8.4 Hz, 2H), 6.78 (d, J = 2.3 Hz, 1H), 4.90 (q, J = 7.0 Hz, 
1H), 4.83 (q, J = 6.5 Hz, 1H), 3.59 (s, 3H), 3.24 (dd, J = 14.7, 6.5 Hz, 1H), 3.14 (ddd, J = 
24.2, 12.0, 5.9 Hz, 3H), 2.29 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 172.16, 170.88, 167.74, 
138.33, 136.58, 136.28, 133.81, 133.46, 129.50, 128.66, 127.35, 127.05, 124.89, 123.26, 
122.25, 119.68, 118.45, 111.45, 109.65, 54.83, 52.95, 52.45, 38.49, 27.58, 21.25. HRMS 
(ESI) m/z calc’d for C30H31N3O4 [M+H]+ 498.2393, found 498.2396. 
 
 
Methyl nicotinoyl-D-phenylalanyl-L-tryptophanate (56d). To a stirring solution of 55 (100 
mg, 0.2 mmol, 1 eq) in anhydrous dichloromethane (5 mL, 0.04 M), trifluoroacetic acid 
(160 µL, 2 mmol, 10 eq) was added dropwise at room temperature (20 °C). The reaction 
mixture was allowed to stir for 18 h. The reaction was then concentrated to dryness in 
vacuo. To the crude amine salt was added nicotinic acid (26 mg, 0.2 mmol, 1 eq), 
anhydrous N,N-diisopropylethylamine (220 µL, 1.3 mmol, 6 eq) and anhydrous acetonitrile 
(0.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and HATU (120 mg, 0.3 
mmol, 1.5 eq) was added. The reaction mixture was allowed to warm to room temperature 
(20 °C) for 18 h. The reaction mixture was quenched with saturated ammonium chloride 
(10 mL) and extracted with ethyl acetate (10 mL). The organic layer was washed twice 
with deionized water (10 mL), followed by brine (10 mL). The organic was then dried over 
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anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as an orange foam. This residue was purified by flash chromatography (2% 
MeOH/CH2Cl2) to afford the product as an off-white foam (101 mg, quant.). IR (solid) 3287, 
1733, 1660, 1634, 1595 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.88 (dd, J 
= 2.3, 0.9 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.67 (dd, J = 4.8, 1.7 Hz, 1H), 8.63 (d, J = 7.9 
Hz, 1H), 8.07 (dt, J = 8.1, 1.9 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.46 (dd, J = 8.0, 4.8 Hz, 
1H), 7.32 (d, J = 8.1 Hz, 1H), 7.27 (d, J = 7.4 Hz, 3H), 7.21 (t, J = 7.5 Hz, 2H), 7.19 – 7.10 
(m, 2H), 7.05 (t, J = 7.6 Hz, 1H), 6.96 (t, J = 7.4 Hz, 1H), 4.77 (d, J = 9.8 Hz, 1H), 4.63 – 
4.55 (m, 1H), 3.62 (s, 3H), 3.19 (dd, J = 14.5, 5.2 Hz, 1H), 3.05 (dd, J = 14.5, 8.7 Hz, 1H), 
2.92 – 2.85 (m, 1H), 2.80 – 2.71 (m, 1H). 13C NMR (126 MHz, DMSO) δ 172.85, 171.71, 
165.32, 152.49, 149.06, 138.72, 136.71, 135.63, 130.12, 129.76, 128.58, 127.62, 126.83, 
124.51, 123.93, 121.56, 119.01, 118.60, 112.01, 109.86, 55.15, 53.58, 52.52, 37.90, 
27.90. HRMS (ESI) m/z calc’d for C27H26N4O4 [M+H]+ 471.2032, found 471.2035. 
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Benzoyl-D-phenylalanyl-L-tryptophan (54a). To a stirring solution of 56a (83 mg, 0.17 
mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.5 mL, 0.067 M), 
lithium hydroxide monohydrate (30 mg, 0.7 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce a white solid (72.8 mg, 90%). m.p. = 110-120 °C. IR (solid) 3300, 2925, 1721, 
1634, 1520 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.05 (d, J = 7.9 Hz, 1H), 7.91 – 7.83 
(m, 2H), 7.62 (d, J = 8.4 Hz, 1H), 7.59 – 7.42 (m, 4H), 7.39 (t, J = 7.7 Hz, 2H), 7.30 (d, J 
= 8.1 Hz, 1H), 7.10 (dd, J = 4.9, 1.9 Hz, 3H), 7.06 (t, J = 8.1 Hz, 1H), 7.03 – 6.99 (m, 2H), 
6.96 (t, J = 7.9 Hz, 1H), 4.89 – 4.80 (m, 0H), 4.75 (td, J = 8.0, 4.9 Hz, 1H), 3.37 – 3.32 (m, 
1H), 3.18 (dd, J = 14.7, 8.1 Hz, 1H), 3.08 (dd, J = 13.8, 5.5 Hz, 1H), 2.85 (dd, J = 8.6, 5.3 
Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.67, 171.94, 168.57, 136.90, 133.78, 131.57, 
131.43, 128.95, 128.14, 128.12, 127.34, 126.94, 126.30, 123.29, 121.13, 118.59, 117.87, 
111.01, 109.28, 54.93, 54.89, 53.16, 37.43, 27.10. HRMS (ESI) m/z calc’d for C27H25N3O4 
[M+H]+ 4561923, found 456.1938.  
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(3,5-Dimethylbenzoyl)-D-phenylalanyl-L-tryptophan (54b). To a stirring solution of 56b (88 
mg, 0.18 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.5 mL, 
0.067 M), lithium hydroxide monohydrate (30 mg, 0.7 mmol, 4 eq) was added portionwise. 
The reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction 
mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was added 
until a solid precipitated. The solid was collected and washed with water. Product was 
dried to produce a white solid (85.5 mg, 81%). m.p. = 110-120 °C.IR (solid) 2918, 1633, 
1601, 1520, 1456 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.55 (d, J = 7.9 Hz, 1H), 7.30 
(d, J = 8.1 Hz, 1H), 7.21 (s, 2H), 7.14 – 6.90 (m, 10H), 4.76 (p, J = 4.0 Hz, 1H), 3.52 – 
3.43 (m, 1H), 3.37 – 3.30 (m, 1H), 3.18 (dd, J = 14.9, 8.1 Hz, 1H), 3.08 (dd, J = 14.0, 5.5 
Hz, 1H), 2.84 (dt, J = 13.3, 5.3 Hz, 1H), 2.27 (t, J = 2.6 Hz, 6H). 13C NMR (126 MHz, 
MeOD) δ 175.02, 173.30, 170.24, 139.31, 138.27, 138.05, 135.11, 134.20, 130.33, 
129.27, 128.72, 127.62, 126.01, 124.63, 122.44, 119.94, 119.21, 112.32, 110.65, 66.87, 
56.13, 38.80, 28.46, 21.24. HRMS (ESI) m/z calc’d for C29H29N3O4 [M+H]+ 484.2236, found 
484.2226.  
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Methyl (4-hydroxybenzoyl)-D-phenylalanyl-L-tryptophanate (56h). To a stirring solution of 
55 (200 mg, 0.4 mmol, 1 eq) in anhydrous dichloromethane (10 mL, 0.04 M), trifluoroacetic 
acid (320 µL, 4 mmol, 10 eq) was added dropwise at room temperature (20 °C). The 
reaction mixture was allowed to stir for 18 h. The reaction was then concentrated to 
dryness in vacuo. To the crude amine salt was added 4-hydroxybenzoic acid (60 mg, 0.4 
mmol, 1 eq), anhydrous N,N-diisopropylethylamine (440 µL, 2.6 mmol, 6 eq) and 
anhydrous acetonitrile (1.4 mL, 0.3M). The reaction mixture was then cooled to 0 °C and 
HATU (240 mg, 0.6 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm 
to room temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (20 mL) and extracted with ethyl acetate (20 mL). The organic layer 
was washed twice with deionized water (20 mL), followed by brine (20 mL). The organic 
was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo to 
afford the crude product as an orange foam. This residue was purified by flash 
chromatography (4% MeOH/CH2Cl2) to afford the product as an off-white foam (63 mg, 
30%). IR (thin film) 3267, 3024, 2921, 1732, 1635, 1606 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.13 (s, 1H), 7.42 (d, J = 8.3 Hz, 4H), 7.29 (d, J = 8.2 Hz, 1H), 7.21 (td, J 
= 7.0, 3.6 Hz, 3H), 7.14 (t, J = 7.2 Hz, 3H), 7.09 – 7.04 (m, 1H), 4.92 – 4.76 (m, 2H), 3.61 
(s, 3H), 3.28 (dd, J = 14.9, 5.8 Hz, 1H), 3.21 – 3.05 (m, 3H). 13C NMR (126 MHz, CDCl3) 
δ 172.21, 172.03, 168.17, 160.81, 136.82, 136.59, 128.86, 128.81, 127.82, 127.06, 
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126.16, 124.36, 123.11, 121.00, 118.43, 117.58, 114.56, 110.88, 108.87, 54.66, 53.16, 
51.24, 37.32, 26.96. HRMS (ESI) m/z calc’d for C28H27N3O5 [M+H]+ 486.2029, found 
486.2006. 
 
 
Nicotinoyl-D-phenylalanyl-L-tryptophan (54d). To a stirring solution of 56d (108 mg, 0.2 
mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 3.5 mL, 0.067 M), 
lithium hydroxide monohydrate (38 mg, 0.9 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce a white solid (96 mg, quant.). m.p. = 148-158 °C. IR (solid) 3061, 2926, 1723, 
1632, 1539 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.76 (s, 1H), 8.66 (d, J = 5.0 Hz, 1H), 
8.53 (d, J = 8.2 Hz, 1H), 8.07 (t, J = 9.8, 8.9 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.29 (d, J = 8.1 
Hz, 1H), 7.13 (dd, J = 5.2, 1.9 Hz, 3H), 7.09 – 7.00 (m, 4H), 6.95 (t, J = 7.7 Hz, 1H), 4.87 
(ddd, J = 8.2, 5.6, 2.5 Hz, 1H), 4.77 (td, J = 8.0, 5.0 Hz, 1H), 3.38 – 3.32 (m, 1H), 3.19 
(dd, J = 14.7, 8.0 Hz, 1H), 3.07 (dd, J = 14.0, 5.5 Hz, 1H), 2.82 (dd, J = 13.9, 9.1 Hz, 1H). 
13C NMR (126 MHz, MeOD) δ 173.72, 171.86, 165.90, 150.53, 147.14, 137.03, 136.78, 
136.67, 129.03, 128.10, 127.49, 126.47, 123.38, 121.20, 118.68, 117.97, 111.09, 109.39, 
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100.11, 55.12, 53.39, 37.49, 27.16. HRMS (ESI) m/z calc’d for C26H24N4O4 [M+H]+ 
457.1876, found 457.1883.  
 
 
(4-Hydroxybenzoyl)-D-phenylalanyl-L-tryptophan (54h). To a stirring solution of 56h (60 
mg, 0.12 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2 mL, 
0.067 M), lithium hydroxide monohydrate (21 mg, 0.5 mmol, 4 eq) was added portionwise. 
The reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction 
mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was added 
until a solid precipitated. The solid was collected and washed with water, then dissolved 
with dichloromethane. Organic was then concentrated to dryness in vacuo to afford the 
product as a white foam (56 mg, 96%). IR (thin film) 3301, 2924, 1607, 1539, 1501 cm-1. 
1H NMR (500 MHz, Methanol-d4) δ 10.35 – 10.15 (m, 0H), 7.96 (dd, J = 60.4, 8.0 Hz, 1H), 
7.54 (t, J = 8.7 Hz, 3H), 7.30 (d, J = 8.1 Hz, 1H), 7.15 – 7.03 (m, 4H), 7.03 – 6.93 (m, 4H), 
6.76 (d, J = 8.7 Hz, 2H), 4.86 – 4.79 (m, 6H), 4.75 (ddd, J = 7.9, 6.5, 3.8 Hz, 1H), 3.34 (d, 
J = 1.6 Hz, 1H), 3.18 (dd, J = 14.7, 8.1 Hz, 1H), 3.07 (dd, J = 13.8, 5.4 Hz, 1H), 2.84 (dd, 
J = 13.9, 8.5 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 175.02, 173.45, 169.62, 162.18, 
138.31, 138.07, 130.34, 130.29, 129.27, 128.69, 127.60, 125.90, 124.62, 122.45, 119.93, 
119.21, 116.03, 112.32, 110.62, 56.18, 54.50, 38.83, 28.47. HRMS (ESI) m/z calc’d for 
C27H25N3O5 [M+H]+ 472.1872, found 472.1873. 
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Methyl (3-hydroxybenzoyl)-D-phenylalanyl-L-tryptophanate (56g). To a stirring solution of 
55 (200 mg, 0.4 mmol, 1 eq) in anhydrous dichloromethane (10 mL, 0.04 M), trifluoroacetic 
acid (320 µL, 4 mmol, 10 eq) was added dropwise at room temperature (20 °C). The 
reaction mixture was allowed to stir for 18 h. The reaction was then concentrated to 
dryness in vacuo. To the crude amine salt was added 3-hydroxybenzoic acid (60 mg, 0.4 
mmol, 1 eq), anhydrous N,N-diisopropylethylamine (440 µL, 2.6 mmol, 6 eq) and 
anhydrous acetonitrile (1.4 mL, 0.3M). The reaction mixture was then cooled to 0 °C and 
HATU (240 mg, 0.6 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm 
to room temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (20 mL) and extracted with ethyl acetate (20 mL). The organic layer 
was washed twice with deionized water (20 mL), followed by brine (20 mL). The organic 
was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo to 
afford the crude product as an orange foam. This residue was purified by flash 
chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (170 mg, 
86%). IR (solid) 3294, 1725, 1663, 1635, 1584 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 
10.86 (d, J = 2.4 Hz, 1H), 9.59 (s, 1H), 8.55 (d, J = 7.9 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H), 
7.52 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.25 – 7.10 (m, 9H), 7.05 (t, J = 7.5 Hz, 
1H), 6.97 (t, J = 7.4 Hz, 1H), 6.88 (dt, J = 7.6, 2.1 Hz, 1H), 4.73 (td, J = 9.2, 8.6, 4.1 Hz, 
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1H), 4.58 (td, J = 8.2, 5.3 Hz, 1H), 3.62 (s, 3H), 3.19 (dd, J = 14.5, 5.4 Hz, 1H), 3.06 (dd, 
J = 14.5, 8.6 Hz, 1H), 2.87 (dd, J = 13.7, 4.1 Hz, 1H), 2.80 (dd, J = 13.7, 10.3 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 172.64, 171.72, 166.50, 157.55, 138.59, 136.49, 136.00, 
135.87, 129.54, 128.30, 127.38, 126.51, 124.29, 121.33, 118.80, 118.52, 118.37, 118.20, 
114.68, 111.79, 109.64, 54.83, 53.36, 52.27, 37.54, 27.71. HRMS (ESI) m/z calc’d for 
C28H27N3O5 [M+Na]+ 508.1848, found 508.1850. 
 
 
(3-Hydroxybenzoyl)-D-phenylalanyl-L-tryptophan (54g). To a stirring solution of SRG-III-
273 (100 mg, 0.2 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
3 mL, 0.067 M), lithium hydroxide monohydrate (35 mg, 0.8 mmol, 4 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
was dried to produce a white solid (98 mg, quant). m.p. = 120-148 °C. IR (solid) 3060, 
1722, 1635, 1583, 1520 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 10.27 (s, 1H), 8.05 (dd, 
J = 19.9, 8.0 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 8.1 Hz, 
1H), 7.13 – 7.00 (m, 7H), 6.97 (t, J = 7.5 Hz, 3H), 6.91 (ddd, J = 8.1, 2.4, 1.1 Hz, 1H), 3.36 
– 3.32 (m, 1H), 3.18 (dd, J = 14.7, 8.3 Hz, 1H), 3.06 (dd, J = 13.9, 5.4 Hz, 1H), 2.82 (dd, 
J = 13.8, 8.5 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.03, 171.94, 168.65, 157.49, 
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136.95, 136.83, 135.34, 129.33, 129.06, 128.04, 127.50, 127.47, 126.38, 123.36, 121.21, 
118.69, 118.52, 117.94, 113.93, 111.08, 109.52, 54.90, 53.47, 37.58, 27.27. HRMS (ESI) 
m/z calc’d for C27H25N3O5 [M+H]+ 472.1872, found 472.1882.  
 
 
Methyl picolinoyl-D-phenylalanyl-L-tryptophanate (56c). To a stirring solution of 55 (100 
mg, 0.2 mmol, 1 eq) in anhydrous dichloromethane (1 mL, 0.2 M), trifluoroacetic acid (160 
µL, 2 mmol, 10 eq) was added dropwise at room temperature (20 °C). The reaction mixture 
was allowed to stir for 18 h. The reaction was then concentrated to dryness in vacuo. To 
the crude amine salt was added picolinic acid (26 mg, 0.2 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (220 µL, 1.3 mmol, 6 eq) and anhydrous acetonitrile (0.7 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (120 mg, 0.3 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (110 mg, quant). IR (solid) 3059, 2951, 1739, 1655, 
1591 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.55 – 8.42 (m, 2H), 8.12 (s, 1H), 8.08 (dt, 
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J = 7.8, 1.1 Hz, 1H), 7.79 (td, J = 7.7, 1.5 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.28 – 7.25 (m, 
1H), 7.25 – 7.16 (m, 5H), 7.14 – 7.08 (m, 1H), 7.04 – 6.98 (m, 1H), 6.70 (d, J = 2.3 Hz, 
1H), 6.57 (d, J = 7.8 Hz, 1H), 4.91 – 4.79 (m, 2H), 3.56 (d, J = 0.9 Hz, 3H), 3.25 (dd, J = 
14.9, 5.7 Hz, 1H), 3.23 – 3.17 (m, 1H), 3.17 – 3.08 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
172.00, 170.46, 164.49, 149.25, 148.41, 137.36, 136.82, 136.18, 129.55, 128.75, 127.48, 
127.05, 126.53, 123.12, 122.32, 122.26, 119.73, 118.51, 111.32, 109.72, 54.99, 52.90, 
52.43, 38.41, 27.65. HRMS (ESI) m/z calc’d for C27H26N4O4 [M+H]+ 471.2032, found 
471.2054. 
 
 
Methyl isonicotinoyl-D-phenylalanyl-L-tryptophanate (56e) To a stirring solution of 55 (100 
mg, 0.2 mmol, 1 eq) in anhydrous dichloromethane (1 mL, 0.2 M), trifluoroacetic acid (160 
µL, 2 mmol, 10 eq) was added dropwise at room temperature (20 °C). The reaction mixture 
was allowed to stir for 18 h. The reaction was then concentrated to dryness in vacuo. To 
the crude amine salt was added isonicotinic acid (26 mg, 0.2 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (220 µL, 1.3 mmol, 6 eq) and anhydrous acetonitrile (0.7 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (120 mg, 0.3 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
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water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (104 mg, quant). IR (solid) 3059, 1737, 1641, 1532, 
1456 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.63 (d, J = 4.4 Hz, 2H), 8.28 (s, 1H), 7.49 
– 7.34 (m, 3H), 7.31 (d, J = 7.3 Hz, 1H), 7.23 – 7.12 (m, 4H), 7.14 – 7.02 (m, 4H), 6.76 (d, 
J = 2.4 Hz, 1H), 6.61 (s, 1H), 4.84 (dq, J = 12.0, 6.5, 5.8 Hz, 2H), 3.63 (s, 3H), 3.26 (dd, J 
= 14.9, 6.2 Hz, 1H), 3.16 (dd, J = 14.9, 5.4 Hz, 1H), 3.09 (d, J = 6.9 Hz, 2H). 13C NMR 
(126 MHz, MeOD) δ 172.44, 171.69, 166.30, 149.56, 142.15, 136.93, 136.81, 129.03, 
128.12, 127.36, 126.51, 123.32, 121.72, 121.62, 121.26, 118.67, 117.84, 117.78, 111.13, 
109.14, 55.04, 53.44, 51.47, 37.47, 27.15. HRMS (ESI) m/z calc’d for C27H26N4O4 [M+H]+ 
471.2032, found 471.2044. 
 
 
Picolinoyl-D-phenylalanyl-L-tryptophan (54c). To a stirring solution of 56c (74.5 mg, 0.16 
mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.5 mL, 0.067 M), 
lithium hydroxide monohydrate (27 mg, 0.6 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
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produce a white solid (72 mg, 92%). m.p. = 105-108 °C. IR (solid) 3302, 2925, 1726, 1652, 
1591 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.52 (d, J = 4.9 Hz, 1H), 8.27 (d, J = 7.9 
Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.88 (t, J = 7.7 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.48 
(dd, J = 7.7, 4.7 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.10 – 7.00 (m, 3H), 6.96 (t, J = 7.5 Hz, 
3H), 6.82 (d, J = 7.2 Hz, 2H), 4.86 (m, J = 3.6 Hz, 1H), 4.78 – 4.68 (m, 1H), 3.35 (dd, J = 
14.7, 4.6 Hz, 1H), 3.15 (dd, J = 14.7, 8.9 Hz, 1H), 3.05 (dd, J = 13.7, 5.6 Hz, 1H), 2.86 
(dd, J = 13.7, 7.3 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.85, 171.66, 164.61, 148.46, 
137.47, 136.85, 136.32, 129.12, 127.97, 127.38, 126.64, 126.39, 123.38, 121.81, 121.23, 
118.68, 117.94, 111.13, 109.55, 54.34, 53.46, 38.12, 27.21. HRMS (ESI) m/z calc’d for 
C26H24N4O4 [M-H]- 455.1719, found 455.1713.  
 
 
Isonicotinoyl-D-phenylalanyl-L-tryptophan (54e). To a stirring solution of 56e (74.2 mg, 
0.16 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.5 mL, 0.067 
M), lithium hydroxide monohydrate (27 mg, 0.6 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce a white solid (48.7 mg, 68%). m.p. = 146-166 °C. IR (solid) 3279, 3062, 2924, 
1721, 1643 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.68 (s, 2H), 7.71 (d, J = 6.4 Hz, 1H), 
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7.55 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.12 (dd, J = 5.0, 1.9 Hz, 2H), 7.08 – 
6.99 (m, 4H), 6.96 (td, J = 7.5, 7.0, 1.0 Hz, 1H), 4.88 – 4.85 (m, 1H), 4.81 – 4.72 (m, 1H), 
3.34 (dd, J = 14.7, 5.0 Hz, 1H), 3.18 (dd, J = 14.7, 8.2 Hz, 1H), 3.04 (dd, J = 13.9, 5.4 Hz, 
1H), 2.80 (dd, J = 13.9, 9.2 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.70, 171.55, 165.22, 
147.28, 144.73, 136.91, 136.78, 129.02, 128.11, 127.47, 126.49, 123.36, 122.81, 121.20, 
118.66, 117.98, 111.09, 109.43, 55.13, 53.29, 37.49, 27.15. HRMS (ESI) m/z calc’d for 
C26H24N4O4 [M+H]+  471.2044, found 471.2032. 
 
 
Methyl (2-acetoxybenzoyl)-D-phenylalanyl-L-tryptophanate (56r). To a stirring solution of 
55 (233 mg, 0.5 mmol, 1 eq) in anhydrous dichloromethane (2.5 mL, 0.2 M), trifluoroacetic 
acid (390 µL, 5 mmol, 10 eq) was added dropwise at room temperature (20 °C). The 
reaction mixture was allowed to stir for 18 h. The reaction was then concentrated to 
dryness in vacuo. To the crude amine salt was added 2-acetoxybenzoic acid6 (90 mg, 0.5 
mmol, 1 eq), anhydrous N,N-diisopropylethylamine (530 µL, 3 mmol, 6 eq) and anhydrous 
acetonitrile (1.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and HATU (285 
mg, 1 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm to room 
temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL). The organic layer 
was washed twice with deionized water (10 mL), followed by brine (10 mL). The organic 
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was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo to 
afford the crude product as an orange foam. This residue was purified by flash 
chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (112 mg, 
43%). IR (solid) 1731, 1661, 1637, 1532, 1480 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 
7.58 – 7.53 (m, 2H), 7.48 (td, J = 7.8, 1.7 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.28 (d, J = 
7.6 Hz, 1H), 7.15 – 7.08 (m, 3H), 7.08 – 7.05 (m, 2H), 7.05 – 6.99 (m, 3H), 6.81 (d, J = 7.5 
Hz, 2H), 4.84 (d, J = 6.4 Hz, 1H), 4.74 (dd, J = 8.8, 5.1 Hz, 1H), 3.68 (s, 3H), 3.33 (d, J = 
5.5 Hz, 1H), 3.17 – 3.03 (m, 2H), 2.83 (d, J = 7.3 Hz, 1H), 1.99 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 172.30, 171.18, 169.16, 165.89, 148.12, 136.69, 136.23, 131.64, 129.13, 
128.94, 127.82, 127.24, 127.03, 126.18, 125.57, 123.18, 122.98, 121.07, 118.46, 117.66, 
110.99, 109.15, 54.29, 53.27, 51.26, 37.32, 27.02, 19.34. HRMS (ESI) m/z calc’d for 
C30H29N3O6 [M+H]+ 528.2135, found 528.2130. 
 
 
(2-Hydroxybenzoyl)-D-phenylalanyl-L-tryptophan (54f). To a stirring solution of 56r (96 
mg, 0.18 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.5 mL, 
0.067 M), lithium hydroxide monohydrate (62 mg, 1.5 mmol, 8 eq) was added portionwise. 
The reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction 
mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was added 
until a solid precipitated. The solid was collected and washed with water. Product was 
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dried to produce a white solid (68.7 mg, 80%). m.p. = 135-140 °C. IR (solid) 3282, 3060, 
2920, 1739, 1635 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.68 (d, J = 7.9 Hz, 1H), 7.56 
(d, J = 7.9 Hz, 1H), 7.33 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.08 – 
7.00 (m, 3H), 6.96 (t, J = 6.9 Hz, 1H), 6.91 (d, J = 6.6 Hz, 1H), 6.88 – 6.80 (m, 2H), 4.86 
(s, 1H), 4.72 (dd, J = 8.4, 4.8 Hz, 1H), 3.34 (s, 1H), 3.16 (dd, J = 14.7, 8.4 Hz, 1H), 3.05 
(dd, J = 13.8, 5.5 Hz, 1H), 2.85 (dd, J = 13.8, 7.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
174.08, 171.54, 168.07, 158.65, 136.57, 136.46, 133.22, 128.86, 128.35, 127.75, 127.24, 
126.12, 123.12, 120.92, 118.76, 118.39, 117.74, 116.57, 116.04, 110.81, 109.38, 54.43, 
53.42, 37.55, 27.06. HRMS (ESI) m/z calc’d for C27H25N3O5 [M+Na]+ 472.1872, found 
472.1871. 
 
 
3-(2-Ethoxy-2-oxoethoxy)benzoic acid (62k). To a solution of 3-hydroxybenzoic acid (140 
mg, 1 mmol, 1 eq) in anhydrous N,N-dimethylformamide (3 mL, 0.33 M), sodium hydride 
(60% dispersion, 120 mg, 3 mmol, 3 eq) was added at 0 °C. After stirring  for 30 minutes, 
ethyl bromoacetate (130 µL, 1.2 mmol, 1.2 eq) was added and the reaction mixture was 
allowed to warm to room temperature for 18 h. The reaction mixture was quenched with 
water at 0 °C then acidified with 1N HCl. The reaction mixture was then extracted with 
ethyl acetate (20 mL) and washed five times with water (20 mL), followed by brine (20 
mL). The organic layer was then sodium sulfate and concentrated in vacuo to yield a crude 
oil, which was used in the next step without purification. 
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Methyl (3-(2-ethoxy-2-oxoethoxy)benzoyl)-D-phenylalanyl-L-tryptophanate (56k). To a 
stirring solution of 55 (465 mg, 1 mmol, 1 eq) in anhydrous dichloromethane (5 mL, 0.2 
M), trifluoroacetic acid (780 µL, 5 mmol, 10 eq) was added dropwise at room temperature 
(20 °C). The reaction mixture was allowed to stir for 18 h. The reaction was then 
concentrated to dryness in vacuo. To the crude amine salt was added crude acid 62k (1 
mmol, 1 eq), anhydrous N,N-diisopropylethylamine (1 mL, 5 mmol, 5 eq) and anhydrous 
acetonitrile (3.3 mL, 0.3 M). The reaction mixture was then cooled to 0 °C and HATU (570 
mg, 1.5 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm to room 
temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (20 mL) and extracted with ethyl acetate (20 mL). The organic layer 
was washed twice with deionized water (20 mL), followed by brine (20 mL). The organic 
was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo to 
afford the crude product as an orange foam. This residue was purified by flash 
chromatography (40-60% EtOAc/Hex) to afford the product as an off-white foam (110 mg, 
20% over three steps). IR (solid) 3287, 1739, 1636, 1583, 1520 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.41 (s, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.27 (dt, J = 11.7, 4.1 Hz, 3H), 7.20 
(d, J = 5.0 Hz, 3H), 7.17 – 7.12 (m, 2H), 7.10 (dd, J = 7.9, 5.2 Hz, 2H), 7.08 – 7.01 (m, 
2H), 6.80 – 6.71 (m, 2H), 6.67 (d, J = 7.8 Hz, 1H), 4.92 – 4.78 (m, 2H), 4.64 (s, 2H), 4.26 
(q, J = 7.2 Hz, 2H), 3.60 (s, 3H), 3.29 (dd, J = 14.8, 5.9 Hz, 1H), 3.20 – 3.04 (m, 3H), 1.29 
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(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.15, 170.63, 168.97, 166.86, 158.11, 
136.53, 136.36, 135.37, 129.95, 129.47, 128.82, 127.33, 127.19, 123.30, 122.31, 119.99, 
119.70, 118.60, 118.51, 113.47, 111.51, 109.42, 65.38, 61.75, 54.95, 52.60, 52.53, 38.21, 
27.57, 14.28. HRMS (ESI) m/z calc’d for C32H33N3O7 [M+Na]+ 594.2216, found 594.2222. 
 
 
3,5-bis(2-ethoxy-2-oxoethoxy)benzoic acid (62i). To a solution of 3,5-hydroxybenzoic acid 
(154 mg, 1 mmol, 1 eq) in anhydrous N,N-dimethylformamide (3 mL, 0.33 M), sodium 
hydride (60% dispersion, 160 mg, 3 mmol, 4 eq) was added at 0 °C. After stirring  for 30 
minutes, ethyl bromoacetate (260 µL, 2.4 mmol, 2.4 eq) was added and the reaction 
mixture was allowed to warm to room temperature for 18 h. The reaction mixture was 
quenched with water at 0 °C then acidified with 1N HCl. The reaction mixture was then 
extracted with ethyl acetate (20 mL) and washed five times with water (20 mL), followed 
by brine (20 mL). The organic layer was then sodium sulfate and concentrated in vacuo 
to yield a crude oil, which was used in the next step without purification. 
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Diethyl 2,2'-((5-(((R)-1-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)-1-oxo-
3-phenylpropan-2-yl)carbamoyl)-1,3-phenylene)bis(oxy))diacetate (56i). To a stirring 
solution of 55 (465 mg, 1 mmol, 1 eq) in anhydrous dichloromethane (5 mL, 0.2 M), 
trifluoroacetic acid (780 µL, 5 mmol, 10 eq) was added dropwise at room temperature (20 
°C). The reaction mixture was allowed to stir for 18 h. The reaction was then concentrated 
to dryness in vacuo. To the crude amine salt was added crude acid 62i (1 mmol, 1 eq), 
anhydrous N,N-diisopropylethylamine (1 mL, 5 mmol, 5 eq) and anhydrous acetonitrile 
(3.3 mL, 0.3 M). The reaction mixture was then cooled to 0 °C and HATU (570 mg, 1.5 
mmol, 1.5 eq) was added. The reaction mixture was allowed to warm to room temperature 
(20 °C) for 18 h. The reaction mixture was quenched with saturated ammonium chloride 
(20 mL) and extracted with ethyl acetate (20 mL). The organic layer was washed twice 
with deionized water (20 mL), followed by brine (20 mL). The organic was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as an orange foam. This residue was purified by flash chromatography (40-60% 
EtOAc/Hex) to afford the product as an off-white foam (191 mg, 28% over three steps). IR 
(solid) 1756, 1740, 1625, 1594, 1521 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.55 (s, 
1H), 7.39 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 4.2 Hz, 1H), 7.18 (d, J = 7.3 Hz, 3H), 7.12 – 7.04 
(m, 3H), 7.01 (t, J = 7.4 Hz, 1H), 6.74 (dd, J = 18.9, 2.3 Hz, 3H), 6.65 (t, J = 7.6 Hz, 2H), 
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6.58 (s, 1H), 4.89 – 4.75 (m, 2H), 4.54 (d, J = 3.5 Hz, 4H), 4.23 (q, J = 7.2 Hz, 4H), 3.60 
(s, 3H), 3.30 (dd, J = 14.9, 5.5 Hz, 1H), 3.08 (ddt, J = 34.0, 13.9, 7.2 Hz, 3H), 1.27 (t, J = 
7.1 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 172.22, 170.61, 168.71, 166.59, 159.09, 
136.58, 136.44, 136.20, 129.44, 128.82, 127.27, 127.18, 123.38, 122.25, 119.61, 118.49, 
111.57, 109.19, 106.68, 105.42, 65.41, 61.79, 54.94, 52.55, 52.34, 37.94, 27.49, 14.27. 
HRMS (ESI) m/z calc’d for C36H39N3O10 [M+H]+ 674.2714, found 674.2713. 
 
 
2,2'-((5-(((R)-1-(((S)-1-Carboxy-2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamoyl)-1,3-phenylene)bis(oxy))diacetic acid (54i). To a stirring solution of 56i (123 
mg, 0.2 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 3 mL, 
0.067 M), lithium hydroxide monohydrate (101 mg, 2.4 mmol, 12 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
was dried to produce a white solid (59 mg, 49%). m.p. = 125-148 °C. IR (solid) 3279, 2923, 
1729, 1634, 1591 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 7.9 Hz, 1H), 7.55 
(d, J = 7.8 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.19 – 7.10 (m, 3H), 7.10 – 7.03 (m, 3H), 7.01 
(s, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 2.3 Hz, 2H), 6.70 (t, J = 2.4 Hz, 1H), 4.81 (d, 
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J = 5.5 Hz, 1H), 4.79 – 4.73 (m, 1H), 4.66 (s, 4H), 3.35 (t, J = 4.7 Hz, 1H), 3.22 (dd, J = 
14.7, 7.6 Hz, 1H), 3.10 (dd, J = 13.9, 5.3 Hz, 1H), 2.84 (dd, J = 13.9, 9.1 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 174.99, 173.24, 172.25, 169.23, 160.50, 138.37, 138.09, 137.38, 
130.28, 129.39, 128.65, 127.71, 124.69, 122.49, 119.95, 119.24, 112.37, 110.48, 107.65, 
106.39, 65.99, 56.41, 54.30, 38.65, 28.40. HRMS (ESI) m/z calc’d for C31H29N3O10 
[M+Na]+ 626.1756, found 626.1754. 
 
 
(3-(carboxymethoxy)benzoyl)-D-phenylalanyl-L-tryptophan (54k). To a stirring solution of 
56k (75 mg, 0.13 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
1.5 mL, 0.067 M), lithium hydroxide monohydrate (44 mg, 1 mmol, 8 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
was dried to produce a white solid (57 mg, 83%). m.p. = 130-145 °C. IR (solid) 3289, 2923, 
1725, 1636, 1582 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.56 (d, J = 7.9 Hz, 1H), 7.31 
(dt, J = 7.9, 3.9 Hz, 2H), 7.27 – 7.17 (m, 2H), 7.17 – 7.11 (m, 3H), 7.11 – 7.05 (m, 2H), 
7.05 – 7.00 (m, 3H), 6.97 (t, J = 7.4 Hz, 1H), 4.85 – 4.82 (m, 1H), 4.77 (dd, J = 7.9, 5.1 
Hz, 1H), 4.68 (s, 2H), 3.35 (d, J = 5.0 Hz, 1H), 3.21 (dd, J = 14.8, 7.9 Hz, 1H), 3.09 (dd, J 
= 13.9, 5.4 Hz, 1H), 2.85 (dd, J = 13.9, 8.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 175.00, 
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173.25, 172.40, 169.53, 159.43, 138.32, 138.09, 136.65, 130.70, 130.29, 129.35, 128.69, 
127.68, 124.66, 122.48, 121.30, 119.95, 119.27, 119.24, 114.44, 112.36, 110.58, 65.88, 
56.32, 54.41, 38.73, 28.44. HRMS (ESI) m/z calc’d for C29H27N3O7 [M+H]+ 530.1909, found 
530.1921. 
 
 
Methyl (4-(2-ethoxy-2-oxoethoxy)benzoyl)-D-phenylalanyl-L-tryptophanate (56j). A 
stirring solution of 56h (74 mg, 0.15 mmol, 1 eq), ethyl bromoacetate (17 µL, 0.15 mmol, 
1 eq) and potassium carbonate (63 mg, 0.45 mmol, 3 eq)  in a acetone (1.5 mL, 0.1 M) 
was heated to 60 °C in a sealed tube. The reaction mixture was stirred for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. This residue was 
purified by flash chromatography (1% MeOH/CH2Cl2) to afford the product as an off-white 
foam (52.4 mg, 60%).  IR (thin film) 3304, 3060, 1742, 1634, 1606 cm-1. 1H NMR (500 
MHz, Chloroform-d) δ 8.42 (s, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.46 – 7.41 (m, 1H), 7.30 – 
7.25 (m, 1H), 7.20 – 7.15 (m, 3H), 7.12 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.08 – 7.01 (m, 
3H), 6.84 (dd, J = 22.6, 8.3 Hz, 4H), 6.73 (d, J = 2.4 Hz, 1H), 4.89 (q, J = 7.0 Hz, 1H), 4.81 
(dt, J = 7.9, 5.8 Hz, 1H), 4.62 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.58 (s, 3H), 3.24 (dd, J = 
14.8, 6.3 Hz, 1H), 3.17 – 3.06 (m, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 172.21, 170.94, 168.51, 166.65, 160.57, 136.60, 136.28, 129.46, 129.05, 128.66, 
127.31, 127.10, 127.02, 123.29, 122.20, 119.62, 118.43, 114.47, 111.47, 109.49, 65.25, 
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61.68, 54.79, 52.45, 38.31, 29.37, 27.53, 14.24. HRMS (ESI) m/z calc’d for C32H33N3O7 
[M+H]+ 572.2397, found 572.2390. 
 
 
(4-(carboxymethoxy)benzoyl)-D-phenylalanyl-L-tryptophan (54j). To a stirring solution of 
56j (52.4 mg, 0.09 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
1.4 mL, 0.067 M), lithium hydroxide monohydrate (30 mg, 1 mmol, 8 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
was dried to produce a white solid (39 mg, 81%). IR (solid) 3322, 2923, 1726, 1605, 1536 
cm-1. m.p. = 155-165 °C. 1H NMR (500 MHz, Chloroform-d) δ 7.62 (d, J = 8.8 Hz, 2H), 
7.55 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.11 (d, J = 3.5 Hz, 3H), 7.06 (t, J = 7.6 
Hz, 1H), 7.04 – 6.99 (m, 3H), 6.96 (dd, J = 15.1, 8.1 Hz, 3H), 4.83 (d, J = 9.2 Hz, 1H), 4.75 
(ddd, J = 7.7, 5.1, 2.6 Hz, 1H), 4.72 (s, 2H), 3.34 (d, J = 5.1 Hz, 1H), 3.20 (dd, J = 14.7, 
8.0 Hz, 1H), 3.09 (dd, J = 13.8, 5.4 Hz, 1H), 2.85 (dd, J = 13.9, 8.8 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 175.01, 173.39, 172.26, 169.29, 162.25, 138.35, 138.06, 130.27, 130.22, 
129.29, 128.68, 127.98, 127.62, 124.63, 122.48, 119.94, 119.22, 115.37, 112.34, 110.56, 
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65.85, 56.25, 54.42, 38.75, 28.42. HRMS (ESI) m/z calc’d for C29H27N3O7 [M-H]- 528.1771, 
found 528.1755. 
 
 
Methyl (tert-butoxycarbonyl)-D-tyrosyl-L-tryptophanate (64). To (tert-butoxycarbonyl)-D-
tyrosine (300 mg, 1 mmol, 1 eq) was added tryptophan methyl ester hydrochloride (260 
mg, 1 mmol, 1 eq), anhydrous N,N-diisopropylethylamine (1 mL, 5 mmol, 5 eq) and 
anhydrous acetonitrile (3.3 mL, 0.3 M). The reaction mixture was then cooled to 0 °C and 
HATU (570 mg, 1.5 mmol, 1.5 eq) was added. The reaction mixture was quenched with 
saturated ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL).  The 
organic layer was washed twice with deionized water (10 mL), followed by brine (10 mL). 
The organic was then dried over anhydrous sodium sulfate and concentrated to dryness 
in vacuo to afford the crude product as an orange foam. This residue was purified by flash 
chromatography plug (40% EtOAc/Hexanes) to afford the product as an off-white foam 
(350 mg, 73%). IR (solid) 3441, 2955, 1668, 1527, 1503 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.45 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.32 – 7.24 (m, 1H), 7.14 (t, J = 7.5 
Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 8.1 Hz, 2H), 6.63 – 6.56 (m, 3H), 5.19 (d, J 
= 8.2 Hz, 1H), 4.81 (q, J = 6.5 Hz, 1H), 4.30 (d, J = 8.9 Hz, 1H), 3.59 (s, 3H), 3.28 – 3.07 
(m, 2H), 2.97 – 2.77 (m, 2H), 1.37 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.44, 171.61, 
155.73, 155.27, 136.32, 130.53, 127.98, 127.38, 123.20, 122.28, 119.71, 118.42, 115.74, 
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111.53, 109.37, 80.59, 56.20, 52.95, 52.61, 37.86, 28.39, 27.63. HRMS (ESI) m/z calc’d 
for C26H31N3O6 [M-H]- 480.2135, found 480.2127. 
 
 
Methyl ((R)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-ethoxy-2-
oxoethoxy)phenyl)propanoyl)-L-tryptophanate (65). To a stirring solution of 64 (200 mg, 
0.4 mmol, 1 eq), ethyl bromoacetate (55 µL, 0.5 mmol, 1.2 eq) and potassium carbonate 
(172 mg, 1.2 mmol, 3 eq) in acetone (4 mL, 0.1 M) was heated to 60 °C in a sealed tube. 
The reaction mixture was stirred for 18 h. The reaction mixture was then concentrated to 
remove the organic solvents. This residue was purified by flash chromatography (1% 
MeOH/CH2Cl2) to afford the product as an off-white foam (46.2 mg, 20%).  IR (thin film) 
3304, 3060, 1742, 1634, 1606 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.64 (s, 1H), 7.43 
(d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.15 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.06 (dd, 
J = 14.2, 8.3 Hz, 3H), 6.73 (d, J = 8.2 Hz, 2H), 6.43 (s, 1H), 6.30 (d, J = 7.4 Hz, 1H), 5.10 
(d, J = 8.3 Hz, 1H), 4.82 – 4.74 (m, 1H), 4.60 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 3.63 (s, 
3H), 3.16 (td, J = 16.3, 15.0, 5.7 Hz, 2H), 2.93 (d, J = 7.2 Hz, 2H), 1.39 (s, 6H), 1.32 (t, J 
= 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.10, 170.99, 169.67, 156.96, 136.29, 
130.61, 130.07, 127.35, 123.12, 122.07, 119.51, 118.37, 114.84, 111.51, 109.17, 65.51, 
61.73, 53.96, 52.50, 29.41, 28.41, 27.53, 14.30. HRMS (ESI) m/z calc’d for C30H37N3O8 
[M+H]+ 568.2659, found 568.2669. 
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Methyl ((R)-2-(3,5-dimethylbenzamido)-3-(4-(2-ethoxy-2-oxoethoxy)phenyl)propanoyl)-L-
tryptophanate (66). To a stirring solution of 65 (46.2 mg, 0.08 mmol, 1 eq) in anhydrous 
dichloromethane (0.4 mL, 0.2 M), trifluoroacetic acid (70 µL, 0.8 mmol, 10 eq) was added 
dropwise at room temperature (20 °C). The reaction mixture was allowed to stir for 18 h. 
The reaction was then concentrated to dryness in vacuo. To the crude amine salt was 
added 3,5-dimethylbenzoic acid (12 mg, 0.08 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (60 µL, 0.33 mmol, 4 eq) and anhydrous acetonitrile (2.7 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (46 mg, 0.12 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (42 mg, 88%). IR (solid) 3300, 2922, 1739, 1637, 
1603 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.74 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.32 
(s, 3H), 7.18 – 7.10 (m, 2H), 7.04 (dd, J = 14.3, 7.6 Hz, 3H), 6.91 (d, J = 7.7 Hz, 1H), 6.68 
(d, J = 8.4 Hz, 2H), 6.56 (d, J = 7.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 4.86 – 4.74 (m, 2H), 
4.59 (s, 2H), 4.30 (q, J = 7.1 Hz, 2H), 3.62 (s, 3H), 3.27 – 3.14 (m, 2H), 3.03 (h, J = 8.2 
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Hz, 2H), 2.32 (s, 6H), 1.32 (t, J = 7.2 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 172.04, 
170.88, 169.71, 167.45, 157.00, 138.39, 136.35, 133.82, 133.52, 130.68, 129.97, 127.27, 
124.96, 123.31, 122.06, 119.49, 118.36, 114.82, 111.57, 109.13, 65.48, 61.75, 55.32, 
52.92, 52.55, 38.08, 27.44, 21.32, 14.30. HRMS (ESI) m/z calc’d for C33H36N4O6 [M+H]+ 
600.2710, found 600.2710. 
 
 
((R)-3-(4-(carboxymethoxy)phenyl)-2-(3,5-dimethylbenzamido)propanoyl)-L-tryptophan 
(60). To a stirring solution of 66 (42 mg, 0.07 mmol, 1 eq) in a mixture of tetrahydrofuran, 
methanol and water (3:1:1, 1 mL, 0.067 M), lithium hydroxide monohydrate (12 mg, 0.28 
mmol, 4 eq) was added portionwise. The reaction mixture was stirred at room temperature 
(20 °C) for 18 h. The reaction mixture was then concentrated to remove the organic 
solvents. 5% NaHSO4 was added until a solid precipitated. The solid was collected and 
washed with water. Product was dried to produce a white solid (27 mg, 69%). m.p. = 169-
175 °C. IR (solid) 2921, 1726, 1635, 1511, 1439 cm-1. 1H NMR (500 MHz, Chloroform-d) 
δ 7.57 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 1.6 Hz, 2H), 7.15 (s, 1H), 
7.08 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.01 (s, 1H), 6.98 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.83 
(d, J = 8.7 Hz, 2H), 6.62 (d, J = 8.6 Hz, 2H), 4.83 – 4.79 (m, 1H), 4.75 (dd, J = 8.6, 4.6 Hz, 
1H), 4.52 (d, J = 1.8 Hz, 2H), 3.36 (dd, J = 14.8, 4.7 Hz, 1H), 3.18 (dd, J = 14.8, 8.6 Hz, 
1H), 3.02 (dd, J = 14.0, 5.8 Hz, 1H), 2.79 (dd, J = 13.5, 7.3 Hz, 1H), 2.31 (s, 6H). 13C NMR 
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(126 MHz, MeOD) δ 175.11, 173.23, 170.14, 158.29, 139.40, 138.10, 135.17, 134.23, 
131.40, 130.96, 126.36, 126.02, 124.64, 122.48, 119.96, 119.23, 115.44, 112.41, 110.75, 
66.07, 56.16, 54.54, 38.01, 28.45, 21.24. HRMS (ESI) m/z calc’d for C31H31N3O7 [M+Na]+ 
580.2060, found 580.2057. 
 
 
Methyl (2-((tert-butoxycarbonyl)amino)benzoyl)-D-phenylalanyl-L-tryptophanate (56q). To 
a stirring solution of 55 (233 mg, 0.5 mmol, 1 eq) in anhydrous dichloromethane (2.5 mL, 
0.2 M), trifluoroacetic acid (390 µL, 5 mmol, 10 eq) was added dropwise at room 
temperature (20 °C). The reaction mixture was allowed to stir for 18 h. The reaction was 
then concentrated to dryness in vacuo. To the crude amine salt was added 2-((tert-
butoxycarbonyl)amino)benzoic acid (119 mg, 0.5 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (350 µL, 2 mmol, 4 eq) and anhydrous acetonitrile (1.7 mL, 0.3M). 
The reaction mixture was then cooled to 0 °C and HATU (285 mg, 1 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (1% MeOH/CH2Cl2) to 
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afford the product as an off-white foam (292 mg, 88%). IR (thin film) 3336, 2979, 1729, 
1634, 1587 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 10.04 (s, 1H), 8.32 (d, J = 8.4 Hz, 
1H), 8.26 (s, 1H), 7.46 – 7.38 (m, 2H), 7.29 (d, J = 8.1 Hz, 1H), 7.22 (d, J = 7.1 Hz, 4H), 
7.17 – 7.12 (m, 1H), 7.12 – 7.09 (m, 2H), 7.09 – 7.04 (m, 1H), 6.94 – 6.86 (m, 1H), 6.83 
(d, J = 7.6 Hz, 1H), 6.77 (d, J = 2.3 Hz, 1H), 6.47 (d, J = 7.7 Hz, 1H), 4.96 – 4.68 (m, 2H), 
3.62 (s, 3H), 3.27 (dd, J = 14.9, 5.9 Hz, 1H), 3.20 – 3.04 (m, 3H), 1.52 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ 172.10, 170.42, 168.71, 153.16, 140.39, 136.34, 136.27, 132.95, 
129.41, 128.84, 127.32, 127.27, 126.95, 123.12, 122.42, 121.65, 119.99, 119.80, 119.06, 
118.43, 111.47, 109.47, 80.70, 54.79, 52.75, 52.55, 38.32, 28.48, 27.55. HRMS (ESI) m/z 
calc’d for C33H36N4O6 [M+H]+ 585.2713, found 585.2718. 
 
 
Methyl D-phenylalanyl-L-tryptophanate (68). To a stirring solution of 55 (930 mg, 2 mmol, 
1 eq) in anhydrous dichloromethane (10 mL, 0.2 M), trifluoroacetic acid (1.6 mL, 20 mmol, 
10 eq) was added dropwise at room temperature (20 °C). The reaction mixture was 
quenched with saturated sodium bicarbonate (20 mL) and partitioned. The organic layer 
was washed with brine (20 mL) and dried over anhydrous sodium sulfate. The organic 
layer was then concentrated to dryness in vacuo to afford the crude product as an off-
white foam (730 mg, quant.). This residue was carried forward without further purification.  
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Methyl 3-(((R)-1-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamoyl)benzoate (56m). To the crude amine 68 (183 mg, 0.5 mmol, 
1 eq)was added 3-(methoxycarbonyl)benzoic acid (90 mg, 0.5 mmol, 1 eq), anhydrous 
N,N-diisopropylethylamine (350 µL, 2 mmol, 4 eq) and anhydrous acetonitrile (1.8 mL, 
0.3M). The reaction mixture was then cooled to 0 °C and HATU (285 mg, 1 mmol, 1.5 eq) 
was added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 
h. The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (1% MeOH/CH2Cl2) to 
afford the product as an off-white foam (130 mg, 49%). IR (solid) 1742, 1715, 1629, 1424 
cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.27 (t, J = 1.8 Hz, 1H), 8.08 (dt, J = 7.7, 1.3 Hz, 
1H), 7.83 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.49 (dt, J = 7.9, 1.0 Hz, 1H), 7.48 – 7.43 (m, 
1H), 7.30 (dt, J = 8.1, 0.9 Hz, 1H), 7.17 – 7.07 (m, 5H), 7.04 (ddd, J = 8.2, 7.0, 1.1 Hz, 
1H), 6.99 (s, 1H), 6.96 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.90 (dd, J = 8.9, 5.7 Hz, 2H), 4.78 
(dd, J = 7.9, 5.5 Hz, 2H), 3.88 (s, 2H), 3.64 (s, 1H), 3.35 (s, 3H), 3.29 – 3.21 (m, 1H), 3.15 
(dd, J = 14.8, 8.0 Hz, 1H), 3.08 (dd, J = 13.8, 5.7 Hz, 1H), 2.89 (dd, J = 13.8, 8.9 Hz, 1H), 
2.78 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 173.70, 173.25, 168.74, 167.59, 138.30, 
H
N
HN
OMe
O
NH2
O
H
N
HN
OMe
O
NH
O
O
HATU, DIPEA
CH3CN
O
OMeHO
O
O
OMe
  
155 
138.01, 135.64, 133.36, 132.78, 131.62, 130.33, 129.79, 129.42, 129.34, 128.58, 127.69, 
124.60, 122.48, 119.92, 119.08, 112.38, 110.38, 56.33, 54.70, 52.79, 52.75, 49.85, 38.85, 
28.44. HRMS (ESI) m/z calc’d for C30H29N3O6 [M+H]+ 528.2135, found 528.2134. 
 
 
Methyl 4-(((R)-1-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamoyl)benzoate (56l). To the crude amine 68 (183 mg, 0.5 mmol, 
1 eq)was added 4-(methoxycarbonyl)benzoic acid (90 mg, 0.5 mmol, 1 eq), anhydrous 
N,N-diisopropylethylamine (350 µL, 2 mmol, 4 eq) and anhydrous acetonitrile (1.8 mL, 
0.3M). The reaction mixture was then cooled to 0 °C and HATU (285 mg, 1 mmol, 1.5 eq) 
was added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 
h. The reaction mixture was quenched with saturated ammonium chloride (10 mL) and 
extracted with ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (1% MeOH/CH2Cl2) to 
afford the product as an off-white foam (89 mg, 34%). IR (solid) 1723, 1662, 1635, 1531, 
1497 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.01 (dd, J = 8.3, 2.5 Hz, 2H), 7.69 (dd, J 
= 8.4, 2.6 Hz, 2H), 7.49 (dd, J = 7.6, 2.5 Hz, 1H), 7.31 (dd, J = 8.3, 2.5 Hz, 1H), 7.13 (s, 
3H), 7.11 – 7.03 (m, 3H), 7.01 – 6.93 (m, 2H), 4.90 – 4.85 (m, 1H), 4.76 (t, J = 6.7, 6.2 Hz, 
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1H), 3.91 (s, 3H), 3.66 (s, 3H), 3.29 – 3.21 (m, 1H), 3.15 (ddd, J = 14.8, 8.1, 2.6 Hz, 1H), 
3.07 (dd, J = 13.0, 7.1 Hz, 1H), 2.91 – 2.82 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 172.21, 
171.68, 167.49, 166.15, 137.88, 136.78, 136.58, 132.50, 129.02, 128.81, 127.87, 127.10, 
127.05, 126.24, 123.11, 121.01, 118.43, 117.60, 110.89, 108.88, 54.83, 53.18, 51.35, 
51.26, 37.26, 26.94. HRMS (ESI) m/z calc’d for C30H29N3O6 [M+H]+ 528.2135, found 
528.2136. 
 
 
3-(((R)-1-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamoyl)benzoic acid (54m). To a stirring solution of 56m (130 mg, 0.25 mmol, 1 eq) 
in a mixture of tetrahydrofuran, methanol and water (3:1:1, 3.8 mL, 0.067 M), lithium 
hydroxide monohydrate (42 mg, 1 mmol, 4 eq) was added portionwise. The reaction 
mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture was then 
concentrated to remove the organic solvents. 5% NaHSO4 was added until a solid 
precipitated. The solid was collected and washed with water. Product was dried to produce 
a white solid (114 mg, 93%). m.p. = 161-171 °C. IR (solid) 3283, 2923, 1704, 1635, 1538 
cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.31 (d, J = 1.9 Hz, 1H), 8.14 (d, J = 7.7 Hz, 1H), 
7.82 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 
Hz, 1H), 7.13 (dt, J = 5.9, 2.9 Hz, 3H), 7.09 – 7.00 (m, 5H), 6.96 (t, J = 7.5 Hz, 1H), 4.91 
– 4.87 (m, 1H), 4.77 (dd, J = 8.0, 4.9 Hz, 1H), 3.38 – 3.33 (m, 1H), 3.20 (dd, J = 14.7, 8.0 
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Hz, 1H), 3.10 (dd, J = 13.9, 5.4 Hz, 1H), 2.86 (dd, J = 13.9, 9.0 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 175.10, 173.18, 169.04, 168.91, 138.32, 138.06, 135.69, 133.66, 132.62, 
130.31, 129.73, 129.66, 129.35, 128.73, 127.68, 124.61, 122.45, 119.94, 119.20, 112.32, 
110.65, 101.38, 56.39, 54.59, 38.78, 28.41. HRMS (ESI) m/z calc’d for C28H25N3O6 
[M+Na]+ 522.1641, found 522.1645. 
 
 
4-(((R)-1-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamoyl)benzoic acid (54l). To a stirring solution of 56l (79 mg, 0.15 mmol, 1 eq) in 
a mixture of tetrahydrofuran, methanol and water (3:1:1, 2.3 mL, 0.067 M), lithium 
hydroxide monohydrate (26 mg, 0.6 mmol, 4 eq) was added portionwise. The reaction 
mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture was then 
concentrated to remove the organic solvents. 5% NaHSO4 was added until a solid 
precipitated. The solid was collected and washed with water. Product was dried to produce 
a white solid (70 mg, 93%). m.p. = 139-145 °C. IR (solid) 3286, 2926, 1703, 1631, 1529 
cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.99 (t, J = 8.7 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 
7.55 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.11 (d, J = 2.0 Hz, 3H), 7.07 – 6.98 (m, 
4H), 6.96 (t, J = 7.4 Hz, 1H), 4.88 – 4.83 (m, 1H), 4.77 (dd, J = 8.1, 4.8 Hz, 1H), 3.34 (dd, 
J = 14.7, 5.1 Hz, 1H), 3.19 (dd, J = 14.6, 8.0 Hz, 1H), 3.07 (ddd, J = 14.1, 5.6, 3.2 Hz, 1H), 
2.83 (ddd, J = 14.0, 9.0, 2.6 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.82, 171.88, 
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167.83, 167.63, 137.88, 137.04, 136.79, 129.46, 129.24, 129.04, 128.08, 127.47, 127.26, 
127.17, 126.43, 123.36, 121.21, 118.68, 117.98, 111.08, 55.07, 53.29, 51.61, 37.50, 
27.17. HRMS (ESI) m/z calc’d for C28H25N3O6 [M+Na]+ 522.1641, found 522.1645. 
 
 
2-(((R)-1-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamoyl)benzenaminium chloride (54q). To a stirring solution of 56q (250 mg, 0.4 
mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 6 mL, 0.067 M), 
lithium hydroxide monohydrate (72 mg, 1.6 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce a white solid (149 mg, 61%). m.p. = 195-203 °C. This solid was carried forward 
to the next step. To a stirring solution of SRG-IV-086 (100 mg, 0.17 mmol, 1 eq) in 
anhydrous dichloromethane (900 µL, 0.2 M), hydrochloric acid (4N in dioxane, 440 µL, 1.7 
mmol, 10 eq) was added dropwise at room temperature (20 °C). The reaction mixture was 
allowed to stir for 18 h. The reaction was then concentrated to dryness in vacuo to produce 
an off-white solid (88.7 mg, quant). IR (solid) 2923, 2854, 1716, 1645, 1532 cm-1. 1H NMR 
(500 MHz, Methanol-d4) δ 7.58 (dd, J = 15.5, 7.7 Hz, 3H), 7.40 – 7.30 (m, 3H), 7.14 (dd, 
J = 5.2, 1.8 Hz, 3H), 7.09 – 7.03 (m, 4H), 6.99 (t, J = 7.5 Hz, 1H), 4.78 (dd, J = 8.4, 5.0 
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Hz, 1H), 3.34 (dd, J = 14.7, 5.0 Hz, 1H), 3.18 (dd, J = 14.7, 8.3 Hz, 1H), 3.02 (dd, J = 13.8, 
5.6 Hz, 1H), 2.83 (ddd, J = 13.9, 9.1, 2.0 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.82, 
171.90, 167.16, 137.01, 136.83, 132.65, 129.04, 128.63, 128.13, 127.47, 127.39, 126.51, 
123.57, 123.38, 121.22, 118.64, 117.99, 111.11, 109.49, 54.82, 53.33, 37.33, 27.27. 
HRMS (ESI) m/z calc’d for C27H26N4O4 [M+H]+ 471.2032, found 471.2031. 
 
 
 Methyl (3,5-bis(trifluoromethyl)benzoyl)-D-phenylalanyl-L-tryptophanate (56n). To a 
stirring solution of 55 (250 mg, 0.5 mmol, 1 eq) in anhydrous dichloromethane (2.7 mL, 
0.2 M), trifluoroacetic acid (410 µL, 5 mmol, 10 eq) was added dropwise at room 
temperature (20 °C). The reaction mixture was allowed to stir for 18 h. The reaction was 
then concentrated to dryness in vacuo. To the crude amine salt was added 3,5-
bis(trifluoromethyl)benzoic acid (138 mg, 0.5 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (560 µL, 3 mmol, 6 eq) and anhydrous acetonitrile (1.8 mL, 0.3 M). 
The reaction mixture was then cooled to 0 °C and HATU (306 mg, 0.8 mmol, 1.5 eq) was 
added. The reaction mixture was allowed to warm to room temperature (20 °C) for 18 h. 
The reaction mixture was quenched with saturated ammonium chloride (20 mL) and 
extracted with ethyl acetate (20 mL). The organic layer was washed twice with deionized 
water (20 mL), followed by brine (20 mL). The organic was then dried over anhydrous 
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sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (210 mg, 70% over two steps). IR (solid) 3284, 
1738, 1644, 1537, 1456 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 10.8 Hz, 
3H), 7.97 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.24 – 7.20 (m, 3H), 
7.15 (t, J = 7.6 Hz, 1H), 7.11 – 7.04 (m, 3H), 7.01 (d, J = 7.6 Hz, 1H), 6.75 (s, 1H), 6.40 
(d, J = 8.0 Hz, 1H), 4.85 (dtd, J = 14.2, 7.9, 7.1, 3.1 Hz, 2H), 3.65 (s, 3H), 3.26 (dd, J = 
14.9, 6.0 Hz, 1H), 3.16 (dd, J = 15.0, 5.6 Hz, 1H), 3.13 – 3.05 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 172.02, 170.27, 164.22, 136.25, 136.18, 135.98, 132.43, 132.15, 129.48, 
128.90, 127.52, 127.43, 125.34, 124.04, 122.84, 122.59, 119.99, 118.45, 111.44, 109.71, 
55.20, 53.02, 52.62, 38.57, 27.57. 19F NMR (471 MHz, C6D6) δ -62.91. HRMS (ESI) m/z 
calc’d for C30H25F6N3O4 [M+H]+ 606.1828, found 606.1830. 
 
 
(3,5-Bis(trifluoromethyl)benzoyl)-D-phenylalanyl-L-tryptophan (54n). To a stirring solution 
of 56n (130 mg, 0.2 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
3 mL, 0.067 M), lithium hydroxide monohydrate (36 mg, 0.9 mmol, 4 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
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was dried to produce a white solid (117 mg, 92%). m.p. = 143-165 °C. IR (solid) 3413, 
3286, 3064, 1736, 1644 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.16 (s, 2H), 8.10 (s, 
1H), 7.53 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.20 – 7.12 (m, 3H), 7.12 – 7.06 
(m, 2H), 7.03 (s, 1H), 6.98 (t, J = 7.8 Hz, 1H), 6.91 (t, J = 7.4 Hz, 1H), 4.91 (dd, J = 9.4, 
5.4 Hz, 1H), 4.78 (dd, J = 7.7, 5.1 Hz, 1H), 3.35 (d, J = 5.1 Hz, 1H), 3.21 (dd, J = 14.8, 7.7 
Hz, 1H), 3.11 (dd, J = 13.9, 5.5 Hz, 1H), 2.84 (dd, J = 13.9, 9.4 Hz, 1H). 13C NMR (126 
MHz, MeOD) δ 175.38, 172.86, 166.56, 138.39, 137.97, 137.69, 133.01, 132.75, 130.28, 
129.36, 129.07, 128.86, 127.73, 124.61, 122.31, 119.89, 119.16, 112.26, 110.70, 56.52, 
54.92, 38.71, 28.38. 19F NMR (471 MHz, MeOD) δ -64.38. HRMS (ESI) m/z calc’d for 
C29H23F6N3O4 [M+H]+ 592.1671, found 592.1673. 
 
 
Methyl (1-naphthoyl)-D-phenylalanyl-L-tryptophanate (56o). To the crude amine 68 (90 
mg, 0.25 mmol, 1 eq) was added 1-naphthoic acid (43 mg, 0.25 mmol, 1 eq), anhydrous 
N,N-diisopropylethylamine (180 µL, 1 mmol, 4 eq) and anhydrous acetonitrile (0.9 mL, 
0.3M). The reaction mixture was then cooled to 0 °C and HATU (142 mg, 0.4 mmol, 1.5 
eq) was added. The reaction mixture was allowed to warm to room temperature (20 °C) 
for 18 h. The reaction mixture was quenched with saturated ammonium chloride (10 mL) 
and extracted with ethyl acetate (10 mL). The organic layer was washed twice with 
deionized water (10 mL), followed by brine (10 mL). The organic was then dried over 
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anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as an orange foam. This residue was purified by flash chromatography (1% 
MeOH/CH2Cl2) to afford the product as an off-white foam (130 mg, quant.). IR (solid) 3284, 
1736, 1661, 1635, 1592 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.07 (s, 1H), 7.89 (dd, 
J = 18.0, 8.4 Hz, 2H), 7.82 (d, J = 8.2 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.37 – 7.30 (m, 3H), 
7.30 – 7.27 (m, 2H), 7.22 – 7.18 (m, 3H), 7.10 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 
6.73 (d, J = 7.8 Hz, 1H), 6.46 (d, J = 8.0 Hz, 1H), 5.01 (q, J = 7.5 Hz, 1H), 4.89 (dt, J = 
7.7, 5.6 Hz, 1H), 3.62 (s, 3H), 3.32 (dd, J = 15.0, 5.8 Hz, 1H), 3.24 (td, J = 14.1, 6.1 Hz, 
2H), 3.11 (dd, J = 14.0, 7.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 172.07, 170.56, 169.64, 
136.69, 136.30, 133.70, 133.53, 131.03, 130.09, 129.50, 128.90, 128.34, 127.49, 127.33, 
127.22, 126.55, 125.32, 125.25, 124.76, 123.25, 122.45, 119.87, 118.64, 111.44, 109.72, 
54.85, 52.86, 52.55, 38.02, 27.64. HRMS (ESI) m/z calc’d for C32H29N3O4 [M+Na]+ 
542.2056, found 542.2041. 
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Methyl (2-naphthoyl)-D-phenylalanyl-L-tryptophanate (56p). To the crude amine 68 (90 
mg, 0.25 mmol, 1 eq) was added 2-naphthoic acid (43 mg, 0.25 mmol, 1 eq), anhydrous 
N,N-diisopropylethylamine (180 µL, 1 mmol, 4 eq) and anhydrous acetonitrile (0.9 mL, 
0.3M). The reaction mixture was then cooled to 0 °C and HATU (142 mg, 0.4 mmol, 1.5 
eq) was added. The reaction mixture was allowed to warm to room temperature (20 °C) 
for 18 h. The reaction mixture was quenched with saturated ammonium chloride (10 mL) 
and extracted with ethyl acetate (10 mL). The organic layer was washed twice with 
deionized water (10 mL), followed by brine (10 mL). The organic was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as an orange foam. This residue was purified by flash chromatography (1% 
MeOH/CH2Cl2) to afford the product as an off-white foam (110 mg, 85%). IR (solid) 3278, 
1739, 1659, 1636, 1528 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.64 – 8.58 
(m, 1H), 8.36 (s, 1H), 7.95 (dd, J = 19.7, 8.4 Hz, 3H), 7.83 (dd, J = 8.6, 1.7 Hz, 1H), 7.58 
(td, J = 6.9, 1.5 Hz, 2H), 7.51 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.27 (d, J = 7.5 
Hz, 2H), 7.18 (dd, J = 14.3, 6.9 Hz, 4H), 7.12 (d, J = 7.3 Hz, 1H), 7.03 (t, J = 7.7 Hz, 1H), 
6.94 (t, J = 7.5 Hz, 1H), 4.82 (dd, J = 10.7, 4.4 Hz, 1H), 4.61 – 4.55 (m, 1H), 3.61 (s, 3H), 
3.18 (dd, J = 14.4, 5.3 Hz, 1H), 3.05 (dd, J = 14.5, 8.7 Hz, 1H), 2.93 – 2.87 (m, 1H), 2.86 
– 2.78 (m, 1H). 13C NMR (126 MHz, DMSO) δ 172.87, 171.95, 166.70, 138.82, 136.72, 
134.73, 132.62, 131.93, 129.80, 129.42, 128.56, 128.34, 128.24, 128.21, 128.18, 127.62, 
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127.30, 126.78, 124.80, 124.52, 121.55, 119.02, 118.60, 112.02, 109.87, 55.49, 53.60, 
52.51, 37.94, 27.92. HRMS (ESI) m/z calc’d for C32H29N3O4 [M+H]+ 520.2236, found 
520.2234. 
 
 
(1-Naphthoyl)-D-phenylalanyl-L-tryptophan (54o) To a stirring solution of 56o (130 mg, 
0.25 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 4 mL, 0.067 
M), lithium hydroxide monohydrate (104 mg, 2.5 mmol, 10 eq) was added portionwise. 
The reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction 
mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was added 
until a solid precipitated. The solid was collected and washed with water. Product was 
dried to produce a white solid (96.3 mg, 76%). m.p. = 126-140 °C. IR (solid) 3278, 3057, 
1725, 1636, 1591 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.88 (d, J = 8.2 Hz, 1H), 7.82 
(d, J = 8.3 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 
1H), 7.38 – 7.31 (m, 2H), 7.28 (t, J = 7.8 Hz, 1H), 7.24 – 7.20 (m, 3H), 7.20 – 7.13 (m, 
3H), 7.10 – 7.05 (m, 2H), 7.00 (t, J = 7.5 Hz, 1H), 5.03 (dd, J = 10.2, 4.8 Hz, 1H), 4.80 (dd, 
J = 7.6, 4.8 Hz, 1H), 3.40 (dd, J = 14.8, 4.8 Hz, 1H), 3.28 – 3.21 (m, 1H), 3.15 (d, J = 14.1 
Hz, 1H), 2.79 (dd, J = 13.9, 10.2 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 173.79, 171.98, 
170.88, 137.34, 136.83, 133.91, 133.61, 130.13, 129.85, 129.21, 128.23, 127.84, 126.66, 
126.51, 126.04, 125.10, 124.91, 124.49, 123.60, 123.43, 121.25, 118.72, 118.12, 111.13, 
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109.40, 54.92, 53.31, 37.46, 27.26. HRMS (ESI) m/z calc’d for C31H27N3O4 [M+H]+ 
506.2080, found 506.2089. 
 
 
(2-Naphthoyl)-D-phenylalanyl-L-tryptophan (54p). To a stirring solution of 56p (99.5 mg, 
0.2 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 3 mL, 0.067 
M), lithium hydroxide monohydrate (33 mg, 0.8 mmol, 4 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce a white solid (93.5 mg, 86%). m.p. = 150-159 °C. IR (solid) 3060, 1728, 1640, 
1520, 1457 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 8.08 (s, 1H), 7.91 – 7.82 (m, 3H), 
7.64 (dd, J = 8.6, 1.8 Hz, 1H), 7.59 – 7.50 (m, 3H), 7.22 (d, J = 7.9 Hz, 1H), 7.14 – 7.09 
(m, 3H), 7.09 – 7.05 (m, 2H), 7.04 (s, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 
4.92 (dd, J = 9.1, 5.2 Hz, 1H), 4.74 (dd, J = 7.4, 4.9 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.26 – 
3.14 (m, 2H), 2.89 (dd, J = 13.9, 9.1 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.50, 
171.97, 168.67, 137.18, 136.77, 134.98, 132.61, 131.08, 129.12, 128.77, 128.13, 128.08, 
127.97, 127.65, 127.58, 127.45, 126.50, 126.41, 123.56, 123.40, 121.15, 118.69, 118.06, 
111.06, 109.58, 55.15, 53.76, 51.55, 37.65, 27.34. HRMS (ESI) m/z calc’d for C31H27N3O4 
[M+H]+ 506.2080, found 506.2099. 
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Methyl ((3,5-dimethylphenyl)sulfonyl)-D-phenylalanyl-L-tryptophanate (70) To the crude 
amine 68 (91 mg, 0.25 mmol, 1 eq) and triethylamine (90 µL, 0.6 mmol, 2.4 eq) in 
anhydrous dichloromethane (1.25 mL, 0.2 M) was added 3,5-dimethylbenzenesulfonyl 
chloride (62 mg, 0.3 mmol, 1.2 eq) at 0 °C. The reaction mixture was allowed to warm to 
room temperature (20 °C) for 18 h. The reaction mixture was then quenched with saturated 
ammonium chloride (10 mL) and extracted with dichloromethane (10 mL). The organic 
was then dried over anhydrous sodium sulfate and concentrated to dryness in vacuo to 
afford the crude product as an off-white foam. This residue was purified by flash 
chromatography (1% MeOH/CH2Cl2) to afford the product as an off-white foam (107 mg, 
80%). IR (solid) 1738, 1658, 1520, 1456, 1436 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 
8.43 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.21 – 7.16 (m, 3H), 7.16 
– 7.08 (m, 6H), 7.05 (t, J = 7.5 Hz, 2H), 6.78 (d, J = 7.4 Hz, 2H), 5.07 (d, J = 6.1 Hz, 1H), 
4.89 (dt, J = 8.4, 5.3 Hz, 1H), 3.91 (dt, J = 8.6, 5.7 Hz, 1H), 3.59 (s, 3H), 3.41 (dd, J = 
14.8, 5.1 Hz, 1H), 3.21 (dd, J = 14.8, 5.6 Hz, 1H), 2.95 (dd, J = 14.1, 5.4 Hz, 1H), 2.74 
(dd, J = 14.2, 8.6 Hz, 1H), 2.27 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 172.00, 170.36, 
139.27, 138.19, 136.34, 135.16, 134.80, 129.05, 128.69, 127.40, 127.16, 124.69, 124.01, 
122.18, 119.63, 118.57, 111.47, 109.16, 58.24, 53.54, 52.45, 38.08, 27.68, 21.26. HRMS 
(ESI) m/z calc’d for C29H31N3O5S [M+H]+ 556.1882, found 556.1872. 
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((3,5-Dimethylphenyl)sulfonyl)-D-phenylalanyl-L-tryptophan (67). To a stirring solution of 
70 (91 mg, 0.17 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol and water (3:1:1, 
2.5 mL, 0.067 M), lithium hydroxide monohydrate (30 mg, 0.7 mmol, 4 eq) was added 
portionwise. The reaction mixture was stirred at room temperature (20 °C) for 18 h. The 
reaction mixture was then concentrated to remove the organic solvents. 5% NaHSO4 was 
added until a solid precipitated. The solid was collected and washed with water. Product 
was dried to produce a white solid (83 mg, 94%). m.p. = 100-110 °C. IR (solid) 3320, 2923, 
1728, 1656, 1525 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 10.29 (s, 1H), 7.55 (d, J = 7.8 
Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.21 (s, 2H), 7.11 (s, 1H), 7.08 – 6.96 (m, 6H), 6.90 – 
6.84 (m, 2H), 4.56 (t, J = 6.1 Hz, 1H), 3.98 (dd, J = 9.0, 5.2 Hz, 1H), 3.17 (qd, J = 14.7, 
6.1 Hz, 2H), 2.81 (dd, J = 13.9, 5.2 Hz, 1H), 2.55 (dd, J = 13.9, 9.0 Hz, 1H), 2.27 (s, 6H). 
13C NMR (126 MHz, MeOD) δ 173.40, 171.58, 139.91, 138.90, 136.38, 133.93, 128.99, 
127.83, 126.39, 124.20, 123.81, 123.64, 121.08, 118.53, 118.14, 111.00, 110.95, 58.23, 
53.02, 38.51, 27.45, 20.01. HRMS (ESI) m/z calc’d for C28H29N3O5S [M+H]+ 520.1906, 
found 520.1901. 
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Methyl N-(3,5-dimethylbenzoyl)-N-(2-ethoxy-2-oxoethyl)-D-phenylalanyl-L-tryptophanate 
(73). To amine 68 (180 mg, 0.5 mmol, 1 eq) in absolute ethanol (1 mL, 0.5 M), ethyl 
glyoxylate (50% w/v in tol, 160 µL, 0.75 mmol, 1.5 eq). After 1 hour, sodium 
cyanoborohydride (40 mg, 0.6 mmol, 1.2 eq) and glacial acetic acid (1 drop, catalytic) 
were added. After stirring for 18 h, the reaction mixture was concentrated to dryness in 
vacuo to afford the crude product as an orange foam. This residue was purified by flash 
chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (160 mg, 
0.4 mmol). To this product and triethylamine (120 µL, 0.9 mmol, 2.4 eq) in anhydrous 
dichloromethane (1.8 mL, 0.2 M) 3,5-dimethylbenzyl chloride (70 µL, 0.3 mmol, 1.2 eq) 
was added at 0 °C. The reaction mixture was allowed to warm to room temperature (20 
°C). After one hour 4-dimethylaminopyridine (5 mg, 0.04 mmol, 0.1 eq) was added to the 
reaction and it was heated to reflux for 18 h. The reaction mixture was then quenched with 
saturated ammonium chloride (10 mL) and extracted with dichloromethane (10 mL). The 
organic was then dried over anhydrous sodium sulfate and concentrated to dryness in 
vacuo to afford the crude product as a yellow foam. This residue was purified by flash 
chromatography (1% MeOH/CH2Cl2) to afford the product as an off-white foam (79.3 mg, 
38% over three steps). IR (solid) 3315, 2952, 1736, 1642, 1603 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.57 (d, J = 6.8 Hz, 1H), 8.45 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.35 – 7.29 
(m, 2H), 7.26 – 7.17 (m, 4H), 7.13 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 6.9 Hz, 2H), 6.78 (s, 
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1H), 6.04 (s, 2H), 4.78 (ddd, J = 11.1, 6.8, 3.8 Hz, 1H), 4.50 (dd, J = 11.6, 3.5 Hz, 1H), 
4.36 (d, J = 15.9 Hz, 1H), 4.28 (qd, J = 7.2, 1.7 Hz, 2H), 3.86 (d, J = 16.1 Hz, 1H), 3.82 (s, 
3H), 3.48 (dd, J = 14.7, 3.7 Hz, 2H), 3.19 (dd, J = 14.6, 11.6 Hz, 1H), 2.64 (dd, J = 14.7, 
11.6 Hz, 1H), 1.89 (s, 6H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.73, 
172.69, 170.98, 170.10, 137.71, 136.75, 136.44, 133.43, 131.40, 129.11, 128.56, 126.82, 
126.70, 123.72, 123.64, 122.06, 119.51, 118.42, 111.45, 110.35, 65.20, 62.00, 53.92, 
52.35, 46.28, 35.48, 26.82, 20.78, 13.98. HRMS (ESI) m/z calc’d for C34H37N3O6 [M+Na]+ 
606.2580, found 606.2589. 
 
 
N-(carboxymethyl)-N-(3,5-dimethylbenzoyl)-D-phenylalanyl-L-tryptophan (71). To a 
stirring solution of 73 (75 mg, 0.13 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol 
and water (3:1:1, 2 mL, 0.067 M), lithium hydroxide monohydrate (54 mg, 0.7 mmol, 10 
eq) was added portionwise. The reaction mixture was stirred at room temperature (20 °C) 
for 18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
NaHSO4 was added until a solid precipitated. The solid was collected and washed with 
water, then dissolved in dichloromethane. Organic was then concentrated to dryness in 
vacuo to produce an off-white foam (59 mg, 83%). IR (solid) 3301, 2923, 1727, 1634, 1538 
cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.62 (dd, J = 30.0, 7.8 Hz, 1H), 7.35 – 7.27 (m, 
3H), 7.25 – 7.20 (m, 3H), 7.10 (d, J = 7.4 Hz, 1H), 7.06 – 6.95 (m, 2H), 6.91 – 6.82 (m, 
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2H), 6.44 (s, 1H), 6.03 (s, 1H), 4.61 (ddd, J = 57.3, 11.4, 3.6 Hz, 1H), 4.40 – 4.20 (m, 1H), 
4.20 – 3.98 (m, 1H), 3.45 (ddd, J = 14.1, 9.6, 3.4 Hz, 1H), 3.16 (ddd, J = 23.2, 11.4, 3.4 
Hz, 1H), 2.83 – 2.69 (m, 1H), 2.26 – 2.11 (m, 2H), 1.89 (s, 6H). 13C NMR (126 MHz, MeOD) 
δ 174.39, 173.55, 172.35, 170.67, 138.33, 137.90, 136.87, 133.54, 131.07 (d, J = 10.3 
Hz), 128.95 (d, J = 20.8 Hz), 128.26 (d, J = 11.1 Hz), 126.90 (d, J = 4.7 Hz), 126.48 (d, J 
= 13.8 Hz), 123.47 (d, J = 20.3 Hz), 122.87, 121.12, 118.58 (d, J = 7.3 Hz), 117.59 (d, J = 
12.2 Hz), 111.22, 109.68, 64.69 (d, J = 178.7 Hz), 54.15 (d, J = 14.6 Hz), 45.73, 34.35 (d, 
J = 131.6 Hz), 26.50 (d, J = 26.6 Hz), 19.51 (d, J = 16.3 Hz). HRMS (ESI) m/z calc’d for 
C31H31N3O6 [M+H]+ 542.2291, 542.2297 found. 
 
Methyl (3,5-dimethylbenzoyl)-D-phenylalanyl-L-histidinate (53c). To the amino ester (121 
mg, 0.5 mmol, 1 eq) was added acid dipeptide (148 mg, 0.5 mmol, 1 eq), anhydrous N,N-
diisopropylethylamine (440 µL, 2.5 mmol, 5 eq) and anhydrous N,N-dimethylformamide 
(1.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and HATU (285 mg, 0.75 
mmol, 1.5 eq) was added. The reaction mixture was allowed to warm to room temperature 
(20 °C) for 18 h. The reaction mixture was poured over 100 mL ice water. After stirring for 
5 mins, precipitate collected and dried in vacuo to afford the product as an off-white solid 
(158 mg, 71%). m.p. = 178-185 °C. IR (solid) 3277, 3183, 1741, 1634, 1601 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 7.56 (s, 1H), 7.44 (s, 1H), 7.33 – 7.25 (m, 5H), 7.22 (t, J = 7.7 
Hz, 3H), 7.11 (s, 1H), 6.85 (s, 1H), 6.71 (s, 1H), 4.84 (t, J = 7.1 Hz, 1H), 4.70 (dd, J = 7.2, 
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4.8 Hz, 1H), 3.64 (s, 3H), 3.26 (dd, J = 13.8, 6.5 Hz, 1H), 3.16 (dd, J = 14.0, 7.1 Hz, 1H), 
3.12 – 2.98 (m, 2H), 2.29 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 171.58, 171.54, 168.47, 
138.41, 136.63, 134.99, 133.70, 133.49, 131.62, 129.45, 128.73, 127.13, 125.04, 117.96, 
55.34, 52.85, 52.65, 38.00, 28.22, 21.24. HRMS (ESI) m/z calc’d for C25H28N4O4 [M+H]+ 
449.2189, found 449.2197.  
 
 
Methyl (3,5-dimethylbenzoyl)-D-phenylalanyl-L-phenylalaninate (53b). To the amino ester 
(107 mg, 0.5 mmol, 1 eq) was added acid dipeptide (148 mg, 0.5 mmol, 1 eq), anhydrous 
N,N-diisopropylethylamine (440 µL, 2.5 mmol, 5 eq) and anhydrous N,N-
dimethylformamide (1.7 mL, 0.3M). The reaction mixture was then cooled to 0 °C and 
HATU (285 mg, 0.75 mmol, 1.5 eq) was added. The reaction mixture was allowed to warm 
to room temperature (20 °C) for 18 h. The reaction mixture was poured over 100 mL ice 
water. After stirring for 5 mins, precipitate collected and dried in vacuo to afford the product 
as an off-white solid (158 mg, 69%). m.p. = 170-188 °C. IR (solid) 3275, 1739, 1663, 1634, 
1600 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.33 – 7.26 (m, 5H), 7.24 – 7.20 (m, 3H), 
7.20 – 7.15 (m, 2H), 7.13 (s, 1H), 6.98 – 6.93 (m, 2H), 6.74 (d, J = 7.6 Hz, 1H), 6.56 (d, J 
= 8.1 Hz, 1H), 4.89 (q, J = 7.1 Hz, 1H), 4.83 (dt, J = 7.9, 6.1 Hz, 1H), 3.64 (s, 3H), 3.14 (d, 
J = 6.9 Hz, 2H), 3.03 (dd, J = 13.8, 6.4 Hz, 1H), 2.96 (dd, J = 13.9, 5.8 Hz, 1H), 2.33 (s, 
6H). 13C NMR (126 MHz, CDCl3) δ 171.33, 170.53, 167.41, 138.16, 136.42, 135.54, 
1) TFA, CH2Cl2 HN
OMe
O
O
NH
O
HO
O H
N
O
MeO
O
NH3
Cl- +
2) HATU, DIPEA,
    DMF
  
172 
133.59, 133.30, 129.32, 129.06, 128.59, 128.54, 127.06, 126.99, 124.72, 54.65, 53.13, 
52.18, 38.33, 37.77, 21.08. HRMS (ESI) m/z calc’d for C28H30N2O4 [M+H]+ 459.2284, found 
459.2282. 
  
 
N-(carboxymethyl)-N-(3,5-dimethylbenzoyl)-D-phenylalanyl-L-tryptophan (51b). To a 
stirring solution of 53b (100 mg, 0.22 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol 
and water (3:1:1, 3.3 mL, 0.067 M), lithium hydroxide monohydrate (93 mg, 2.2 mmol, 10 
eq) was added portionwise. The reaction mixture was stirred at room temperature (20 °C) 
for 18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
NaHSO4 was added until a solid precipitated. The solid was collected and washed with 
water. Product was dried to produce a white solid (97 mg, quant). m.p. = 105-112 °C. IR 
(solid) 3280, 3031, 2920, 1717, 1635 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.29 – 7.10 
(m, 13H), 4.70 (dd, J = 8.0, 5.1 Hz, 1H), 3.15 (ddd, J = 18.7, 13.9, 5.2 Hz, 2H), 3.01 (dd, 
J = 13.8, 8.0 Hz, 1H), 2.88 (dd, J = 13.9, 9.2 Hz, 1H), 2.32 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.26, 171.77, 168.80, 137.85, 137.02, 136.70, 133.64, 132.71, 128.94, 
128.81, 127.98, 127.87, 126.29, 126.20, 124.60, 54.85, 53.66, 37.28, 37.01, 19.73. HRMS 
(ESI) m/z calc’d for C27H28N2O4 [M+H]+ 445.2127, found 445.2138. 
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Benzyl (S)-(1-cyano-2-(1H-indol-3-yl)ethyl)carbamate (50). To a solution of N-Cbz-L-trp 
(1.35 g, 4 mmol, 1 eq) in anhydrous tetrahydrofuran (20 mL, 0.2 M) at -10 °C, N-
methylmorpholine (490 µL, 4.4 mmol, 1.1 eq) was added dropwise, followed by isobutyl 
chloroformate (570 µL, 4.4 mmol, 1.1 eq). After the reaction had been stirring 20 mins, 
aqueous ammonium hydroxide (1.6 mL, 2.5 M) was added and the reaction was allowed 
to warm to room temperature (20 °C) for 18 h. The reaction was then diluted with ethyl 
acetate (20 mL) and partitioned with saturated sodium bicarbonate (20 mL). The aqueous 
was further extracted one time with ethyl acetate (20 mL). The combined organic was 
washed with saturated sodium bicarbonate (20 mL), brine (20 mL) and dried over 
anhydrous sodium sulfate. The organic was then concentrated to dryness in vacuo to 
afford the product as a white solid (1.35 g, quant). This solid was then suspended in 
anhydrous tetrahydrofuran (20 mL, 0.2 M) and anhydrous triethylamine (1.7 mL, 12 mmol, 
3 eq). Trifluoroacetic anhydride (840 µL, 6 mmol, 1.5 eq) was then added dropwise at -10 
°C. The reaction was allowed to warm to room temperature for 18 h. The reaction was 
quenched with sodium bicarbonate until gas stopped evolving. The reaction mixture was 
then diluted with ethyl acetate (20 mL) and partitioned. The organic layer was washed with 
brine (20 mL), dried over anhydrous sodium sulfate and concentrated to dryness in vacuo 
to afford the product as a white solid (1.3 g, quant over two steps). m.p. = 160-162 °C. IR 
(solid) 1691, 1531, 1460, 1346, 1312 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.17 (s, 
1H), 7.59 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.35 (q, J = 8.1, 7.5 Hz, 5H), 7.24 
(s, 2H), 7.15 (t, J = 7.5 Hz, 1H), 5.13 (s, 2H), 5.10 (s, 1H), 4.99 (s, 1H), 3.30 (d, J = 5.9 
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Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 156.19, 136.55, 136.36, 127.99, 127.60, 127.36, 
126.89, 123.58, 121.13, 118.74, 118.59, 117.51, 110.92, 107.85, 66.50, 43.80, 28.69. 
HRMS (ESI) m/z calc’d for C19H17N3O2 [M+H]+ 320.1399, found 320.1406. 
 
 
(S)-2-(1H-indol-3-yl)-1-(1H-tetrazol-5-yl)ethan-1-amine (48). A sealed vessel containing 
50 (320 mg, 1 mmol, 1 eq), sodium azide (72 mg, 1.1 mmol, 1.1 eq) and ammonium 
chloride (62 mg, 1.15 mmol, 1.15 eq in anhydrous N,N-dimethylformamide (3.3 mL, 0.3 
M) was heated to 90 °C for 18 h. The reaction mixture was then cooled and poured over 
ice water (50 mL). The aqueous was adjusted to pH ~4 with saturated sodium bisulfate, 
then extracted three times with ethyl acetate (30 mL). The organic layer was washed four 
times with water (30 mL), once with brine (30 mL), dried over anhydrous sodium sulfate 
and then concentrated to dryness in vacuo to afford the product as a yellow solid (320 mg, 
0.88 mmol, 1 eq). This solid was taken up in methanol (8.8 mL, 1 M) and palladium on 
carbon (32 mg, 10% w/w) was added. The reaction mixture was then sparged with argon 
for 15 mins, followed by hydrogen for 15 mins. The reaction was then left to stir under a 
hydrogen atmosphere for 18 h. The reaction mixture was then filtered through celite with 
an excess of methanol and concentrated to dryness to afford the product was a yellow 
solid (214 mg, 88% over two steps). m.p. = 195-210 °C. IR (solid) 2918, 1616, 1491, 1456, 
1418 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.49 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.1 
Hz, 1H), 7.10 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.02 (ddd, J = 8.1, 7.0, 1.0 Hz, 1H), 6.99 (s, 
1H), 4.89 (dd, J = 7.7, 6.8 Hz, 1H), 3.59 (dd, J = 14.7, 6.8 Hz, 1H), 3.43 (dd, J = 14.7, 7.7 
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Hz, 1H). 13C NMR (126 MHz, MeOD) δ 159.53, 136.93, 127.13, 124.07, 121.43, 118.88, 
117.69, 111.20, 107.64, 48.48, 29.73. HRMS (ESI) m/z calc’d for C11H12N6 [M+H]+ 
229.1202, found 229.1199. 
 
 
N-((R)-1-(((S)-2-(1H-Indol-3-yl)-1-(2H-tetrazol-5-yl)ethyl)amino)-1-oxo-3-phenylpropan-2-
yl)-3,5-dimethylbenzamide (47). To a flask containing 39 (156mg, 0.5 mmol, 1 eq), 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (115 mg, 0.6 mmol, 1.2 eq) and 
hydroxybenzotriazole (81 mg, 0.6 mmol, 1.2 eq), anhydrous N,N-dimethylformamide (3 
mL, 0.17 M) was added. After 10 mins, 48 (115 mg, 0.5 mmol, 1 eq) was added, followed 
by N,N-diisopropylethylamine (180 µL, 1 mmol, 2 eq). The reaction mixture was stirred at 
room temperature (20 °C) for 18 h, then poured over ice water (10 mL). The precipitate 
was filtered and purified by flash chromatography (5% MeOH/CH2Cl2) to afford the product 
as an off-white solid (94 mg, 37%). m.p. = 199-209 °C. IR (solid) 2919, 1636, 1600, 1513, 
1456 cm-1. 1H NMR (500 MHz, DMSO-d6) δ 16.24 (s, 1H), 10.84 (s, 1H), 8.92 (dd, J = 
40.0, 7.7 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.52 (dd, J = 55.3, 7.9 Hz, 1H), 7.37 (d, J = 
11.3 Hz, 2H), 7.31 (dd, J = 8.1, 5.2 Hz, 1H), 7.26 (d, J = 7.0 Hz, 1H), 7.23 – 7.16 (m, 3H), 
7.13 (dd, J = 8.4, 6.3 Hz, 2H), 7.06 (td, J = 8.0, 7.1, 2.1 Hz, 2H), 6.96 (dt, J = 14.8, 7.5 Hz, 
1H), 5.49 – 5.40 (m, 1H), 4.79 – 4.70 (m, 1H), 3.36 (dd, J = 11.8, 7.5 Hz, 1.5H), 3.25 (dd, 
J = 14.4, 8.2 Hz, 0.5H), 3.06 (dd, J = 13.9, 4.2 Hz, 0.5H), 2.91 (dd, J = 14.1, 10.2 Hz, 1H), 
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2.85 – 2.76 (m, 0.5H), 2.28 (d, J = 10.2 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 171.97 
(d, J = 24.4 Hz), 167.05 (d, J = 27.9 Hz), 158.07, 138.73 (d, J = 12.9 Hz), 137.87, 136.69 
(d, J = 10.7 Hz), 134.66 (d, J = 10.0 Hz), 133.11, 129.75 (d, J = 10.9 Hz), 128.57 (d, J = 
4.5 Hz), 127.62, 126.79, 125.71 (d, J = 8.1 Hz), 124.50 (d, J = 21.7 Hz), 121.61, 119.07, 
118.66 (d, J = 17.8 Hz), 112.04, 109.78 (d, J = 26.6 Hz), 55.10 (d, J = 8.9 Hz), 45.61 (d, J 
= 53.3 Hz), 37.80 (d, J = 40.4 Hz), 30.05, 21.42 (d, J = 3.5 Hz). HRMS (ESI) m/z calc’d for 
C29H29N7O2 [M+H]+ 508.2461, found 508.2454. 
 
 
Methyl ((R)-2-amino-3-(4-iodophenyl)propanoyl)-L-tryptophanate (79). To the tryptophan 
methyl ester (7.6 g, 30 mmol, 1 eq) and iodide 787 (11.7 g, 30 mmol, 1 eq) in anhydrous 
N,N-dimethylformamide (100 mL, 0.3M) was added N,N-diisopropylethylamine (25 mL, 
150 mmol, 5 eq). The reaction mixture was then cooled to 0 °C and HATU (17 g, 45 mmol, 
1.5 eq) was added. The reaction mixture was allowed to warm to room temperature (20 
°C) for 18 h. The reaction mixture was poured over ice water (500 mL), filtered and dried 
in vacuo to afford the crude product as a purple solid. The crude product was then 
dissolved in anhydrous dichloromethane (150 mL, 0.2 M) and trifluoroacetic acid (20 mL, 
300 mmol, 10 eq) was added. After stirring for 18 h at room temperature (20 °C), the 
reaction was quenched slowly with saturated sodium bicarbonate (200 mL). Layers were 
then partitioned and the aqueous was extracted a further two times with dichloromethane. 
The combined organic was washed with brine (100 mL) and dried over sodium sulfate. 
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The reaction was concentrated in vacuo to yield the crude product as an orange foam. 
This residue was purified by flash chromatography (1-2% MeOH/CH2Cl2) to afford the 
product as an off-white foam (10.5 g, 71% over two steps). IR (solid) 3300, 2949, 1737, 
1651, 1511 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.04 (s, 1H), 7.64 (d, J = 8.1 Hz, 
1H), 7.63 – 7.57 (m, 2H), 7.53 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.17 (t, J = 7.1 
Hz, 1H), 7.09 (t, J = 7.2 Hz, 1H), 6.98 – 6.89 (m, 3H), 4.92 (dt, J = 8.2, 5.6 Hz, 1H), 3.70 
(s, 3H), 3.50 (dd, J = 9.3, 4.2 Hz, 1H), 3.39 – 3.25 (m, 2H), 3.15 (dd, J = 13.9, 4.2 Hz, 1H), 
2.61 (dd, J = 13.8, 9.3 Hz, 1H), 1.10 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 173.94, 172.40, 
137.83, 137.67, 136.25, 131.45, 127.80, 122.79, 122.35, 119.66, 118.66, 111.47, 110.32, 
92.22, 56.43, 52.91, 52.51, 40.39, 27.75. HRMS (ESI) m/z calc’d for C21H22IN3O3 [M+H]+ 
492.0784, found 492.0789. 
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Methyl ((R)-2-(3,5-dimethylbenzamido)-3-(4-iodophenyl)propanoyl)-L-tryptophanate (80). 
To the amine 79 (1.15 g, 2.3 mmol, 1 eq) and 3,5-dimethylbenzoic acid (350 mg, 2.3 mmol, 
1 eq) in anhydrous N,N-dimethylformamide (7.5 mL, 0.3 M) was added N,N-
diisopropylethylamine (1.6 mL, 9 mmol, 4 eq). The reaction mixture was then cooled to 0 
°C and HATU (1.3 g, 3.4 mmol, 1.5 eq) was added. The reaction mixture was allowed to 
warm to room temperature (20 °C) for 18 h. The reaction mixture was poured over ice 
water (200 mL), filtered and dried in vacuo to afford the product as an off white solid (1.5 
g, quant). m.p. = 128-142 °C. IR (solid) 1758, 1662, 1637, 1600, 1528 cm-1. 1H NMR (500 
MHz, DMSO-d6) δ 10.89 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H), 7.52 
(dd, J = 7.9, 5.2 Hz, 3H), 7.36 (s, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 
7.13 (s, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 8.0 Hz, 2H), 6.97 (t, J = 7.4 Hz, 1H), 4.74 
(td, J = 10.1, 9.6, 3.9 Hz, 1H), 4.57 (q, J = 8.0 Hz, 1H), 3.62 (s, 3H), 3.19 (dd, J = 14.5, 
5.3 Hz, 1H), 3.04 (dd, J = 14.5, 8.9 Hz, 1H), 2.78 (dd, J = 13.6, 4.1 Hz, 1H), 2.71 (dd, J = 
11.7, 9.3 Hz, 1H), 2.28 (s, 6H). 13C NMR (126 MHz, DMSO) δ 172.85, 171.74, 166.88, 
138.63, 137.89, 137.26, 136.72, 134.51, 133.14, 132.23, 127.61, 125.64, 124.54, 121.57, 
119.05, 118.62, 112.03, 109.86, 92.72, 54.66, 53.57, 52.53, 37.36, 27.93, 21.41. HRMS 
(ESI) m/z calc’d for C30H30IN3O4 [M+H]+ 624.1359, found 624.1361. 
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Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-iodophenyl)propanamido)-3-
methoxy-3-oxopropyl)-1H-indole-1-carboxylate (81). To a stirring solution of 80 (215 mg, 
0.35 mmol, 1 eq) in anhydrous N,N-dimethylformamide (1.4 mL, 0.1 M), di-tert-butyl 
dicarbonate (94 mg, 0.43 mmol, 1.3 eq) was added portionwise, followed by N,N-
dimethylamino pyridine (4 mg, 0.04 mmol, 0.1 eq)  at 0 °C. Allowed to warm to room 
temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL) two times. The 
organic layer was washed with water (10 mL) ten times, brine (10 mL) and dried over 
anhydrous sodium sulfate. The organic layer was then concentrated to dryness in vacuo 
to afford the crude product as an off-white foam. This residue was purified by flash 
chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (250 mg, 
quant). IR (solid) 3277, 2977, 1732, 1634, 1602 cm-1. 1H NMR (500 MHz, Chloroform-d) 
δ 8.11 (s, 1H), 7.53 – 7.41 (m, 4H), 7.38 – 7.29 (m, 1H), 7.27 (d, J = 4.6 Hz, 2H), 7.26 – 
7.16 (m, 2H), 7.11 (s, 1H), 6.86 (d, J = 7.7 Hz, 1H), 6.76 (d, J = 8.1 Hz, 2H), 4.98 (q, J = 
6.9 Hz, 1H), 4.88 (td, J = 7.4, 5.7 Hz, 1H), 3.62 (s, 3H), 3.19 (dd, J = 14.7, 5.7 Hz, 1H), 
3.12 (dt, J = 14.2, 7.3 Hz, 2H), 3.02 (dd, J = 13.9, 6.2 Hz, 1H), 2.31 (s, 6H), 1.64 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 171.84, 170.87, 167.77, 149.63, 138.43, 137.64, 136.12, 
133.68, 133.63, 131.50, 130.37, 124.94, 124.83, 124.33, 122.87, 118.84, 115.55, 115.13, 
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100.11, 92.58, 83.96, 54.26, 52.75, 52.62, 37.98, 28.33, 27.66, 21.34. HRMS (ESI) m/z 
calc’d for C35H38IN3O6 [M+H]+ 724.1884, found 724.1882. 
 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(pyridin-4-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83b). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), 4-pyridyl boronic acid (69 
mg, 0.55 mmol, 2 eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 
complex with dichloromethane (23 mg, 0.03 mmol, 0.1 eq) and sodium carbonate (240 
mg, 2.2 mmol, 8 eq) was added in deionized water (1.1 mL, 2 M {relative to Na2CO3}) and 
N,N-dimethylformamide (7 mL, 0.04 M) at room temperature (20 °C). The reaction mixture 
was then heated to 80 °C for 18 h. The reaction mixture was then diluted with ethyl acetate 
and then quenched with saturated ammonium chloride (10 mL). The organic layer was 
extracted and washed 4 times with deionized water (10 mL), followed by brine (10 mL). 
The organic layer was then dried over anhydrous sodium sulfate and concentrated to 
dryness in vacuo to afford the crude product as a brown foam. This residue was purified 
by flash chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam 
(64 mg, 34%). IR (solid) 2926, 1732, 1637, 1599, 1537 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.59 (d, J = 5.1 Hz, 2H), 8.08 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.45 – 7.36 
(m, 5H), 7.28 (s, 3H), 7.20 (d, J = 7.4 Hz, 1H), 7.16 (d, J = 7.9 Hz, 2H), 7.10 (s, 2H), 6.90 
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(d, J = 7.7 Hz, 1H), 5.01 (q, J = 6.9 Hz, 1H), 4.91 (q, J = 6.7 Hz, 1H), 3.61 (s, 3H), 3.28 – 
3.17 (m, 2H), 3.15 (dd, J = 6.4, 2.9 Hz, 2H), 2.29 (s, 6H), 1.61 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 171.79, 170.92, 167.69, 150.31, 150.27, 147.93, 138.40, 137.75, 136.76, 
133.78, 133.58, 130.41, 130.26, 127.23, 127.17, 124.95, 124.81, 124.26, 122.81, 121.54, 
118.82, 115.52, 115.08, 83.92, 54.53, 52.62, 52.59, 38.26, 28.28, 27.72, 21.30. HRMS 
(ESI) m/z calc’d for C40H42N4O6 [M+H]+ 675.3183, found 675.3174. 
 
 
Tert-butyl 3-((S)-2-((R)-3-([1,1'-biphenyl]-4-yl)-2-(3,5-dimethylbenzamido)propanamido)-
3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83a). To a sealed vessel containing 
iodide 81 (200 mg, 0.28 mmol, 1 eq), phenyl boronic acid (67 mg, 0.55 mmol, 2 eq), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (23 
mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 mmol, 5 eq) was added in 
anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room temperature (20 °C). The 
reaction mixture was then heated to 80 °C for 18 h. The reaction mixture was then diluted 
with ethyl acetate and then quenched with saturated ammonium chloride (10 mL). The 
organic layer was extracted and washed 4 times with deionized water (10 mL), followed 
by brine (10 mL). The organic layer was then dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the crude product as a brown foam. This 
residue was purified by flash chromatography (30% EtOAc/Hex) to afford the product as 
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an off-white foam (141 mg, 76%). IR (solid) 3276, 1732, 1635, 1602, 1537 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 8.11 (s, 1H), 7.50 (d, J = 8.2 Hz, 3H), 7.45 (s, 1H), 7.44 – 7.37 
(m, 4H), 7.35 – 7.29 (m, 4H), 7.26 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.18 (d, J 
= 8.1 Hz, 2H), 7.10 (s, 1H), 7.01 (d, J = 7.7 Hz, 1H), 5.10 (q, J = 7.0 Hz, 1H), 4.94 (dt, J = 
8.0, 6.4 Hz, 1H), 3.60 (s, 3H), 3.28 – 3.19 (m, 2H), 3.15 (d, J = 6.4 Hz, 2H), 2.30 (s, 6H), 
1.63 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.86, 171.21, 167.84, 149.66, 140.86, 
139.96, 138.37, 135.65, 133.91, 133.53, 130.44, 129.97, 128.85, 127.36, 127.32, 127.11, 
125.04, 124.77, 124.34, 122.82, 118.91, 115.52, 115.22, 83.84, 54.71, 52.71, 52.54, 
38.31, 28.30, 27.77, 21.32. HRMS (ESI) m/z calc’d for C41H43N3O6 [M+H]+ 674.3230, found 
674,3233. 
 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(3,5-dimethylisoxazol-4-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83e). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), 3,5-dimethylisooxazole-4-
boronic ester (123 mg, 0.55 mmol, 2 eq), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (23 
mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 mmol, 5 eq) was added in 
anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room temperature (20 °C). The 
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reaction mixture was then heated to 80 °C for 18 h. The reaction mixture was then diluted 
with ethyl acetate and then quenched with saturated ammonium chloride (10 mL). The 
organic layer was extracted and washed 4 times with deionized water (10 mL), followed 
by brine (10 mL). The organic layer was then dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the crude product as a brown foam. This 
residue was purified by flash chromatography (30% EtOAc/Hex) to afford the product as 
an off-white foam (144 mg, 75%). IR (solid) 3280, 2928, 1732, 1635, 1603 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 8.09 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.43 (s, 1H), 7.28 (d, J 
= 9.7 Hz, 3H), 7.21 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 8.9 Hz, 3H), 7.06 (d, J = 7.5 Hz, 2H), 
6.99 (d, J = 7.9 Hz, 1H), 6.85 (d, J = 7.7 Hz, 1H), 5.00 (q, J = 7.0 Hz, 1H), 4.90 (q, J = 6.8 
Hz, 1H), 3.63 (s, 3H), 3.23 – 3.10 (m, 4H), 2.32 (d, J = 7.1 Hz, 9H), 2.19 (s, 3H), 1.62 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 171.81, 170.90, 167.73, 165.23, 158.71, 149.61, 
138.41, 135.90, 135.47, 133.82, 133.58, 130.37, 129.94, 129.26, 124.92, 124.82, 124.33, 
122.83, 118.81, 116.31, 115.51, 115.03, 83.94, 54.50, 52.72, 52.59, 38.17, 28.28, 27.74, 
21.31, 21.27, 11.64, 10.89. HRMS (ESI) m/z calc’d for C40H44N4O7 [M+H]+ 693.3288, found 
693.3295. 
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Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(1-methyl-1H-pyrazol-4-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83f). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), 1-methyl-4-pyrazole 
boronic ester (115 mg, 0.55 mmol, 2 eq), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (23 
mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 mmol, 5 eq) was added in 
anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room temperature (20 °C). The 
reaction mixture was then heated to 80 °C for 18 h. The reaction mixture was then diluted 
with ethyl acetate and then quenched with saturated ammonium chloride (10 mL). The 
organic layer was extracted and washed 4 times with deionized water (10 mL), followed 
by brine (10 mL). The organic layer was then dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the crude product as a brown foam. This 
residue was purified by flash chromatography (1% MeOH/CH2Cl2) to afford the product as 
an off-white foam (149 mg, 80%). IR (solid) 1732, 1636, 1602, 1532, 1452 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 8.08 (s, 1H), 7.66 (s, 1H), 7.48 (s, 1H), 7.43 (d, J = 7.7 Hz, 
1H), 7.37 (s, 1H), 7.31 – 7.23 (m, 5H), 7.19 (td, J = 7.5, 2.6 Hz, 1H), 7.08 (d, J = 8.7 Hz, 
3H), 6.84 (t, J = 7.9 Hz, 2H), 4.98 – 4.85 (m, 2H), 3.89 (d, J = 2.2 Hz, 3H), 3.59 (d, J = 2.0 
Hz, 3H), 3.12 (ddd, J = 13.9, 6.8, 4.2 Hz, 4H), 2.29 (s, 6H), 1.63 (s, 9H). 13C NMR (126 
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MHz, CDCl3) δ 171.78, 171.01, 167.68, 149.63, 138.37, 136.77, 135.46, 134.52, 133.85, 
133.51, 131.50, 130.39, 129.94, 126.99, 125.76, 124.96, 124.73, 124.23, 122.93, 122.78, 
118.83, 115.47, 115.03, 83.88, 54.74, 52.55, 39.16, 38.29, 28.30, 27.72, 24.99, 21.30. 
HRMS (ESI) m/z calc’d for C39H43N5O6 [M+H]+ 678.3292, found 678.3291. 
 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(pyrimidin-5-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83d). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), pyrimidin-5-ylboronic acid 
(68 mg, 0.55 mmol, 2 eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 
complex with dichloromethane (23 mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 
mg, 1.4 mmol, 5 eq) was added in anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at 
room temperature (20 °C). The reaction mixture was then heated to 80 °C for 18 h. The 
reaction mixture was then diluted with ethyl acetate and then quenched with saturated 
ammonium chloride (10 mL). The organic layer was extracted and washed 4 times with 
deionized water (10 mL), followed by brine (10 mL). The organic layer was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as a brown foam. This residue was purified by flash chromatography (50% 
EtOAc/Hex) to afford the product as an off-white foam (146 mg, 78%). IR (solid) 1731, 
1636, 1602, 1533, 1451 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 9.10 (s, 1H), 8.76 (d, J 
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= 1.5 Hz, 2H), 8.04 (s, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.45 (s, 1H), 
7.28 (s, 3H), 7.26 – 7.23 (m, 2H), 7.19 (d, J = 7.6 Hz, 2H), 7.10 (d, J = 7.7 Hz, 2H), 7.05 
(s, 1H), 5.13 (q, J = 6.9 Hz, 1H), 4.92 (q, J = 7.2 Hz, 1H), 3.59 (s, 3H), 3.33 – 3.05 (m, 
4H), 2.24 (s, 6H), 1.56 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.99, 171.15, 167.77, 
157.37, 154.75, 149.61, 138.32, 137.75, 135.42, 133.91, 133.74, 133.56, 132.69, 130.59, 
130.35, 126.91, 124.99, 124.80, 124.39, 122.81, 118.88, 115.52, 115.29, 83.90, 54.40, 
52.59, 38.25, 28.24, 27.70, 21.29. HRMS (ESI) m/z calc’d for C39H41N5O6 [M+H]+ 
676.3135, found 676.3132. 
 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(furan-2-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83c). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), 2-furyl boronic acid (61 mg, 
0.55 mmol, 2 eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex 
with dichloromethane (23 mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 
mmol, 5 eq) was added in anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room 
temperature (20 °C). The reaction mixture was then heated to 80 °C for 18 h. The reaction 
mixture was then diluted with ethyl acetate and then quenched with saturated ammonium 
chloride (10 mL). The organic layer was extracted and washed four times with deionized 
water (10 mL), followed by brine (10 mL). The organic layer was then dried over anhydrous 
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sodium sulfate and concentrated to dryness in vacuo to afford the crude product as a 
brown foam. This residue was purified by flash chromatography (30% EtOAc/Hex) to 
afford the product as an off-white foam (176 mg, 96%). IR (thin film) 3280, 2979, 1735, 
1637, 1602 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.10 (s, 1H), 7.47 (d, J = 7.9 Hz, 
3H), 7.45 – 7.39 (m, 2H), 7.35 – 7.27 (m, 3H), 7.20 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 7.9 Hz, 
1H), 7.13 – 7.02 (m, 3H), 6.91 (d, J = 7.6 Hz, 1H), 6.55 (d, J = 3.3 Hz, 1H), 6.43 (dd, J = 
3.4, 1.8 Hz, 1H), 5.03 (q, J = 6.9 Hz, 1H), 4.95 – 4.82 (m, 1H), 3.59 (s, 3H), 3.22 – 3.07 
(m, 4H), 2.28 (s, 6H), 1.62 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.85, 171.06, 167.75, 
153.86, 149.63, 142.05, 138.37, 135.63, 135.47, 133.83, 133.53, 130.40, 129.82, 129.77, 
124.98, 124.75, 124.29, 124.05, 122.81, 118.87, 115.50, 115.17, 111.75, 105.02, 83.83, 
54.59, 52.71, 52.56, 38.37, 28.30, 27.72, 21.31. HRMS (ESI) m/z calc’d for C39H41N3O7 
[M+Na]+ 686.2842, found 686.2845. 
 
 
((R)-3-([1,1'-biphenyl]-4-yl)-2-(3,5-dimethylbenzamido)propanoyl)-L-tryptophan (74a). To 
a stirring solution of 83a (161 mg, 0.23 mmol, 1 eq) in anhydrous dichloromethane (1.2 
mL, 0.2 M), trifluoroacetic acid (370 µL, 2.7 mmol, 20 eq) was added dropwise at room 
temperature (20 °C). After stirring for 18 h, the reaction mixture was quenched with 
saturated sodium bicarbonate (20 mL) and partitioned. The organic layer was washed with 
brine (20 mL) and dried over anhydrous sodium sulfate. The organic layer was then 
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concentrated to dryness in vacuo to afford the crude product as an off-white foam. This 
residue was purified by flash chromatography (2% MeOH/CH2Cl2) to afford the product as 
an off-white foam (61 mg, 0.1 mmol). This foam was then dissolved in a mixture of 
tetrahydrofuran, methanol and water (3:1:1, 1.5 mL, 0.067 M) and lithium hydroxide 
monohydrate (45 mg, 1 mmol, 10 eq) was added portionwise. The reaction mixture was 
stirred at room temperature (20 °C) for 18 h. The reaction mixture was then concentrated 
to remove the organic solvents. 5% NaHSO4 was added until a solid precipitated. The 
solid was collected and washed with water. Product was dried to produce an off-white 
solid (59 mg, 45% over 2 steps). m.p. = 145-150 °C. IR (solid) 3288, 2920, 1723, 1634, 
1600 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 7.59 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 7.1 
Hz, 2H), 7.37 (t, J = 7.8 Hz, 2H), 7.33 – 7.27 (m, 4H), 7.23 (s, 2H), 7.14 (s, 1H), 7.08 (s, 
1H), 7.06 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.01 (d, J = 8.1 Hz, 2H), 6.97 (t, J = 7.8 Hz, 1H), 
4.92 – 4.86 (m, 1H), 4.78 (dd, J = 8.1, 4.9 Hz, 1H), 3.37 (dd, J = 14.8, 4.8 Hz, 1H), 3.21 
(dd, J = 14.7, 8.1 Hz, 1H), 3.15 (dd, J = 13.9, 5.4 Hz, 1H), 2.89 (dd, J = 13.9, 8.2 Hz, 1H), 
2.29 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 175.63, 173.06, 170.27, 142.13, 140.77, 
139.37, 138.11, 137.37, 135.19, 134.22, 130.87, 129.74, 128.12, 127.80, 126.10, 126.02, 
124.67, 122.43, 119.96, 119.34, 112.33, 110.92, 101.39, 56.04, 54.91, 38.50, 28.61, 
21.24. HRMS (ESI) m/z calc’d for C35H33N3O4 [M+H]+ 560.2549, found 560.2552. 
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((R)-2-(3,5-Dimethylbenzamido)-3-(4-(3,5-dimethylisoxazol-4-yl)phenyl)propanoyl)-L-
tryptophan (74e). To a stirring solution of 83e (100 mg, 0.14 mmol, 1 eq) in anhydrous 
dichloromethane (0.7 mL, 0.2 M), trifluoroacetic acid (110 µL, 1.5 mmol, 10 eq) was added 
dropwise at room temperature (20 °C). After stirring for 18 h, the reaction mixture was 
quenched with saturated sodium bicarbonate (10 mL) and partitioned. The organic layer 
was washed with brine (10 mL) and dried over anhydrous sodium sulfate. The organic 
layer was then concentrated to dryness in vacuo to afford the crude product as an off-
white foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (60.3 mg, 0.1 mmol, 70%). This foam was then 
dissolved in a mixture of tetrahydrofuran, methanol and water (3:1:1, 1.5 mL, 0.067 M) 
and lithium hydroxide monohydrate (42 mg, 1 mmol, 10 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce an off-white solid (58.9 mg, 70% over two steps). m.p. = 140-150 °C. IR (solid) 
3302, 2923, 1726, 1635, 1602 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 10.33 (s, 1H), 8.22 
– 8.01 (m, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.25 (s, 2H), 7.17 – 7.10 
(m, 1H), 7.10 – 7.01 (m, 2H), 6.97 (s, 5H), 4.78 (s, 1H), 3.36 (dd, J = 15.5, 4.2 Hz, 1H), 
3.15 (ddd, J = 20.9, 14.5, 7.1 Hz, 2H), 2.87 (dd, J = 13.9, 7.7 Hz, 1H), 2.28 (s, 9H), 2.12 
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(s, 3H). 13C NMR (126 MHz, MeOD) δ 173.91, 171.74, 168.86, 165.43, 158.66, 138.12, 
136.51, 133.01, 129.70, 128.73, 128.34, 127.47, 124.76, 123.62, 123.46, 121.22, 118.72, 
118.03, 116.35, 111.17, 111.11, 109.61, 54.60, 53.34, 37.34, 27.32, 19.99, 10.11, 9.41. 
HRMS (ESI) m/z calc’d for C34H34N4O5 [M+Na]+ 601.2451, found 601.2429. 
 
 
((R)-2-(3,5-Dimethylbenzamido)-3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoyl)-L-
tryptophan (74f). To a stirring solution of 83f (100 mg, 0.14 mmol, 1 eq) in anhydrous 
dichloromethane (0.7 mL, 0.2 M), trifluoroacetic acid (110 µL, 1.5 mmol, 10 eq) was added 
dropwise at room temperature (20 °C). After stirring for 18 h, the reaction mixture was 
quenched with saturated sodium bicarbonate (10 mL) and partitioned. The organic layer 
was washed with brine (10 mL) and dried over anhydrous sodium sulfate. The organic 
layer was then concentrated to dryness in vacuo to afford the crude product as an off-
white foam. This residue was purified by flash chromatography (3% MeOH/CH2Cl2) to 
afford the product as an off-white foam (62.4 mg, 0.11 mmol, 73%). This foam was then 
dissolved in a mixture of tetrahydrofuran, methanol and water (3:1:1, 1.5 mL, 0.067 M) 
and lithium hydroxide monohydrate (42 mg, 1 mmol, 10 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
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produce an off-white solid (60.9 mg, 70% over two steps). m.p. = 132-145 °C. IR (solid) 
3300, 2922, 1726, 1643, 1602 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.77 (s, 1H), 7.67 
(s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.26 – 7.15 (m, 4H), 7.12 (s, 
1H), 7.10 – 7.00 (m, 3H), 6.97 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 7.8 Hz, 2H), 4.86 – 4.82 (m, 
1H), 4.77 (dd, J = 8.3, 4.9 Hz, 1H), 3.86 (s, 3H), 3.34 (dd, J = 14.8, 5.0 Hz, 1H), 3.18 (dd, 
J = 14.7, 8.2 Hz, 1H), 3.07 (dd, J = 13.8, 5.4 Hz, 1H), 2.83 (dd, J = 13.8, 8.3 Hz, 1H), 2.28 
(s, 6H). 13C NMR (126 MHz, MeOD) δ 173.87, 171.92, 168.93, 138.11, 136.84, 135.95, 
135.03, 132.97, 130.87, 129.60, 127.64, 127.49, 124.96, 124.81, 124.76, 123.40, 123.00, 
121.18, 118.70, 118.03, 111.11, 109.50, 54.79, 53.30, 37.61, 37.26, 27.25, 19.97. HRMS 
(ESI) m/z calc’d for C34H34N4O5 [M+Na]+ 586.2430, found 586.2430. 
 
 
((R)-2-(3,5-dimethylbenzamido)-3-(4-(furan-2-yl)phenyl)propanoyl)-L-tryptophan (74c). 
To a stirring solution of 83c (176 mg, 0.27 mmol, 1 eq) in anhydrous dichloromethane (1.4 
mL, 0.2 M), trifluoroacetic acid (200 µL, 2.7 mmol, 10 eq) was added dropwise at room 
temperature (20 °C). After stirring for 18 h, the reaction mixture was quenched with 
saturated sodium bicarbonate (20 mL) and partitioned. The organic layer was washed with 
brine (20 mL) and dried over anhydrous sodium sulfate. The organic layer was then 
concentrated to dryness in vacuo to afford the crude product as an off-white foam. This 
residue was purified by flash chromatography (50% EtOAc/Hexanes) to afford the product 
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as an off-white foam (61 mg, 0.1 mmol). This foam was then dissolved in a mixture of 
tetrahydrofuran, methanol and water (3:1:1, 1.5 mL, 0.067 M) and lithium hydroxide 
monohydrate (45 mg, 1 mmol, 10 eq) was added portionwise. The reaction mixture was 
stirred at room temperature (20 °C) for 18 h. The reaction mixture was then concentrated 
to remove the organic solvents. 5% NaHSO4 was added until a solid precipitated. The 
solid was collected and washed with water. Product was dried to produce an off-white 
solid (63 mg, 43% over 2 steps). m.p. = 168-170 °C. IR (solid) 2920, 1720, 1633, 1600, 
1516 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 7.56 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.38 
(d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 7.8 Hz, 3H), 7.11 (s, 1H), 7.07 (q, 
J = 7.8, 5.9 Hz, 2H), 6.96 (dd, J = 11.2, 7.6 Hz, 3H), 6.61 (d, J = 3.1 Hz, 1H), 6.44 (s, 1H), 
4.90 – 4.83 (m, 1H), 4.77 (dd, J = 8.2, 4.8 Hz, 1H), 3.36 (dd, J = 14.8, 4.9 Hz, 1H), 3.19 
(dd, J = 14.7, 8.3 Hz, 1H), 3.08 (dd, J = 13.9, 5.5 Hz, 1H), 2.88 – 2.79 (m, 1H), 2.27 (s, 
6H). 13C NMR (126 MHz, MeOD) δ 173.97, 171.90, 169.01, 153.92, 141.89, 138.10, 
136.98, 136.17, 133.86, 132.97, 129.48, 127.53, 124.76, 123.57, 123.41, 123.34, 121.22, 
118.75, 118.02, 111.34, 111.17, 109.58, 104.47, 54.69, 53.42, 37.34, 27.27, 19.98. HRMS 
(ESI) m/z calc’d for C33H31N3O5 [M+Na]+ 572.2185, found 572.2166. 
  
  
193 
 
((R)-2-(3,5-dimethylbenzamido)-3-(4-(pyrimidin-5-yl)phenyl)propanoyl)-L-tryptophan 
(74d). To a stirring solution of 83d (100 mg, 0.15 mmol, 1 eq) in anhydrous 
dichloromethane (750 µL, 0.2 M), trifluoroacetic acid (120 µL, 1.5 mmol, 10 eq) was added 
dropwise at room temperature (20 °C). After stirring for 18 h, the reaction mixture was 
quenched with saturated sodium bicarbonate (20 mL) and partitioned. The organic layer 
was washed with brine (20 mL) and dried over anhydrous sodium sulfate. The organic 
layer was then concentrated to dryness in vacuo to afford the crude product as an off-
white foam. This residue was purified by flash chromatography (4% MeOH/CH2Cl2) to 
afford the product as an off-white foam (51.4 mg, 0.09 mmol). This foam was then 
dissolved in a mixture of tetrahydrofuran, methanol and water (3:1:1, 1.5 mL, 0.067 M) 
and lithium hydroxide monohydrate (38 mg, 0.9 mmol, 10 eq) was added portionwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then concentrated to remove the organic solvents. 5% NaHSO4 was added until a 
solid precipitated. The solid was collected and washed with water. Product was dried to 
produce an off-white solid (47 mg, 56% over 2 steps). m.p. = 175-180 °C. IR (solid) 3301, 
2926, 2467, 1722, 1634 cm-1. 1H NMR (500 MHz, Methanol-d4) δ 9.05 (s, 1H), 8.87 (s, 
2H), 8.09 (dd, J = 34.1, 7.9 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.34 – 7.21 (m, 5H), 7.14 – 
7.01 (m, 5H), 6.96 (t, J = 7.5 Hz, 1H), 4.96 – 4.88 (m, 1H), 4.80 – 4.73 (m, 1H), 3.37 (dd, 
2) LiOH•H2O
    THF:MeOH:H2O
1) TFA, CH2Cl2
N
HN
OMe
O
O
NH
O
H
N
HN
OH
O
O
NH
O
Boc
N
N
N
N
  
194 
J = 14.8, 4.6 Hz, 1H), 3.17 (ddd, J = 19.6, 14.3, 7.0 Hz, 2H), 2.90 (dd, J = 13.8, 8.0 Hz, 
1H), 2.27 (s, 6H). 13C NMR (126 MHz, MeOD) δ 174.14, 171.62, 168.82, 156.35, 154.53, 
138.40, 138.14, 136.85, 133.81, 133.01, 132.04, 130.25, 127.57, 126.52, 124.84, 124.75, 
123.40, 121.19, 118.71, 118.09, 111.11, 109.71, 54.58, 53.54, 37.29, 27.31, 19.97. HRMS 
(ESI) m/z calc’d for C33H31N5O4 [M+H]+ 562.2454, found 562.2451. 
 
 
Methyl 4-iodo-5-methylisoxazole-3-carboxylate (89a). To a flask containing isoxazole 88a9 
(212 mg, 1.5 mmol, 1 eq) and N-iodosuccinamide (405 mg, 1.8 mmol, 1.2 eq), 
trifluoroacetic acid (8.5 mL, 0.18 M) was added at room temperature (20 °C). After stirring 
for 18 h, the reaction mixture was concentrated in vacuo, diluted with water (20 mL) and 
extracted with diethyl ether (20 mL). The organic layer was then washed with 1N NaOH 
(20 mL), 5% NaHSO4 (20 mL) and brine (20 mL). The organic was then dried over 
anhydrous sodium sulfate and concentrated in vacuo to afford the product as an off-white 
solid (410 mg, quant). m.p. = 57-60 °C. IR (solid) 2964, 1730, 1575, 1465, 1418 cm-1. 1H 
NMR (500 MHz, Chloroform-d) δ 3.99 (s, 3H), 2.56 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
173.59, 159.74, 155.28, 56.74, 53.04, 12.81. HRMS (ESI) m/z calc’d for C6H6INO3 [M+H]+ 
267.9471, found 267.9481. 
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Methyl 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole-3-carboxylate 
(90a). To a flask containing iodide 89a (410 mg, 1.5 mmol, 1 eq) and 
bis(triphenylphosphine)palladium(II) dichloride (53 mg, 0.075 mmol, 0.05 eq) in degassed 
anhydrous dioxane (2.8 mL, 0.53 M) was added pinacol borane (330 µL, 2.3 mmol, 1.5 
eq) followed by degassed anhydrous triethylamine (630 µL, 4.5 mmol, 3 eq) at room 
temperature (20 °C). The reaction mixture was then heated to reflux for one hour. The 
reaction mixture was then cooled to room temperature and concentrated in vacuo to afford 
the crude product as a yellow oil. This was taken up in diethyl ether, run through Celite, 
concentrated in vacuo and triturated with hexane. The hexane was concentrated in vacuo 
to yield the product as a yellow solid (410 mg, quant). m.p. = 100-105 °C. IR (solid) 1737, 
1596, 1470, 1456, 1383 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 3.94 (s, 3H), 2.56 (s, 
3H), 1.35 (s, 12H). 13C NMR (126 MHz, CDCl3) δ 178.05, 161.23, 158.88, 84.25, 52.73, 
24.85, 12.87 (carbon bearing boron not observed). 11B NMR (128 MHz, CDCl3) δ 29.02. 
HRMS (ESI) m/z calc’d for C12H18BNO5 [M+Na]+ 290.1176, found 290.1179. 
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(4-Iodo-5-methylisoxazol-3-yl)methanol (89b). To a flask containing isoxazole 88b10 (500 
mg, 4.4 mmol, 1 eq) and N-iodosuccinamide (1.2 g, 5.3 mmol, 1.2 eq), trifluoroacetic acid 
(24 mL, 0.18 M) was added at room temperature (20 °C). After stirring for 18 h, the reaction 
mixture was concentrated in vacuo, diluted with water (20 mL) and extracted with diethyl 
ether (20 mL). The organic layer was then washed with 1N NaOH (20 mL), 5% NaHSO4 
(20 mL) and brine (20 mL). The organic was then dried over anhydrous sodium sulfate 
and concentrated in vacuo to afford a crude solid. This solid purified by flash 
chromatography (10% EtOAc/Hexanes) to afford the product as an off-white solid (773 
mg, 73%). m.p. = 78-80 °C. IR (solid) 3340, 1584, 1485, 1408, 1378 cm-1. 1H NMR (500 
MHz, Chloroform-d) δ 4.67 (s, 2H), 2.46 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.18, 
163.56, 100.11, 57.51, 12.44. HRMS (ESI) m/z calc’d for C5H6INO2 [M+H]+ 239.9522, 
found 239.9529. 
 
 
3-(((Tert-butyldimethylsilyl)oxy)methyl)-4-iodo-5-methylisoxazole (89c) To a flask 
containing isoxazole 89b (500 mg, 2.1 mmol, 1 eq) in anhydrous N,N-dimethylformamide 
(2.1 mL, 1 M), imidazole (356 mg, 5.2 mmol, 2.5 eq) was added, followed by tert-
butyldimethylsilyl chloride (380 mg, 2.5 mmol, 1.2 eq) at room temperature (20 °C). After 
stirring for two hours, the reaction mixture was quenched with saturated ammonium 
chloride (20 mL) and extracted two times with ethyl acetate (20 mL). The combined organic 
was then washed four times with water (20 mL) and brine (20 mL). The organic was then 
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dried over anhydrous sodium sulfate and concentrated in vacuo to afford a crude oil. This 
oil purified by flash chromatography (10% EtOAc/Hexanes) to afford the product as a clear 
oily solid (710 mg, 96%). IR (solid) 2956, 2928, 2857, 1592, 1485 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 4.66 (s, 2H), 2.45 (s, 3H), 0.92 (s, 9H), 0.12 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 170.86, 163.12, 57.56, 57.37, 25.98, 18.49, 12.45, -5.19. HRMS (ESI) m/z calc’d 
for C11H20INO2Si [M+H]+ 354.0386, found 354.0380. 
 
 
Methyl 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole-3-carboxylate 
(90c). To a flask containing iodide 89c (353 mg, 1 mmol, 1 eq) and 
bis(triphenylphosphine)palladium(II) dichloride (35 mg, 0.075 mmol, 0.05 eq) in degassed 
anhydrous dioxane (1.9 mL, 0.53 M) was added pinacol borane (220 µL, 2.3 mmol, 1.5 
eq) followed by anhydrous triethylamine (420 µL, 4.5 mmol, 3 eq) at room temperature (20 
°C). The reaction mixture was then heated to reflux for one hour. The reaction mixture was 
then cooled to room temperature and concentrated in vacuo to afford the crude product 
as a yellow oil. This was taken up in diethyl ether, run through celite, concentrated in vacuo 
and triturated with hexane. The hexane was concentrated in vacuo to yield the crude 
product as a yellow solid (226 mg, quant). Carried forward without further purification. 
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Methyl 4-(4-((R)-3-(((S)-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)-1-methoxy-1-
oxopropan-2-yl)amino)-2-(3,5-dimethylbenzamido)-3-oxopropyl)phenyl)-5-
methylisoxazole-3-carboxylate (83h). To a sealed vessel containing iodide 81 (200 mg, 
0.28 mmol, 1 eq), boronic ester 90a (145 mg, 0.55 mmol, 2 eq), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (23 
mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 mmol, 5 eq) was added in 
anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room temperature (20 °C). The 
reaction mixture was then heated to 80 °C for 18 h. The reaction mixture was then diluted 
with ethyl acetate and then quenched with saturated ammonium chloride (10 mL). The 
organic layer was extracted and washed 4 times with deionized water (10 mL), followed 
by brine (10 mL). The organic layer was then dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the crude product as a brown foam. This 
residue was purified by flash chromatography (20-40% EtOAc/Hex) to afford the product 
as an off-white foam (63 mg, 32%). IR (solid) 3278, 2924, 1733, 1635, 1602 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 8.07 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.40 (s, 1H), 7.28 (d, J 
= 6.3 Hz, 3H), 7.17 (qd, J = 7.8, 4.1 Hz, 5H), 7.11 (s, 1H), 6.83 (t, J = 7.3 Hz, 2H), 4.96 (q, 
J = 7.1 Hz, 1H), 4.88 (q, J = 6.7 Hz, 1H), 3.78 (s, 3H), 3.60 (s, 3H), 3.18 (dd, J = 6.9, 4.0 
Hz, 2H), 3.14 (d, J = 6.4 Hz, 2H), 2.35 (s, 3H), 2.31 (s, 6H), 1.62 (s, 9H). 13C NMR (126 
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MHz, CDCl3) δ 171.80, 170.87, 168.37, 167.73, 160.74, 153.84, 149.63, 138.41, 136.68, 
135.46, 133.81, 133.56, 130.41, 130.15, 129.50, 127.43, 124.94, 124.76, 124.30, 122.78, 
118.83, 117.31, 115.47, 115.06, 83.92, 54.57, 52.76, 52.56, 38.23, 28.30, 27.72, 21.30, 
11.52. HRMS (ESI) m/z calc’d for C41H44N5O9 [M+Na]+ 759.3006, found 759.3018. 
 
 
4-(4-((R)-3-(((S)-1-Carboxy-2-(1H-indol-3-yl)ethyl)amino)-2-(3,5-dimethylbenzamido)-3-
oxopropyl)phenyl)-5-methylisoxazole-3-carboxylic acid (74h). To a stirring solution of 83h 
(63 mg, 0.09 mmol, 1 eq) in anhydrous dichloromethane (430 µL, 0.2 M), trifluoroacetic 
acid (70 µL, 0.9 mmol, 10 eq) was added dropwise at room temperature (20 °C). After 
stirring for 18 h, the reaction mixture was quenched with saturated sodium bicarbonate 
(20 mL) and partitioned. The organic layer was washed with brine (20 mL) and dried over 
anhydrous sodium sulfate. The organic layer was then concentrated to dryness in vacuo 
to afford the crude product as an off-white foam. This residue was purified by flash 
chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (49.3 mg, 
0.08 mmol). This foam was then dissolved in a mixture of tetrahydrofuran, methanol and 
water (3:1:1, 1 mL, 0.067 M) and lithium hydroxide monohydrate (33 mg, 0.8 mmol, 10 eq) 
was added portionwise. The reaction mixture was stirred at room temperature (20 °C) for 
18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
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NaHSO4 was added until a solid precipitated. The solid was collected and washed with 
water. Product was dried to produce an off-white solid (45.7 mg, 88% over 2 steps). m.p. 
= 130-142 °C. IR (solid) 3331, 2924, 1722, 1634, 1601 cm-1. 1H NMR (500 MHz, Methanol-
d4) δ 8.09 (dd, J = 38.3, 8.0 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 
7.25 (s, 2H), 7.13 (s, 1H), 7.07 – 7.01 (m, 4H), 7.01 – 6.90 (m, 3H), 4.79 (td, J = 8.1, 4.9 
Hz, 2H), 3.35 (dd, J = 14.7, 4.9 Hz, 1H), 3.18 (dd, J = 14.7, 8.3 Hz, 1H), 3.11 (dd, J = 13.9, 
5.7 Hz, 1H), 2.89 (dd, J = 13.8, 7.9 Hz, 1H), 2.28 (s, 9H). 13C NMR (126 MHz, MeOD) δ 
173.77, 171.95, 171.87, 169.03, 168.26, 161.91, 138.14, 136.86, 136.83, 133.89, 132.99, 
129.44, 129.12, 127.46, 127.27, 124.78, 123.43, 121.23, 118.72, 118.00, 116.76, 111.13, 
109.48, 54.69, 53.33, 53.24, 37.30, 27.28, 19.99, 10.05. HRMS (ESI) m/z calc’d for 
C34H32N4O7 [M+H]+ 609.2349, found 609.2372. 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(5-formylfuran-2-
yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate (83k). To a 
sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), (5-formylfuran-2-yl)boronic 
acid (77 mg, 0.55 mmol, 2 eq), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (23 
mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 mg, 1.4 mmol, 5 eq) was added in 
anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at room temperature (20 °C). The 
N
HN
OMe
O
O
NH
O
Boc
N
HN
OMe
O
O
NH
O
I
Boc
PdCl2(dppf)•CH2Cl2
KOAc, DMF
O
O B
O
H OH
OH
H
O
  
201 
reaction mixture was then heated to 80 °C for 18 h. The reaction mixture was then diluted 
with ethyl acetate and then quenched with saturated ammonium chloride (10 mL). The 
organic layer was extracted and washed four times with deionized water (10 mL), followed 
by brine (10 mL). The organic layer was then dried over anhydrous sodium sulfate and 
concentrated to dryness in vacuo to afford the crude product as a brown foam. This 
residue was purified by flash chromatography (40% EtOAc/Hex) to afford the product as 
an off-white foam (145 mg, 76%). IR (solid) 1732, 1670, 1636, 1603, 1530 cm-1. 1H NMR 
(500 MHz, Chloroform-d) δ 9.60 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 7.9 Hz, 2H), 
7.46 (d, J = 7.8 Hz, 1H), 7.40 (s, 1H), 7.33 – 7.24 (m, 4H), 7.20 (t, J = 7.5 Hz, 1H), 7.13 
(d, J = 8.0 Hz, 2H), 7.09 (s, 1H), 7.02 (s, 1H), 6.85 (s, 1H), 6.72 (d, J = 3.6 Hz, 1H), 4.99 
(s, 1H), 4.89 (q, J = 6.7 Hz, 1H), 3.61 (s, 3H), 3.24 – 3.08 (m, 4H), 2.29 (s, 6H), 1.62 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ 177.29, 171.77, 170.81, 167.71, 159.28, 152.09, 
149.60, 138.43, 135.47, 133.69, 133.62, 130.36, 130.07, 127.84, 125.56, 124.91, 124.79, 
124.22, 122.81, 118.78, 115.51, 115.00, 107.77, 83.93, 54.46, 53.55, 52.62, 38.41, 28.30, 
27.70, 21.30. HRMS (ESI) m/z calc’d for C40H41N3O8 [M+H]+ 692.2972, found 692.2979. 
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Tert-butyl 3-((S)-2-((R)-3-(4-(5-((dimethylamino)methyl)furan-2-yl)phenyl)-2-(3,5-
dimethylbenzamido)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-carboxylate 
(83j). To a flask containing 83k (70 mg, 0.1 mmol, 1 eq), dimethylamine hydrochloride (27 
mg, 0.3 mmol, 3 eq) and sodium triacetoxyborohydride (26 mg, 0.12 mmol, 1.15 eq) in 
dichloromethane (560 µL, 0.2 M) at room temperature (20 °C), triethylamine (40 µL, 0.26 
mmol, 2.4 eq) was added. After four hours, the reaction mixture was diluted with ethyl 
acetate and then quenched with water (10 mL). The organic layer was extracted and 
washed with brine (10 mL). The organic layer was then dried over anhydrous sodium 
sulfate and concentrated to dryness in vacuo to afford the product as an orange foam (68 
mg, 93%). IR (solid) 3268, 2934, 1733, 1636, 1602 cm-1. 1H NMR (500 MHz, Chloroform-
d) δ 8.09 (d, J = 7.8 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 7.8 Hz, 1H), 7.41 (s, 
1H), 7.32 – 7.24 (m, 3H), 7.19 (t, J = 7.6 Hz, 1H), 7.14 – 7.05 (m, 3H), 6.91 (d, J = 7.9 Hz, 
1H), 6.79 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 3.2 Hz, 1H), 6.24 (d, J = 3.2 Hz, 1H), 4.95 (q, J 
= 6.9 Hz, 1H), 4.92 – 4.83 (m, 1H), 3.59 (s, 3H), 3.51 (s, 2H), 3.13 (t, J = 7.1 Hz, 4H), 2.28 
(d, J = 5.2 Hz, 12H), 1.62 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.78, 170.97, 167.74, 
153.31, 152.05, 149.61, 138.37, 135.50, 135.40, 133.83, 133.52, 130.38, 129.86, 129.71, 
124.94, 124.73, 124.28, 124.02, 122.80, 118.83, 115.47, 115.06, 110.77, 105.67, 83.83, 
55.93, 54.61, 52.69, 52.54, 45.03, 38.26, 28.30, 27.73, 21.30. HRMS (ESI) m/z calc’d for 
C40H44N4O8 [M+H]+, found. 
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((R)-3-(4-(5-((dimethylamino)methyl)furan-2-yl)phenyl)-2-(3,5-
dimethylbenzamido)propanoyl)-L-tryptophan (74j). To a stirring solution of 83j (67 mg, 
0.09 mmol, 1 eq) in anhydrous dichloromethane (450 µL, 0.2 M), trifluoroacetic acid (70 
µL, 0.9 mmol, 10 eq) was added dropwise at room temperature (20 °C). After stirring for 
18 h, the reaction mixture was quenched with saturated sodium bicarbonate (20 mL) and 
partitioned. The organic layer was washed with brine (20 mL) and dried over anhydrous 
sodium sulfate. The organic layer was then concentrated to dryness in vacuo to afford the 
crude product as an off-white foam. This residue was purified by preparative thin layer 
chromatography (4% MeOH/CH2Cl2) to afford the product as an off-white foam (33 mg, 
0.05 mmol). This foam was then dissolved in a mixture of tetrahydrofuran, methanol and 
water (3:1:1, 750 µL, 0.067 M) and lithium hydroxide monohydrate (22 mg, 0.5 mmol, 10 
eq) was added portionwise. The reaction mixture was stirred at room temperature (20 °C) 
for 18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
NaHSO4 was added until a solid precipitated. The solid was collected and washed with 
water. Product was dried to produce an off-white solid (33 mg, 59% over 2 steps). m.p. = 
152-169 °C. IR (solid) 3288, 2922, 1644, 1602, 1498 cm-1. 1H NMR (500 MHz, Chloroform-
d) δ 7.61 – 7.57 (m, 1H), 7.42 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 1H), 7.15 (s, 2H), 
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7.08 (d, J = 11.2 Hz, 2H), 7.01 (dd, J = 17.7, 7.8 Hz, 3H), 6.94 (t, J = 7.4 Hz, 1H), 6.68 (s, 
2H), 4.70 (dd, J = 7.1, 4.8 Hz, 1H), 4.29 – 4.19 (m, 2H), 3.35 (dd, J = 14.6, 5.0 Hz, 1H), 
3.21 (ddd, J = 23.2, 14.3, 6.1 Hz, 2H), 2.87 (dd, J = 13.9, 8.8 Hz, 1H), 2.72 (s, 6H), 2.24 
(s, 6H). 13C NMR (126 MHz, CDCl3) δ 175.75, 171.06, 171.03, 155.78, 137.75, 137.35, 
136.48, 133.53, 132.64, 129.42, 128.17, 127.65, 124.50, 123.43, 123.14, 120.77, 118.35, 
118.00, 115.52, 115.41, 110.73, 109.82, 105.35, 54.58, 52.68, 41.41, 41.30, 37.05, 27.27, 
19.71. HRMS (ESI) m/z calc’d for C36H38N4O5 [M+H]+ 607.2920, found 607.2913. 
 
 
Tert-butyl 3-((S)-2-((R)-2-(3,5-dimethylbenzamido)-3-(4-(3-(hydroxymethyl)-5-
methylisoxazol-4-yl)phenyl)propanamido)-3-methoxy-3-oxopropyl)-1H-indole-1-
carboxylate (83i). To a sealed vessel containing iodide 81 (200 mg, 0.28 mmol, 1 eq), 90c 
(194 mg, 0.55 mmol, 2 eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 
complex with dichloromethane (23 mg, 0.03 mmol, 0.1 eq) and potassium acetate (135 
mg, 1.4 mmol, 5 eq) was added in anhydrous N,N-dimethylformamide (2.8 mL, 0.1 M) at 
room temperature (20 °C). The reaction mixture was then heated to 80 °C for 18 h. The 
reaction mixture was then diluted with ethyl acetate and then quenched with saturated 
ammonium chloride (10 mL). The organic layer was extracted and washed four times with 
deionized water (10 mL), followed by brine (10 mL). The organic layer was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
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product as a brown foam. This residue was purified by flash chromatography (40-50% 
EtOAc/Hex) to afford the product as an off-white foam (59 mg, 30% over 2 steps). IR (thin 
film) 3289, 2925, 1733, 1637, 1603 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.08 (s, 1H), 
7.47 (d, J = 7.8 Hz, 1H), 7.41 (s, 1H), 7.29 (s, 3H), 7.20 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 7.9 
Hz, 2H), 7.11 (d, J = 8.4 Hz, 3H), 7.04 (d, J = 7.8 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H), 4.99 
(q, J = 7.0 Hz, 1H), 4.88 (q, J = 6.4 Hz, 1H), 4.61 (d, J = 4.5 Hz, 2H), 3.61 (s, 3H), 3.20 – 
3.08 (m, 4H), 2.86 (s, 1H), 2.34 (s, 3H), 2.29 (s, 6H), 1.60 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 171.96, 170.98, 167.77, 166.08, 161.58, 149.66, 138.40, 136.27, 135.49, 
133.77, 133.58, 130.39, 130.03, 129.28, 128.47, 124.94, 124.82, 124.34, 122.84, 118.84, 
115.65, 115.49, 115.09, 83.99, 55.94, 54.51, 52.76, 52.64, 38.27, 28.27, 27.68, 21.30, 
11.64. HRMS (ESI) m/z calc’d for C40H44N4O8 [M+H]+ 709.3237, found 709.3250. 
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((R)-2-(3,5-Dimethylbenzamido)-3-(4-(3-(hydroxymethyl)-5-methylisoxazol-4-
yl)phenyl)propanoyl)-L-tryptophan (74i). To a stirring solution of 83i (58 mg, 0.08 mmol, 1 
eq) in anhydrous dichloromethane (400 µL, 0.2 M), trifluoroacetic acid (70 µL, 0.9 mmol, 
10 eq) was added dropwise at room temperature (20 °C). After stirring for 18 h, the 
reaction mixture was quenched with saturated sodium bicarbonate (20 mL) and 
partitioned. The organic layer was washed with brine (20 mL) and dried over anhydrous 
sodium sulfate. The organic layer was then concentrated to dryness in vacuo to afford the 
crude product as an off-white foam. This residue was purified by preparative thin layer 
chromatography (4% MeOH/CH2Cl2) to afford the product as an off-white foam (15.6 mg, 
0.03 mmol). This foam was then dissolved in a mixture of tetrahydrofuran, methanol and 
water (3:1:1, 400 µL, 0.067 M) and lithium hydroxide monohydrate (11 mg, 0.3 mmol, 10 
eq) was added portionwise. The reaction mixture was stirred at room temperature (20 °C) 
for 18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
NaHSO4 was added until a solid precipitated. The solid was collected and washed with 
water. Product was dried to produce an off-white solid (24.3 mg, 35% over 2 steps). m.p. 
= 160-175 °C. IR (solid) 3302, 2923, 1640, 1602, 1516 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 7.58 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.22 (s, 2H), 7.13 (d, J 
= 8.1 Hz, 3H), 7.07 (s, 1H), 7.02 (t, J = 8.3 Hz, 3H), 6.94 (t, J = 7.5 Hz, 1H), 4.90 (dd, J = 
2) LiOH•H2O
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8.3, 5.4 Hz, 1H), 4.75 (dd, J = 7.8, 4.8 Hz, 1H), 4.52 (s, 2H), 3.36 (dd, J = 14.7, 4.8 Hz, 
1H), 3.25 – 3.14 (m, 2H), 2.89 (dd, J = 13.8, 8.3 Hz, 1H), 2.33 (s, 3H), 2.30 (s, 6H). 13C 
NMR (126 MHz, CDCl3) δ 171.26, 168.68, 165.75, 162.51, 161.20, 139.53, 137.85, 
136.51, 133.66, 132.71, 129.37, 128.62, 127.78, 127.43, 124.51, 123.14, 120.84, 118.41, 
117.88, 115.54, 110.72, 109.61, 54.49, 54.25, 53.89, 37.12, 27.23, 19.74, 9.92. HRMS 
(ESI) m/z calc’d for C34H34N4O6 [M+H]+ 595.2557, found 595.2542. 
 
 
Methyl (R)-2-((S)-2-(1,3-dioxoisoindolin-2-yl)-3-(1H-indol-3-yl)propanamido)-3-(4-
iodophenyl)propanoate (103). To the amino ester (3.41 g, 10 mmol, 1 eq) was added acid 
phthalate11 (3.4 g, 10 mmol, 1 eq), anhydrous N,N-diisopropylethylamine (8.7 mL, 50 
mmol, 5 eq) and anhydrous N,N-dimethylformamide (33 mL, 0.3M). The reaction mixture 
was then cooled to 0 °C and HATU (5.7 mg, 15 mmol, 1.5 eq) was added. The reaction 
mixture was allowed to warm to room temperature (20 °C) for 18 h. The reaction mixture 
was poured over 200 mL ice water. After stirring for 5 mins, precipitate collected and 
purified by flash chromatography (40% EtOAc/Hexanes) to afford the product as an off-
white foam (5.8 mg, 93%). IR (solid) 1740, 1708, 1668, 1524, 1484 cm-1. 1H NMR (500 
MHz, Chloroform-d) δ 8.23 (s, 1H), 7.76 (dd, J = 5.4, 3.0 Hz, 2H), 7.67 (dd, J = 5.5, 3.1 
Hz, 2H), 7.59 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 7.9 Hz, 1H), 7.17 – 
7.12 (m, 1H), 7.12 – 7.06 (m, 1H), 6.86 – 6.81 (m, 2H), 6.78 (d, J = 8.2 Hz, 2H), 5.28 (t, J 
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= 7.9 Hz, 1H), 4.81 (q, J = 7.1, 5.8, 5.3 Hz, 1H), 3.73 (dd, J = 15.0, 7.8 Hz, 1H), 3.64 (s, 
3H), 3.57 (dd, J = 15.0, 8.2 Hz, 1H), 3.12 (dd, J = 13.9, 5.8 Hz, 1H), 3.00 (dd, J = 13.9, 
5.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 171.32, 168.56, 168.16, 137.63, 136.44, 
135.52, 134.39, 131.69, 131.58, 126.88, 123.66, 123.05, 122.52, 119.92, 118.71, 111.48, 
110.75, 92.77, 54.55, 53.47, 52.61, 36.98, 25.81. HRMS (ESI) m/z calc’d for C29H24IN3O5 
[M+H]+ 622.0839,  found 622.0822. 
 
 
Ethyl 3-((S)-2-(1,3-dioxoisoindolin-2-yl)-3-(((R)-3-(4-iodophenyl)-1-methoxy-1-
oxopropan-2-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (104). To a stirring solution 
of 103 (1.9 g, 3 mmol, 1 eq) in anhydrous N,N-dimethylformamide (6 mL, 0.5 M), di-diethyl 
dicarbonate (520 µL, 3.6 mmol, 1.2 eq) was added portionwise, followed by N,N-
dimethylamino pyridine (40 mg, 0.3 mmol, 0.1 eq)  at 0 °C. Allowed to warm to room 
temperature (20 °C) for 18 h. The reaction mixture was quenched with saturated 
ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL) two times. The 
organic layer was washed with water (10 mL) ten times, brine (10 mL) and dried over 
anhydrous sodium sulfate. The organic layer was then concentrated to dryness in vacuo 
to afford the crude product as an off-white foam. This residue was purified by flash 
chromatography (30% EtOAc/Hex) to afford the product as an off-white foam (1.2 g, 60%, 
95% brsm). IR (thin film) 3358, 2952, 1714, 1527, 1455 cm-1. 1H NMR (500 MHz, 
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Chloroform-d) δ 8.09 (d, J = 8.3 Hz, 1H), 7.79 (dd, J = 5.4, 3.1 Hz, 2H), 7.71 (dd, J = 5.6, 
2.9 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.33 (s, 1H), 7.29 (t, J = 7.7 
Hz, 2H), 7.23 (t, J = 7.5 Hz, 1H), 6.78 (dd, J = 14.7, 7.6 Hz, 3H), 5.23 (dd, J = 9.1, 7.1 Hz, 
1H), 4.82 (q, J = 6.9, 5.9, 5.7 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 3.61 (qt, J = 
9.3, 7.5, 7.0, 5.9, 3.1 Hz, 2H), 3.12 (dd, J = 13.9, 5.8 Hz, 1H), 3.01 (dd, J = 13.9, 5.3 Hz, 
1H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.25, 168.06, 167.98, 150.78, 
137.63, 135.67, 135.44, 134.56, 131.54, 131.44, 129.74, 125.08, 123.92, 123.80, 123.17, 
118.97, 116.31, 115.40, 92.77, 63.25, 54.16, 53.41, 52.65, 36.99, 25.13, 14.54. HRMS 
(ESI) m/z calc’d for C32H28IN3O7 [M+H]+ 694.1050, found 694.1066. 
 
 
Ethyl 3-((S)-2-(1,3-dioxoisoindolin-2-yl)-3-((ethoxycarbonyl)((R)-3-(4-iodophenyl)-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)-1H-indole-1-carboxylate (105). To a 
stirring solution of 104 (280 mg, 0.4 mmol, 1 eq) in anhydrous tetrahydrofuran (1.3 mL, 
0.3 M) at -78 °C, LHMDS (500 µL, 0.48 mmol, 1.2 eq) was added slowly dropwise down 
the side of the flask. After 15 mins stirring at -78 °C, ethyl chloroformate (100 µL, 1 mmol, 
2.5 eq) was added slowly dropwise down the side of the flask. After stirring for one hour 
reaction was slowly warmed to room temperature (20 °C). The reaction mixture was 
opened to the air and quenched for 30 mins. The reaction was then diluted with ethyl 
acetate (50 mL) then quenched for of water (10 mL). The organic layer was washed with 
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then washed with brine (10 mL) and dried over anhydrous sodium sulfate. The organic 
layer was then concentrated to dryness in vacuo to afford the crude product as an off-
white foam. This residue was purified by flash chromatography (20% EtOAc/Hex) to afford 
the product as an white foam (210 g, 68%). IR (solid) 1734, 1717, 1611, 1455, 1379 cm-1. 
1H NMR (500 MHz, Chloroform-d) δ 8.08 (s, 1H), 7.82 – 7.73 (m, 3H), 7.73 – 7.61 (m, 4H), 
7.43 (s, 1H), 7.32 – 7.23 (m, 2H), 6.95 (d, J = 8.3 Hz, 2H), 6.45 (dd, J = 11.5, 4.4 Hz, 1H), 
5.46 (dd, J = 10.2, 5.7 Hz, 1H), 4.46 – 4.33 (m, 2H), 4.31 – 4.14 (m, 2H), 3.76 (s, 3H), 
3.50 (dd, J = 14.3, 5.8 Hz, 2H), 3.22 (dd, J = 14.3, 10.1 Hz, 1H), 3.08 – 2.96 (m, 1H), 1.40 
(t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.85, 170.47, 
169.64, 167.74, 152.68, 137.72, 136.63, 133.92, 133.84, 131.61, 131.30, 124.51, 123.98, 
123.27, 122.84, 119.36, 117.75, 116.30, 114.90, 92.13, 63.98, 62.87, 55.44, 52.54, 35.50, 
23.93, 14.30, 13.91, 13.54. HRMS (ESI) m/z calc’d for C35H32IN3O9 [M+Na]+ 788.1081, 
found 788.1088. 
 
 
(R)-3-(4-iodophenyl)-1-methoxy-N-methyl-1-oxopropan-2-aminium chloride (109). To a 
solution of (R)-2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoic acid (1.62 g, 4.1 
mmol, 1 eq)  in anhydrous tetrahydrofuran (11.5 mL, 0.36 M) at 0 °C was added sodium 
hydride (60% disp, 660 mg, 16 mmol, 4 eq). After 15 minutes, iodomethane (770 µL, 12 
mmol, 3 eq) was added and the reaction mixture was allowed to warm to room temperature 
(20 °C) for 18 h. The reaction was then cooled to 0 °C and quenched with water until no 
further gas evolved. This solution was then extracted with two times ethyl acetate (50 mL). 
HO
O
NHBoc
I
1) NaH, MeI, THF
2) SOCl2, MeOH MeO
O H2
N
I
Cl-
  
211 
The combined organic was washed with brine (50 mL), dried over sodium sulfate and 
concentrated to dryness in vacuo to afford the methylated product as a white foam (1.67 
g). The product from step one was taken up in methanol (9 mL, 0.45 M) and cooled to 0 
°C. Thionyl chloride (1.5 mL, 20 mmol, 5 eq) was then added dropwise. Heated to reflux 
for 2 hours. When cooled methanol was extracted with hexanes to remove oil. 
concentrated to dryness in vacuo and triturated with ether. Concentrated to dryness in 
vacuo to afford the product as a yellow foam (1.47 g, quant). IR (solid) 2949, 2691, 1752, 
1741, 1588 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 10.67 (s, 1H), 9.52 (s, 1H), 7.64 (d, 
J = 8.3 Hz, 2H), 7.04 (d, J = 8.2 Hz, 2H), 4.01 (s, 1H), 3.71 (s, 3H), 3.55 (dd, J = 13.9, 5.0 
Hz, 1H), 3.33 (dd, J = 14.0, 9.1 Hz, 1H), 2.76 (t, J = 5.2 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 168.22, 138.07, 134.06, 131.43, 93.46, 62.24, 53.30, 35.36, 32.39. HRMS (ESI) 
m/z calc’d for C11H15ClINO2 [M+H]+ 320.0148, found 320.0145. 
 
 
Methyl (R)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)-N-
methylpropanamido)-3-(4-iodophenyl)propanoate (110). To the amine 1098 (200 mg, 0.56 
mmol, 1 eq), N-boc trp (OH)3 (172 mg, 0.56 mmol, 1 eq) and 2-bromo-1-ethylpyridinium 
tetrafluoroborate (BEP, 200 mg, 0.73 mmol, 1.3 eq) in anhydrous dichloromethane (5.6 
mL, 0.1 M) at 0 °C, was added N,N-diisopropylethylamine (300 µL, 1.7 mmol, 3 eq) and 
anhydrous acetonitrile (0.9 mL, 0.3M). The reaction mixture was allowed to warm to room 
temperature (20 °C) for 18 h. The reaction mixture was concentrated to dryness in vacuo 
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and taken up in ethyl acetate (10 mL). The organic layer was washed twice with deionized 
water (10 mL), followed by brine (10 mL). The organic was then dried over anhydrous 
sodium sulfate and concentrated to dryness in vacuo to afford the crude product as an 
orange foam. This residue was purified by flash chromatography (40% EtOAc/Hex) to 
afford the product as a yellow foam (266 mg, 79%). IR (solid) 3316, 2975, 1738, 1697, 
1640 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.24 (s, 1H), 7.58 (dd, J = 14.0, 8.0 Hz, 
3H), 7.32 (d, J = 8.1 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 6.90 (dd, J 
= 21.4, 8.1 Hz, 2H), 6.71 (d, J = 2.4 Hz, 1H), 5.36 (d, J = 9.0 Hz, 1H), 5.12 (dd, J = 10.0, 
5.9 Hz, 1H), 4.92 (q, J = 7.4 Hz, 1H), 3.67 (s, 3H), 3.20 – 3.10 (m, 1H), 2.96 – 2.86 (m, 
2H), 2.72 (dd, J = 14.4, 10.0 Hz, 1H), 2.64 (s, 3H), 1.41 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 173.34, 170.74, 155.41, 137.74, 136.87, 136.15, 131.23, 127.74, 122.89, 
122.17, 119.72, 118.83, 111.31, 110.39, 92.22, 79.82, 58.80, 52.52, 51.01, 34.33, 33.02, 
29.18, 28.50. HRMS (ESI) m/z calc’d for C27H32IN3O5 [M+H]+ 606.1465, found 606.1464. 
 
 
(3S,6R)-3-((1H-indol-3-yl)methyl)-6-(4-iodobenzyl)-1-methylpiperazine-2,5-dione (111). 
To a stirring solution of 110 (300 mg, 0.5 mmol, 1 eq) in anhydrous dichloromethane (2.5 
mL, 0.2 M), trifluoroacetic acid (390 µL, 5 mmol, 10 eq) was added dropwise at room 
temperature (20 °C). After stirring for 18 h, the reaction mixture was quenched with 
saturated sodium bicarbonate (10 mL) and partitioned. The organic layer was washed with 
brine (10 mL) and dried over anhydrous sodium sulfate. The organic layer was then 
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concentrated to dryness in vacuo to afford the crude product as an off-white foam. This 
residue was then dissolved in anhydrous tetrahydrofuran (8 mL, 0.063 M) and morpholine 
(1.5 mL, 0.33 M) was added dropwise. The reaction mixture was stirred at room 
temperature (20 °C) for 18 h. The reaction mixture was then partitioned between ethyl 
acetate (10 mL) and saturated ammonium chloride (10 mL). The organic layer was 
washed with water (10 mL), followed by brine (10 mL) and dried over sodium sulfate. The 
organic layer was then concentrated to dryness in vacuo to afford the crude product as an 
off-white foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to 
afford the product as a white foam (197 mg, 82% over two steps). IR (solid) 3402, 1677, 
1639, 1484, 1457 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.08 (s, 1H), 7.59 (d, J = 8.1 
Hz, 2H), 7.38 (dt, J = 7.5, 1.1 Hz, 1H), 7.27 (d, J = 4.0 Hz, 2H), 7.25 – 7.22 (m, 1H), 6.97 
(d, J = 2.3 Hz, 1H), 6.81 (d, J = 8.1 Hz, 2H), 5.49 (s, 1H), 4.12 (t, J = 4.0 Hz, 1H), 3.51 
(dd, J = 14.8, 3.8 Hz, 1H), 3.17 (dd, J = 14.0, 3.5 Hz, 1H), 3.11 – 3.03 (m, 4H), 2.87 (dd, 
J = 11.2, 3.7 Hz, 1H), 2.70 (dd, J = 14.7, 11.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
167.28, 166.84, 138.14, 136.77, 134.27, 131.97, 126.44, 123.71, 122.91, 120.43, 118.89, 
111.56, 109.51, 93.59, 63.90, 52.17, 36.37, 32.98, 29.03. HRMS (ESI) m/z calc’d for 
C21H20IN3O2 [M+H]+ 474.0679, found 474.0695. 
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Tert-butyl 3-(((2S,5R)-1-(tert-butoxycarbonyl)-5-(4-iodobenzyl)-4-methyl-3,6-
dioxopiperazin-2-yl)methyl)-1H-indole-1-carboxylate (112). To a stirring solution of 111 
(200 mg, 0.4 mmol, 1 eq) and anhydrous triethylamine (150 µL, 1 mmol, 2.5 eq) in 
anhydrous dichloromethane (3.2 mL, 0.13 M), di-tert-butyl dicarbonate (280 mg, 1.3 mmol, 
3 eq) was added portionwise, followed by N,N-dimethylamino pyridine (16 mg, 0.13 mmol, 
0.3 eq) at room temperature (20 °C). After stirring for 3 hours, reaction was complete by 
TLC. The reaction mixture was then concentrated to dryness in vacuo to afford the crude 
product as an yellow foam. This residue was purified by flash chromatography (10-15% 
EtOAc/Hex) to afford the product as an off-white foam (290 mg, quant). IR (solid) 1776, 
1725, 1661, 1485, 1454 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 8.2 Hz, 1H), 
7.51 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 7.8 Hz, 1H), 7.32 – 7.25 (m, 1H), 7.25 – 7.15 (m, 2H), 
6.71 (d, J = 7.9 Hz, 2H), 4.46 (s, 1H), 3.40 (dd, J = 14.8, 2.9 Hz, 1H), 3.33 (dd, J = 14.7, 
5.0 Hz, 1H), 3.03 (dd, J = 20.7, 3.8 Hz, 2H), 2.89 (dd, J = 14.2, 4.2 Hz, 1H), 2.70 (s, 3H), 
1.65 (s, 10H), 1.52 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 166.28, 166.13, 149.97, 149.48, 
137.64, 135.39, 133.73, 131.63, 130.11, 126.59, 124.86, 122.77, 119.55, 115.25, 113.54, 
93.06, 84.32, 84.00, 62.48, 58.53, 37.20, 32.08, 29.60, 28.32, 28.08. HRMS (ESI) m/z 
calc’d for C31H36IN3O6 [M+H]+ 674.1727, found 674.1736. 
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Tert-butyl 3-(((2S,5R)-1-(tert-butoxycarbonyl)-5-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-4-
methyl-3,6-dioxopiperazin-2-yl)methyl)-1H-indole-1-carboxylate (113). To a sealed vessel 
containing iodide 112 (600 mg, 0.9 mmol, 1 eq), 3,5-dimethylisooxazole-4-boronic ester 
(398 mg, 1.8 mmol, 2 eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 
complex with dichloromethane (73 mg, 0.09 mmol, 0.1 eq) and potassium acetate (440 
mg, 4.5 mmol, 5 eq) was added in anhydrous N,N-dimethylformamide (9 mL, 0.1 M) at 
room temperature (20 °C). The reaction mixture was then heated to 80 °C for 18 h. The 
reaction mixture was then diluted with ethyl acetate and then quenched with saturated 
ammonium chloride (30 mL). The organic layer was extracted and washed 5 times with 
deionized water (30 mL), followed by brine (30 mL). The organic layer was then dried over 
anhydrous sodium sulfate and concentrated to dryness in vacuo to afford the crude 
product as a brown foam. This residue was purified by flash chromatography (20% 
EtOAc/Hex) to afford the product as an off-white foam (447 mg, 78%). IR (solid) 2979, 
2933, 1775, 1728, 1662 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 8.3 Hz, 
1H), 7.54 (d, J = 7.7 Hz, 1H), 7.31 (t, J = 8.0, 7.3 Hz, 1H), 7.29 – 7.22 (m, 3H), 7.16 (d, J 
= 7.7 Hz, 2H), 7.08 (d, J = 7.8 Hz, 2H), 4.95 (dd, J = 7.2, 4.7 Hz, 1H), 4.24 (t, J = 5.2 Hz, 
1H), 2.90 (ddd, J = 13.7, 7.9, 4.8 Hz, 2H), 2.85 (s, 3H), 2.68 (dd, J = 14.2, 5.9 Hz, 1H), 
2.34 (dd, J = 15.7, 8.4 Hz, 1H), 2.22 (s, 3H), 2.10 (s, 3H), 1.63 (s, 9H), 1.25 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 166.24, 165.86, 165.36, 158.61, 150.00, 149.52, 135.83, 
135.53, 130.41, 130.37, 129.99, 129.75, 124.96, 124.89, 123.04, 119.40, 116.10, 115.51, 
PdCl2(dppf2)2•CH2Cl2
N
N
O
O
N
I
Boc
Boc
N
N
O
O
N Boc
Boc
KOAc, DMF
N
O
(pin)B
O
N
  
216 
115.21, 84.65, 83.95, 65.67, 58.79, 38.19, 33.43, 30.54, 28.29, 28.26, 27.57, 11.49, 10.74. 
HRMS (ESI) m/z calc’d for C36H42N4O7 [M+Na]+ 665.2951,  found 665.2958. 
 
 
(3S,6R)-3-((1H-indol-3-yl)methyl)-6-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-1-
methylpiperazine-2,5-dione (108). To a stirring solution of 113 (94.5 mg, 0.15 mmol, 1 eq) 
in anhydrous dichloromethane (750 µL, 0.2 M), trifluoroacetic acid (110 µL, 1.5 mmol, 10 
eq) was added dropwise at room temperature (20 °C). After stirring for 18 h, the reaction 
mixture was quenched with saturated sodium bicarbonate (20 mL) and partitioned. The 
organic layer was washed with brine (20 mL) and dried over anhydrous sodium sulfate. 
The organic layer was then concentrated to dryness in vacuo to afford the crude product 
as an off-white foam. This residue was purified by preparative TLC (2% MeOH/CH2Cl2) to 
afford the product as an off-white foam (46 mg, 71%). IR (thin film) 3274, 2922, 1675, 
1458, 1333 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.48 (s, 1H), 7.47 (d, J = 8.0 Hz, 
1H), 7.31 (d, J = 8.2 Hz, 1H), 7.27 – 7.20 (m, 4H), 7.16 (t, J = 7.9, 7.0 Hz, 1H), 7.06 (t, J 
= 7.6 Hz, 1H), 6.70 (s, 1H), 5.93 (s, 1H), 4.21 (t, J = 4.2 Hz, 1H), 3.99 (dt, J = 11.2, 2.7 
Hz, 1H), 3.24 – 3.04 (m, 6H), 2.20 (s, 3H), 2.08 (s, 3H), 1.20 (dd, J = 13.9, 10.8 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 165.93, 165.90, 165.54, 158.72, 136.68, 134.73, 131.03, 
130.13, 129.84, 126.56, 123.57, 122.65, 119.97, 118.79, 116.18, 111.64, 109.76, 63.19, 
55.71, 36.65, 33.35, 31.47, 11.45, 10.71. HRMS (ESI) m/z calc’d for C26H26N4O3 [M+H]+ 
443.2083, found 443.2082. 
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(3S,6R)-3-((1H-indol-3-yl)methyl)-6-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-1-methyl-5-
thioxopiperazin-2-one (123). To a stirring solution of 108 (200 mg, 0.45 mmol, 1 eq) in 
anhydrous tetrahydrofuran (2.3 mL, 0.2 M), Lawesson’s reagent (220 mg, 0.54 mmol, 1.2 
eq) was added at room temperature (20 °C). After stirring for 18 h, anhydrous 
tetrahydrofuran (2.3 mL, 0.2 M) and Lawesson’s reagent (220 mg, 0.54 mmol, 1.2 eq) 
were added. After stirring for 18 h, the reaction mixture was concentrated to dryness in 
vacuo. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) followed by 
preparative TLC (2% MeOH/CH2Cl2) to afford the product as an off-white foam (50 mg, 
24%). IR (thin film) 3280, 3059, 2928, 2797, 2244 (CDCl3), 1643 cm-1. 1H NMR (500 MHz, 
Chloroform-d) δ 8.30 (s, 1H), 7.87 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.38 – 7.30 (m, 3H), 
7.27 (d, J = 7.9 Hz, 2H), 7.19 (dd, J = 8.2, 7.0 Hz, 1H), 7.10 (t, J = 7.8, 7.1 Hz, 1H), 6.74 
(d, J = 2.3 Hz, 1H), 4.75 (t, J = 4.3 Hz, 1H), 3.96 (dt, J = 11.4, 3.2 Hz, 1H), 3.63 (dd, J = 
14.0, 3.8 Hz, 1H), 3.36 (dd, J = 14.0, 4.7 Hz, 1H), 3.18 – 3.07 (m, 4H), 2.19 (s, 3H), 2.07 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.90, 165.53, 164.72, 158.70, 136.67, 134.43, 
131.23, 130.38, 129.86, 126.37, 123.53, 122.88, 120.20, 118.79, 116.14, 111.69, 109.40, 
70.11, 58.03, 39.51, 33.43, 30.35, 11.44, 10.71. HRMS (ESI) m/z calc’d for C26H26N4O2S 
[M+H]+ 459.1855, found 459.1857. 
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(6R)-3-((1H-indol-3-yl)methyl)-6-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-1-
methylpiperazine-2,5-dithione (116). To a suspension of 108 (100 mg, 0.23 mmol, 1 eq) 
in anhydrous toluene (1.2 mL, 0.2 M), Lawesson’s reagent (110 mg, 0.27 mmol, 1.2 eq) 
was added at room temperature (20 °C). Heated to reflux for 1h. The reaction mixture was 
cooled and run through a plug of Celite with excess ethyl acetate. The filtrate was 
concentrated to dryness in vacuo. This residue was purified by flash chromatography 
(20% EtOAc/Hex) followed by preparative TLC (20% EtOAc/Hex) to afford the two 
epimeric products as orange films (top spot: 35 mg, bottom spot: 36 mg, 66% 1:1 dr). Top 
spot: IR (thin film) 3316, 3049, 2926, 1630, 1512 cm-1. 1H NMR (500 MHz, Chloroform-d) 
δ 8.26 (s, 1H), 7.84 (s, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.21 – 7.14 (m, 3H), 7.14 – 7.08 (m, 
3H), 7.01 (d, J = 2.3 Hz, 1H), 6.77 (t, J = 7.5 Hz, 1H), 4.95 (t, J = 4.3 Hz, 1H), 4.18 (ddd, 
J = 14.8, 3.7, 1.1 Hz, 1H), 3.57 – 3.54 (m, 1H), 3.53 (s, 3H), 3.38 (dd, J = 13.9, 4.8 Hz, 
1H), 2.97 (dd, J = 11.5, 3.7 Hz, 1H), 2.76 (dd, J = 14.9, 11.3 Hz, 1H), 2.40 (s, 3H), 2.25 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.47, 193.96, 165.56, 158.58, 136.81, 133.14, 
130.83, 130.67, 129.37, 126.30, 123.73, 123.26, 119.95, 118.57, 116.00, 111.80, 109.73, 
73.77, 60.72, 42.33, 39.49, 33.25, 11.98, 11.18. HRMS (ESI) m/z calc’d for C26H26N4O1S2 
[M+H]+ 475.1626, found 475.1627. Bottom spot: IR (thin film) 3324, 3061, 2927, 1519, 
1423 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (s, 1H), 7.84 (s, 1H), 7.63 – 7.58 (m, 
1H), 7.36 (d, J = 8.2 Hz, 1H), 7.32 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 7.22 (ddd, 
J = 8.2, 7.1, 1.2 Hz, 1H), 7.14 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.78 (d, J = 2.4 Hz, 1H), 4.90 
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(td, J = 4.4, 1.3 Hz, 1H), 4.51 (d, J = 11.1 Hz, 1H), 3.72 (dd, J = 14.1, 4.2 Hz, 1H), 3.65 – 
3.59 (m, 1H), 3.58 (s, 3H), 3.49 – 3.45 (m, 1H), 2.22 (s, 3H), 2.09 (s, 3H), 1.05 (dd, J = 
14.1, 11.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 193.00, 192.84, 165.57, 158.69, 136.63, 
134.04, 131.21, 130.63, 129.97, 126.48, 123.49, 122.95, 120.27, 119.06, 116.09, 111.64, 
109.89, 72.25, 65.24, 42.44, 40.22, 35.02, 11.49, 10.75. HRMS (ESI) m/z calc’d for 
C26H26N4O1S2 [M+H]+ 475.1626, found 475.1617. 
 
 
Tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-oxopropyl)-1H-indole-
1-carboxylate (131). To the weinreb amide13 (445 mg, 0.78 mmol, 1 eq) in anhydrous 
tetrahydrofuran (3.2 mL, 0.25 M) at 0 °C, lithium aluminum hydride (77 mg, 2 mmol, 2.6 
eq) was added slowly over ten minute. The reaction mixture was allowed to stir for 30 mins 
then slowly quenched with 10% citric acid until gas stopped evolving. This mixture was 
stirred for another 10 minutes at 0 °C. This solution was diluted with diethyl ether (10 mL) 
and partitioned. The aqueous was extracted three more times with diethyl ether (10 mL) 
and the combined organic was washed with saturated sodium bicarbonate (10 mL), water 
(10 mL), 10% citric acid (10 mL), water (10 mL), then brine (10 mL). The organic was then 
dried over anhydrous magnesium sulfate and concentrated to dryness in vacuo to afford 
the crude product as an off-white foam which was used in the next step without further 
purification. 
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Tert-butyl 3-((2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-cyano-3-(((R)-1-
methoxy-1-oxo-3-phenylpropan-2-yl)amino)propyl)-1H-indole-1-carboxylate (132). To the 
D-Phe methyl ester (337 mg, 1.6 mmol, 2 eq) in methanol (3 mL), triethylamine (220 µL, 
1.6 mmol, 2 eq) was added at room temperature (20 °C). The reaction mixture was allowed 
to stir for 20 mins then cooled to -20 °C and then an ethereal solution of zinc chloride (1 
M, 780 µL, 0.78 mmol, 1 eq) was added, followed by aldehyde 131 (0.78 mmol, 1 eq) in 
methanol (4.8 mL, total vol 0.1 M). The reaction mixture was stirred at -20 °C for one hour, 
then trimethylsilylcyanide (180 µL, 1.4 mmol, 1.8 eq) was added dropwise. The reaction 
mixture was allowed to warm to room temperature for 18 h. The reaction was then filtered 
to afford the product as a white solid (324 mg, 59%, one diastereomer). m.p. = 155-160 
°C. IR (solid) 1740, 1730, 1683, 1520, 1464 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 
8.15 (d, J = 8.6 Hz, 1H), 7.77 (d, J = 7.6 Hz, 2H), 7.54 (t, J = 9.5 Hz, 3H), 7.44 – 7.27 (m, 
7H), 7.06 (s, 5H), 4.89 (d, J = 8.6 Hz, 1H), 4.42 (d, J = 6.9 Hz, 2H), 4.29 (s, 1H), 4.21 (s, 
1H), 3.71 (s, 3H), 3.50 (d, J = 8.1 Hz, 1H), 3.35 (d, J = 10.8 Hz, 1H), 3.05 – 2.86 (m, 3H), 
2.76 (ddd, J = 13.5, 8.3, 1.9 Hz, 1H), 2.36 (s, 1H), 1.66 (s, 9H). 13C NMR (126 MHz, CDCl3) 
δ 173.48, 149.61, 143.85, 143.77, 141.46, 136.85, 135.71, 130.04, 129.23, 128.48, 
127.91, 127.26, 126.96, 125.18, 124.92, 124.25, 123.00, 120.16, 118.97, 117.97, 115.57, 
114.95, 83.98, 67.30, 61.73, 53.30, 53.19, 52.36, 47.29, 40.03, 28.34, 27.75. HRMS (ESI) 
m/z calc’d for C42H42N4O6 [M+H]+ 699.3183, found 699.3190. 
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Tert-butyl 3-(((2S,5R)-5-benzyl-3-cyano-6-oxopiperazin-2-yl)methyl)-1H-indole-1-
carboxylate (133). To a stirring solution of 132 (300 mg, 0.4 mmol, 1 eq) in anhydrous 
tetrahydrofuran (7 mL, 0.063 M), morpholine (1.3 mL, 0.33 M) was added dropwise. The 
reaction mixture was stirred at room temperature (20 °C) for 18 h. The reaction mixture 
was then partitioned between ethyl acetate (10 mL) and saturated ammonium chloride (10 
mL). The organic layer was washed with water (10 mL), followed by brine (10 mL) and 
dried over sodium sulfate. The organic layer was then concentrated to dryness in vacuo 
to afford the crude product as an off-white foam. This residue was purified by flash 
chromatography (20-30% EtOAc/Hex) to afford the product as a white foam (162 mg, 
85%). IR (solid) 1732, 1669, 1475, 1453, 1367 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 
8.18 (d, J = 8.3 Hz, 1H), 7.56 (s, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 
7.30 (q, J = 6.3, 5.0 Hz, 2H), 7.27 – 7.20 (m, 4H), 6.60 (s, 1H), 4.11 (td, J = 7.6, 3.9 Hz, 
1H), 4.05 (s, 1H), 3.94 (dt, J = 10.3, 3.2 Hz, 1H), 3.55 (dd, J = 13.8, 3.2 Hz, 1H), 3.06 (d, 
J = 8.4 Hz, 2H), 2.74 (dd, J = 13.7, 10.4 Hz, 1H), 2.01 (s, 1H), 1.68 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 169.55, 149.45, 137.25, 135.91, 129.47, 129.42, 129.02, 127.20, 125.23, 
124.86, 123.03, 118.75, 116.11, 115.76, 113.35, 84.31, 56.50, 53.40, 49.05, 38.13, 28.64, 
28.33. HRMS (ESI) m/z calc’d for C26H28N4O3 [M+H]+ 445.2240, found 445.2253. 
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Tert-butyl 3-(((2S,5R)-5-benzyl-3-carbamoyl-6-oxopiperazin-2-yl)methyl)-1H-indole-1-
carboxylate (137). To a stirring solution of 133 (110 mg, 0.25 mmol, 1 eq) and potassium 
carbonate (7 mg, 0.05 mmol, 0.2 eq) in anhydrous dimethylsulfoxide (1.3 mL, 0.2 M), 
hydrogen peroxide (130 µL, 1 mmol, 4.5 eq) was added dropwise at 0 °C. Reaction mixture 
was warmed to 40 °C for 18 h, then cooled to room temperature (20 °C), diluted with ethyl 
acetate (10 mL), washed five times with water (10 mL) and one time with brine (10 mL).. 
The organic layer was dried over anhydrous sodium sulfate and concentrated to dryness 
in vacuo to afford the crude product as an off-white foam. This residue was purified by 
flash chromatography (2% MeOH/CH2Cl2) to afford the product as an off-white foam (113 
mg, 98%). IR (solid) 3314, 2979, 1728, 1660, 1452 cm-1. 1H NMR (500 MHz, Chloroform-
d) δ 8.10 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.46 (s, 1H), 7.33 – 7.28 (m, 3H), 7.22 (dt, J = 
7.4, 5.6 Hz, 4H), 6.75 (d, J = 4.1 Hz, 1H), 6.51 (s, 1H), 6.15 (d, J = 4.1 Hz, 1H), 4.11 (hept, 
J = 4.1, 3.7, 3.4, 2.8, 2.8 Hz, 1H), 3.88 (d, J = 4.1 Hz, 1H), 3.65 (dd, J = 10.5, 3.7 Hz, 1H), 
3.18 (dd, J = 14.0, 3.7 Hz, 1H), 3.05 (ddd, J = 13.9, 2.7, 1.2 Hz, 1H), 2.93 (dd, J = 14.0, 
10.5 Hz, 1H), 2.84 (dd, J = 13.9, 10.2 Hz, 1H), 2.01 (s, 1H), 1.64 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 172.45, 171.42, 149.73, 138.48, 135.75, 130.06, 129.56, 128.73, 126.91, 
124.94, 124.39, 123.00, 119.39, 115.63, 115.50, 84.09, 58.79, 54.26, 52.83, 37.72, 28.33, 
27.25. HRMS (ESI) m/z calc’d for C26H30N4O4 [M+H]+463.2345, found 463.2352. 
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Methyl (3S)-3-amino-4-(1H-indol-3-yl)-2-(((R)-1-methoxy-1-oxo-3-phenylpropan-2-
yl)amino)butanoate (138). To a stirring solution of 137 (265 mg, 0.57 mmol, 1 eq) in 
anhydrous methanol (8.5 mL, 0.067 M), thionyl chloride (1.5 mL, 20 mmol, 35 eq) was 
added dropwise at 0 °C. Reaction vessel was sealed and heated to 60 °C over two days. 
Upon cooling to 0 °C, the flask was opened and TLC indicated incomplete conversion. 
Reaction mixture was concentrated to dryness in vacuo. The residue was redissolved in 
anhydrous methanol (8.5 mL, 0.067 M) and thionyl chloride (1.5 mL, 20 mmol, 35 eq) was 
added dropwise at 0 °C. Reaction vessel was sealed and heated to 60 °C for 18 h. Upon 
cooling to 0 °C, the reaction mixture was diluted with 20 mL dichloromethane and 
saturated sodium bicarbonate was added to quench. The organic layer was partitioned 
and washed an additional time with saturated sodium bicarbonate (30 mL) and dried over 
anhydrous sodium sulfate. The organic layer was then concentrated to dryness in vacuo 
to afford the crude product as a brown oil. This residue was purified by flash 
chromatography (5% MeOH/CH2Cl2) to afford the product as brown film (185 mg, 79%). 
IR (thin film) 3347, 3029, 2951, 1735, 1495 cm-1. 1H NMR (500 MHz, Chloroform-d) δ 8.41 
(s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.26 – 7.22 
(m, 2H), 7.22 – 7.15 (m, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.88 (d, J = 2.2 Hz, 1H), 3.66 (d, J 
= 5.1 Hz, 6H), 3.54 (q, J = 7.1, 6.5 Hz, 1H), 3.30 – 3.21 (m, 2H), 3.05 (dd, J = 13.6, 5.7 
Hz, 1H), 2.96 – 2.84 (m, 2H), 2.58 (dd, J = 14.3, 8.9 Hz, 1H), 2.43 (s, 1H), 1.51 (s, 2H). 
13C NMR (126 MHz, CDCl3) δ 174.80, 174.00, 137.94, 136.56, 129.62, 128.49, 127.72, 
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126.80, 123.02, 122.09, 119.41, 118.98, 112.50, 111.39, 65.70, 63.25, 54.33, 51.96, 
51.94, 40.21, 29.78. HRMS (ESI) m/z calc’d for C23H27N3O4 [M+H]+ 410.2080, found 
410.2084. 
 
 
Methyl (3S,6R)-3-((1H-indol-3-yl)methyl)-6-benzyl-5-oxopiperazine-2-carboxylate (139). 
To a stirring solution of 138 (185 mg, 0.45 mmol, 1 eq) in anhydrous tetrahydrofuran (7 
mL, 0.063 M), morpholine (1.4 mL, 0.33 M) was added dropwise. The reaction mixture 
was refluxed for 18 h. The reaction mixture was then partitioned between ethyl acetate 
(10 mL) and saturated ammonium chloride (10 mL). The organic layer was washed with 
water (10 mL), followed by brine (10 mL) and dried over sodium sulfate. The organic layer 
was then concentrated to dryness in vacuo to afford the crude product as an off-white 
foam. This residue was purified by flash chromatography (2% MeOH/CH2Cl2) to afford the 
product as a white foam (120 mg, 70%). IR (solid) 3282, 2924, 1732, 1652, 1455 cm-1. 1H 
NMR (500 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.2 
Hz, 1H), 7.36 – 7.30 (m, 2H), 7.28 – 7.18 (m, 4H), 7.13 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H), 
6.95 (d, J = 2.3 Hz, 1H), 5.93 (s, 1H), 4.03 – 3.95 (m, 3H), 3.79 (s, 3H), 3.28 (dd, J = 13.7, 
3.5 Hz, 1H), 3.01 – 2.95 (m, 2H), 2.92 (dd, J = 13.7, 10.2 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 171.25, 170.87, 137.91, 136.75, 129.46, 128.96, 127.11, 127.01, 123.55, 
122.49, 119.80, 118.54, 111.72, 110.22, 58.04, 54.62, 53.63, 52.36, 38.34, 27.93. HRMS 
(ESI) m/z calc’d for C22H23N3O3 [M+H]+ 378.1818, found 378.1834. 
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(3S,6R)-3-((1H-indol-3-yl)methyl)-6-benzyl-5-oxopiperazine-2-carboxylic acid (142). To a 
stirring solution of 139 (30 mg, 0.08 mmol, 1 eq) in a mixture of tetrahydrofuran, methanol 
and water (3:1:1, 1.2 mL, 0.067 M), lithium hydroxide monohydrate (33 mg, 0.8 mmol, 10 
eq) was added portionwise. The reaction mixture was stirred at room temperature (20 °C) 
for 18 h. The reaction mixture was then concentrated to remove the organic solvents. 5% 
NaHSO4 was added until a solid precipitated. The aqueous mixture extracted with four 
times with ethyl acetate (5 mL). The combined organic was then washed with brine and 
dried over anhydrous sodium sulfate.  The organic layer was then concentrated to dryness 
in vacuo to afford the crude product as an off-white solid, which was triturated in a mixture 
of acetone and dichloromethane to yield the product as a white solid (13.2 mg, 46%). m.p. 
= 188-194 °C. IR (solid) 1680, 1635, 1456, 1406, 1367 cm-1. 1H NMR (500 MHz, DMSO-
d6) δ 10.85 (s, 1H), 7.54 – 7.39 (m, 2H), 7.33 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 7.4 Hz, 1H), 
7.26 – 7.16 (m, 2H), 7.12 (s, 1H), 7.06 (t, J = 7.6 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 3.70 (s, 
3H), 2.98 (d, J = 13.5 Hz, 1H), 2.95 – 2.78 (m, 3H). 13C NMR (126 MHz, DMSO) δ 172.05, 
170.02, 138.97, 136.26, 129.45, 128.22, 127.38, 126.18, 123.73, 120.90, 118.29, 118.16, 
111.42, 109.83, 57.17, 54.25, 53.45, 37.88, 27.26. HRMS (ESI) m/z calc’d for C21H21N3O3 
[M+H]+ 364.1661, found 364.1676. 
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APPENDIX B. SPECTRAL IMAGES 
 
229 
 
 
1HNMR spectrum for compound 39 
230 
 
 
13CNMR spectrum for compound 39 
231 
 
 
IR spectrum for compound 39 
232 
 
 
1HNMR spectrum for compound 41 
233 
 
 
13CNMR spectrum for compound 41 
234 
 
 
31PNMR spectrum for compound 41 
235 
 
 
IR spectrum for compound 41 
236 
 
  
1HNMR spectrum for compound 42 
237 
 
 
13CNMR spectrum for compound 42 
238 
 
IR spectrum for compound 42 
8110
0 859095 4
00
0
60
0
10
00
20
00
30
00
%
T
W
av
en
um
be
r [
cm
-1
]
239 
 
 
1HNMR spectrum for compound 44 
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1HNMR spectrum for compound 47 
247 
 
 
13CNMR spectrum for compound 47 
248 
 
 
IR spectrum for compound 47 
249 
 
 
1HNMR spectrum for compound 48 
250 
 
 
13CNMR spectrum for compound 48 
251 
 
 
IR spectrum for compound 48 
252 
 
 
1HNMR spectrum for compound 50 
253 
 
 
13CNMR spectrum for compound 50 
254 
 
 
IR spectrum for compound 50 
255 
 
 
1HNMR spectrum for compound 51a 
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1HNMR spectrum for compound 51b 
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1HNMR spectrum for compound 53a 
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1HNMR spectrum for compound 54i 
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1HNMR spectrum for compound 54j 
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1HNMR spectrum for compound 56a 
326 
 
 
13CNMR spectrum for compound 56a 
327 
 
 
IR spectrum for compound 56a 
 
6010
0 708090 4
00
0
60
0
10
00
20
00
30
00
%
T
W
av
en
um
be
r [
cm
-1
]
328 
 
 
1HNMR spectrum for compound 56b 
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1HNMR spectrum for compound 56c 
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1HNMR spectrum for compound 56i 
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1HNMR spectrum for compound 90a 
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1HNMR spectrum for compound 104 
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1HNMR spectrum for compound 105 
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1HNMR spectrum for compound 109 
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1HNMR spectrum for compound 110 
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1HNMR spectrum for compound 111 
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1HNMR spectrum for compound 112 
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1HNMR spectrum for compound 113 
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1HNMR spectrum for compound 108 
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1HNMR spectrum for compound 116bottom 
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1HNMR spectrum for compound 116top 
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1HNMR spectrum for compound 123 
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1HNMR spectrum for compound 132 
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1HNMR spectrum for compound 133 
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1HNMR spectrum for compound 139 
520 
 
 
13CNMR spectrum for compound 139 
521 
 
 
IR spectrum for compound 139 
 
522 
 
 
1HNMR spectrum for compound 137 
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528 
 
 
13CNMR spectrum for compound 138 
529 
 
 
IR spectrum for compound 138 
 
5010
0 60708090 4
00
0
60
0
10
00
20
00
30
00
%
T
W
av
en
um
be
r [
cm
-1
]
530 
 
 
1HNMR spectrum for compound 142 
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13CNMR spectrum for compound 142 
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